WO2006069290A2 - Enzymes for starch processing - Google Patents

Enzymes for starch processing Download PDF

Info

Publication number
WO2006069290A2
WO2006069290A2 PCT/US2005/046725 US2005046725W WO2006069290A2 WO 2006069290 A2 WO2006069290 A2 WO 2006069290A2 US 2005046725 W US2005046725 W US 2005046725W WO 2006069290 A2 WO2006069290 A2 WO 2006069290A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acids
nucleotides
polypeptide
starch
Prior art date
Application number
PCT/US2005/046725
Other languages
French (fr)
Other versions
WO2006069290A3 (en
Inventor
Shiro Fukuyama
Tomoko Matsui
Chee-Leong Soong
Eric Allain
Anders Vikso-Nielsen
Hiroaki Udagawa
Ye Liu
Junxin Duan
Wenping Wu
Lene Nonboe Andersen
Sara Landvik
Original Assignee
Novozymes A/S
Novozymes North America, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes A/S, Novozymes North America, Inc. filed Critical Novozymes A/S
Priority to CN200580048598.0A priority Critical patent/CN101128580B/en
Priority to DK05855308.2T priority patent/DK1831385T3/en
Priority to MX2007007030A priority patent/MX2007007030A/en
Priority to ES05855308.2T priority patent/ES2543131T3/en
Priority to EP05855308.2A priority patent/EP1831385B1/en
Priority to AU2005319074A priority patent/AU2005319074B2/en
Priority to CA2592104A priority patent/CA2592104C/en
Priority to JP2007548502A priority patent/JP5452869B2/en
Publication of WO2006069290A2 publication Critical patent/WO2006069290A2/en
Publication of WO2006069290A3 publication Critical patent/WO2006069290A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C12N9/242—Fungal source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2428—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/02—Monosaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present application contains information in the form of a sequence listing, which is appended to the application and also submitted on a data carrier accompanying this application.
  • the present application refers to deposited microorganisms. The contents of the data carrier and the deposited microorganisms are fully incorporated herein by reference.
  • the present invention relates to polypeptides comprising a carbohydrate-binding module ("CBM”) and an alpha-amylase catalytic domain. Furthermore, the invention relates
  • polypeptides comprising useful alpha-amylase catalytic domains and/or CBMs as well as to the catalytic domain sequences and/or CBM sequences.
  • the invention also relates to the use of such polypeptides in a starch liquefaction process in which starch is degraded to smaller oligo- and/or polysaccharide fragments.
  • Glucose may also be fermented to ethanol or other fermentation products, such as citric acid, monosodium glutamate, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta lactone, or sodium erythorbate, itaconic acid, lactic acid, gluconic acid; ketones; amino acids, glutamic acid (sodium monoglutaminate), penicillin, tetracyclin; enzymes; vitamins, such as riboflavin, B12, beta-carotene or hormones.
  • Starch is a high molecular-weight polymer consisting of chains of glucose units. It usually consists of about 80% amylopectin and 20% amylose. Amylopectin is a branched polysaccharide in which linear chains of alpha-1,4 D-glucose residues are joined by alpha- 1 ,6 glucosidic linkages.
  • Amylose is a linear polysaccharide built up of D-glucopyranose units linked together by alpha-1 ,4 glucosidic linkages.
  • the conventional depolymerization process consists of a gelatinization step and two consecutive process steps, namely a liquefaction process and a saccharification process.
  • Granular starch consists of microscopic granules, which are insoluble in water at room temperature. When an aqueous starch slurry is heated, the granules swell and eventually burst, dispersing the starch molecules into the solution.
  • the temperature is then lowered to 60 0 C, a glucoamylase (also known as GA or AMG) or a beta- amylase and optionally a debranching enzyme, such as an isoamylase or a pullulanase are added, and the saccharification process proceeds for about 24 to 72 hours.
  • a glucoamylase also known as GA or AMG
  • a beta- amylase and optionally a debranching enzyme, such as an isoamylase or a pullulanase are added, and the saccharification process proceeds for about 24 to 72 hours.
  • CBM carbohydrate- binding module
  • Such hybrids consisting of a polypeptide having alpha-amylase activity and a carbohydrate binding module, primarily having affinity for starch, have the advantage over existing alpha-amylases that by selecting a catalytic domain with desire properties eg.
  • the pH profile, the temperature profile, the oxidation resistance, the calcium stability, the substrate affinity or the product profile can be combined with a carbohydrate binding module with stronger or weaker binding affinities, e.g., specific affinities for amylose, specific affinities for amylopectin or affinities for specific structure in the carbohydrate.
  • the invention relates to hybrids having altered properties relative to the alpha-amylase without the CBM and/or relative to prior art amylases, such as having increased stability and/or activity at low pH, e.g., at pH below 4, such as at 3.5, increased activity towards granular starch, and/or increased degradation of granular starch at low pH even in the absence of glucoamylase or at low glucoamylase levels, and/or with altered product profile.
  • the overall starch conversion process can be performed without having to gelatinize the starch, i.e., the polypeptides hydrolyses granular starch in a raw starch process as well as fully or partially gelatinized starch in a traditional starch process.
  • the invention provides in a first aspect a polypeptide comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module, wherein said second amino acid sequence has at least 60% homology to any amino acid sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 109, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141 and SEQ ID NO: 143.
  • the invention provides a polypeptide having alpha-amylase activity, selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has at least 75% homology with amino acids for the mature polypeptide selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, as amino acids 1-471 in SEQ ID NO: 18, as amino acids 1-450 in SEQ ID NO: 20, as amino acids 1-445 in SEQ ID NO: 22, as amino acids 1-498 in SEQ ID NO: 26, as amino acids 18-513 in SEQ ID NO: 28, as amino acids 1-507 in SEQ ID NO: 30, as amino acids 1-481 in SEQ ID NO: 32, as amino acids 1-495 in SEQ ID NO: 34, as amino acids 1-477 in SEQ ID NO: 38, as amino acids 1-449 in SEQ ID NO: 42, as amino acids 1-442 in SEQ ID NO: 115, as amino acids 1- 441 in SEQ ID NO: 117, as amino acids 1-477 in SEQ ID NO:
  • the invention provides a polypeptide having carbohydrate-binding affinity, selected from the group consisting of: (a) i) a polypeptide comprising an amino acid sequence which has at least 60% homology with a sequence selected from the group consisting of amino acids 529-626 of SEQ ID NO: 159, amino acids 533-630 of SEQ ID NO: 161 , amino acids 508-602 of SEQ ID NO: 163, amino acids 540-643 of SEQ ID NO: 165, amino acids 502-566 of SEQ ID NO: 167, amino acids 513-613 of SEQ ID NO: 169, 492-587 of SEQ ID NO: 173, amino acids 30-287 of SEQ ID NO: 175, amino acids 487-586 of SEQ ID NO: 177 and amino acids 482-582 of SEQ ID NO: 179; (b) a polypeptide which is encoded by a nucleotide sequence which hybridizes under low stringency conditions with a polynucleotide probe selected from the group consisting
  • the invention provides uses of the polypeptide of the first, second and/or third aspect for saccharification, in a process comprising fermentation, in a starch conversion process, in a process for producing oligosaccharides, e.g., a process for producing maltodextrins or glucose and/or fructose syrups, in a process for producing fuel or drinking ethanol, for producing a beverage, and/or in a fermentation process for producing organic compounds, such as citric acid, ascorbic acid, lysine, glutamic acid.
  • oligosaccharides e.g., a process for producing maltodextrins or glucose and/or fructose syrups
  • organic compounds such as citric acid, ascorbic acid, lysine, glutamic acid.
  • the invention provides a composition comprising the polypeptide of the first, second and/or third aspect.
  • the invention provides a process for saccharifying starch, wherein a starch is treated with the polypeptide of the first, second and/or third aspect.
  • the invention provides a process comprising; a) contacting a starch with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first, second and/or third aspect; b) incubating said starch with said polypeptide; c) fermenting to produce a fermentation product, d) optionally recovering the fermentation product, wherein an enzyme having glucoamylase activity is either absent or present in an amount of less than 0.5 AGU/g DS of starch substrate and wherein step a, b, c, and/or d may be performed separately or simultaneously.
  • the invention provides a process comprising; a) contacting a starch substrate with a yeast cell transformed to express a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first and/or second aspect; b) holding said starch substrate with said yeast; c) fermenting to produce ethanol; d) optionally recovering ethanol, wherein steps a), b), and c) are performed separately or simultaneously.
  • steps a), b), and c) are performed separately or simultaneously.
  • steps a), b), and c) are performed separately or simultaneously.
  • the invention provides a process of producing ethanol from starch- containing material by fermentation, said process comprises: (i) liquefying said starch- containing material with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first and/or second aspect; (ii) saccharifying the liquefied mash obtained; (iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism and optionally comprising recovery of the ethanol.
  • the invention provides a DNA sequence encoding a polypeptide according to the first, second and/or third aspect, a DNA construct comprising said DNA sequence, a recombinant expression vector which carries said DNA construct, a host cell which is transformed with said DNA construct or said vector, said host cell, which is a microorganism, in particular a bacterium or a fungal cell, a yeast or a plant cell.
  • granular starch is understood as raw uncooked starch, i.e., starch that has not been subjected to a gelatinization. Starch is formed in plants as tiny granules insoluble in water. These granules are preserved in starches at temperatures below the initial gelatinization temperature. When put in cold water, the grains may absorb a small amount of the liquid. Up to 50 0 C to 70 0 C the swelling is reversible, the degree of reversibility being dependent upon the particular starch. With higher temperatures an irreversible swelling called gelatinization begins.
  • initial gelatinization temperature is understood as the lowest temperature at which gelatinization of the starch commences. Starch heated in water begins to gelatinize between 50°C and 75 " C; the exact temperature of gelatinization depends on the specific starch and can readily be determined by the skilled artisan. Thus, the initial gelatinization temperature may vary according to the plant species, to the particular variety of the plant species as well as with the growth conditions. In the context of this invention the initial gelatinization temperature of a given starch is the temperature at which birefringence is lost in 5% of the starch granules using the method described by Gorinstein. S. and Lii. C, Starch/Starke, Vol. 44 (12) pp. 461-466 (1992).
  • soluble starch hydrolysate is understood as the soluble products of the processes of the invention and may comprise mono-, di-, and oligosaccharides, such as glucose, maltose, maltodextrins, cyclodextrins and any mixture of these.
  • oligosaccharides such as glucose, maltose, maltodextrins, cyclodextrins and any mixture of these.
  • at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97% or at least 98% of the dry solids of the granular starch is converted into a soluble starch hydrolysate.
  • polypeptide "homology" is understood as the degree of identity between two sequences indicating a derivation of the first sequence from the second.
  • the homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-453.
  • GAP creation penalty of 3.0
  • GAP extension penalty of 0.1.
  • the relevant part of the amino acid sequence for the homology determination is the mature polypeptide, i.e., without the signal peptide.
  • Suitable experimental conditions for determining hybridization at low, medium, or high stringency between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5% SDS and 100 micrograms/ml of denatured sonicated salmon sperm DNA (Sambrook et al.
  • 5 x SSC Sodium chloride/Sodium citrate, Sambrook et al. 1989
  • the polypeptide of the invention may be a hybrid enzyme or the polypeptide may be a wild type enzyme which already comprises a catalytic module having alpha-amylase activity and a carbohydrate-binding module.
  • the polypeptide of the invention may also be a variant of such a wild type enzyme.
  • the hybrid may be produced by fusion of a first DNA sequence encoding a first amino acid sequences and a second DNA sequence encoding a second amino acid sequences, or the hybrid may be produced as a completely synthetic gene based on knowledge of the amino acid sequences of suitable CBMs, linkers and catalytic domains.
  • hybrid enzyme or “hybrid polypeptide” is used herein to characterize those of the polypeptides of the invention that comprises a first amino acid sequence comprising at least one catalytic module having alpha-amylase activity and a second amino acid sequence comprising at least one carbohydrate-binding module wherein the first and the second are derived from different sources.
  • source being understood as, e.g., but not limited to a parent enzyme, e.g., an amylase or glucoamylase, or other catalytic activity comprising a suitable catalytic module and/or a suitable CBM and/or a suitable linker.
  • Enzyme classification numbers are in accordance with the Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Academic Press Inc., 1992.
  • Polypeptides as referred to herein include species comprising an amino acid sequence of an alpha-amylase enzyme (EC 3.2.1.1) linked (i.e., covalently bound) to an amino acid sequence comprising a carbohydrate-binding module (CBM).
  • CBM carbohydrate-binding module
  • CBM-containing hybrid enzymes as well as detailed descriptions of the preparation and purification thereof, are known in the art [see, e.g., WO 90/00609, WO 94/24158 and WO 95/16782, as well as Greenwood et al. Biotechnology and Bioenqineerinq 44 (1994) pp. 1295- 1305]. They may, e.g., be prepared by transforming into a host cell a DNA construct comprising at least a fragment of DNA encoding the carbohydrate-binding module ligated, with or without a linker, to a DNA sequence encoding the polypeptide of interest, and growing the transformed host cell to express the fused gene.
  • the CBM in a polypeptide of the invention may be positioned C-terminally, N-terminally or internally in polypeptide.
  • a polypeptide may comprise more than one CBM, e.g., two CBMs; one positioned C-terminally, the other N-terminally or the two CBMs in tandem positioned C-terminally, N-terminally or internally.
  • polypeptides with more than two CBMs are equally contemplated.
  • the invention relates to alpha-amylase polypeptides useful as donors (parent amylases) of CBMs, linkers and/or catalytic modules.
  • the polypeptide of the invention may be a wild type alpha-amylase enzyme (EC 3.2.1.1) or the polypeptide may also be a variant of such a wild type enzyme.
  • the polypeptide of the invention may be a fragment of such an enzyme, e.g., such as a catalytic domain, i.e., a fragment having alpha-amylase activity but which is separated from a CBM if such is present in the wild-type enzyme, or such as a CBM, i.e., a fragment having a carbohydrate binding module.
  • It may also be a hybrid enzyme comprising a fragment of such an alpha-amylase enzyme, e.g., comprising a catalytic domain, a linker and/or a CBM derived from an alpha-amylase enzyme of the invention.
  • polypeptide of the invention may be a fragment of such an enzyme, e.g., a fragment which still comprises a functional catalytic domain as well as a CBM if such is present in the wild type enzyme, or, e.g., a fragment of a wild-type enzyme, which wild-type enzyme does not comprise a CBM, and wherein said fragment comprises a functional catalytic domain.
  • Alpha-amylase enzymes The invention relates to novel polypeptides comprising a carbohydrate-binding module ("CBM") and aving alpha-amylase activity.
  • CBM carbohydrate-binding module
  • Such polypeptides may be derived from any organism, preferred are those of fungal or bacterial origin.
  • the alpha-amylases of the invention include alpha-amylases obtainable from a species within a genus selected from the list consisting of Absidia, Acremonium, Coniochaeta, Coriolus, Cryptosporiopsis, Dichotomocladium, Dinemasporium, Diplodia, Fusarium, Gliocladium, Malbranchea, Meripilus, Necteria, Penicillium, Rhizomucor, Stereum, Streptomyces, Subulispora, Syncephalastrum, Thamindium, Thermoascus, Thermomyces, Trametes, Trichophaea and Valsaria.
  • the alpha-amylase may be derived from any genus, species or sequence listed in table 1.
  • the alpha-amylase is derived from any species selected from the group consisting of Thermomyces lanuginosus; in particular a polypeptide having the amino acids 1-441 in SEQ ID NO: 14, Malbranchea sp.; in particular a polypeptide having the amino acids 1-471 in SEQ ID NO: 18, Rhizomucor pusillus; in particular a polypeptide having the amino acids 1-450 in SEQ ID NO: 20, Dichotomocladium hesseltinei; in particular a polypeptide having the amino acids 1-445 in SEQ ID NO: 22, Stereum sp.; in particular a polypeptide having the amino acids 1-498 in SEQ ID NO: 26, Trametes sp.; in particular a polypeptide having the amino acids 18-513 in SEQ ID NO: 28, Coriolus consors; in particular a polypeptide having the amino acids 1-507 in SEQ ID NO: 30, Dinemasporium sp.; in particular a polypeptide having the amino acids 1
  • alpha-amylase amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or even at least 98% homology to the mature peptide of any of the aforementioned polypeptides.
  • the alpha-amylase amino acid sequence have an amino acid sequence which differs from any of the aforementioned amino acid sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • alpha-amylase amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or even at least 98% homology to any sequence selected from the group consisting of the polynucleotides shown as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID
  • SEQ ID NO: 13 SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 , SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 41 , SEQ ID NO: 114, SEQ ID NO:
  • alpha-amylase amino acid sequence encoded by a DNA sequence which hybridizes under low, medium, midium/high, high and/or very high stringency to any of the aforementioned alpha-amylase DNA sequences.
  • DNA sequences encoding an alpha-amylase amino acid sequence and having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or even 100% homology any of the aforementioned alpha-amylase DNA sequences.
  • Alpha-amylase catalytic domains in one embodiment the invention relates to catalytic domains derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity, such as catalytic domains derived from a polypeptide selected from the alpha-amyiases shown in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 115, SEQ ID NO:
  • CBM carbohydrate-binding module
  • amino acids 1-441 in SEQ ID NO: 14 are the catalytic domains shown in the amino acids 1-441 in SEQ ID NO: 14, the amino acids 1-471 in SEQ ID NO: 18, the amino acids 1-450 in SEQ ID NO: 20, the amino acids 1- 445 in SEQ ID NO: 22, the amino acids 1-498 in SEQ ID NO: 26, the amino acids 18-513 in SEQ ID NO: 28, the amino acids 1-507 in SEQ ID NO: 30, the amino acids 1-481 in SEQ ID NO: 32, the amino acids 1-495 in SEQ ID NO: 34, the amino acids 1-477 in SEQ ID NO: 38, the amino acids 1-449 in SEQ ID NO: 42, the amino acids 1-442 in SEQ ID NO: 115, the amino acids 1-441 in SEQ ID NO: 117, the amino acids 1-477 in SEQ ID NO: 125, the amino acids 1-446 in SEQ ID NO: 131 , the amino acids
  • catalytic domain sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned catalytic domain sequences.
  • the catalytic domain sequence have an amino acid sequence which differs from any of the aforementioned catalytic domain sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • Linker sequences In one embodiment the invention relates to linker sequences derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity.
  • CBM carbohydrate-binding module
  • linker amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned linker sequences.
  • the linker sequence have an amino acid sequence which differs from any of the aforementioned linker sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • Carbohvdrate-bindin ⁇ modules In one embodiment the invention relates to CBMs derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity, said CBM derived from a polypeptide selected from the alpha- amylases shown in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 131 , SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161 , SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 173, SEQ
  • a CBM amino acid sequence selected from the group consisting of the sequence having the amino acids 529-626 in SEQ ID NO: 159, the amino acids 533-630 in SEQ ID NO: 161 , the amino acids 508-602 in SEQ ID NO: 163, the amino acids 540-643 in SEQ ID NO: 165, the amino acids 502-566 in SEQ ID NO: 167, the amino acids 513-613 in SEQ ID NO: 169, the amino acids 492-587 in SEQ ID NO: 173, the amino acids 30-287 in SEQ ID NO: 175, the amino acids 487-586 in SEQ ID NO: 177 and the amino acids 482-582 in SEQ ID NO: 179.
  • CBM amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned CBM amino acid sequences.
  • the CBM sequence have an amino acid sequence which differs from any of the aforementioned CBM sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • SEQ ID NO: 1 SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ JD NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 154 and SEQ ID NO
  • the DNA sequences shown as nucleotides 1504-1701 in SEQ ID NO: 166 and nucleotides 61-861 in SEQ ID NO: 174 and the encoded amino acid sequences comprise in addition to the CBD also a linker sequence.
  • Table 1 The DNA sequences shown as nucleotides 1504-1701 in SEQ ID NO: 166 and nucleotides 61-861 in SEQ ID NO: 174 and the encoded amino acid sequences comprise in addition to the CBD also a linker sequence.
  • the alpha-amylase polypeptides may be applied in starch degradation processes and/or used as donors of catalytic domain and/or CBM for a hybrid polypeptide.
  • a preferred polypeptide of the invention e.g., a hybrid polypeptide, comprises a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module, wherein said second amino acid sequence has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of amino acids 529-626 in SEQ ID NO: 159, the amino acids 533-630 in SEQ ID NO: 161 , the amino acids 508-602 in SEQ ID NO: 163, the amino acids 540-643 in SEQ ID NO: 165, the amino acids 502-566 in SEQ ID NO: 167, the amino acids 513-613 in SEQ ID NO: 169, the amino acids
  • polypeptides e.g., hybrid polypeptides, wherein said first amino acid sequence has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, the amino acids 1-471 in SEQ ID NO: 18, the amino acids 1-450 in SEQ ID NO: 20, the amino acids 1-445 in SEQ ID NO: 22, the amino acids 1- 498 in SEQ ID NO: 26, the amino acids 18-513 in SEQ ID NO: 28, the amino acids 1-507 in SEQ ID NO: 30, the amino acids 1-481 in SEQ ID NO: 32, the amino acids 1-495 in SEQ ID NO: 34, the amino acids 1-477 in SEQ ID NO: 38, the amino acids 1-449 in SEQ ID NO: 42, the amino acids 1-442 in SEQ ID NO: 115, the amino acids 1-441 in SEQ ID NO: 117, the amino acids 1-477 in SEQ ID NO: 14
  • polypeptides e.g., hybrid polypeptides, wherein a linker sequence is present in a position between said first and said second amino acid sequence, said linker sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of as amino acids 503-528 in SEQ ID NO: 159, amino acids 500-532 in SEQ ID NO: 161, amino acids 493-507 in SEQ ID NO: 163, amino acids 497-539 in SEQ ID NO: 165, amino acids 488-512 in SEQ ID NO: 169 in 478-491 in SEQ ID NO: 173, amino acids 472-486 in SEQ ID NO: 177 and amino acids 471-481 in SEQ ID NO: 179.
  • Catalytic domains i.e., alpha-amylase catalytic domains (in particular acid stable alpha- amylases), which are appropriate for construction of polypeptides of the types of the present invention may be derived from any organism, preferred are those of fungal or bacterial origin.
  • the alpha-amylase is a wild type enzyme. More preferably the alpha-amylase is a variant alpha-amylases comprising amino acid modifications leading to increased activity, increased protein stability at low pH, and/or at high pH, increased stability towards calcium depletion, and/or increased stability at elevated temperature.
  • alpha-amylases for use in a hybrid of the invention include alpha-amylases obtainable from a species selected from the list consisting of Absidia, Acremonium, Aspergillus, Coniochaeta, Coniochaeta, Cryptosporiopsis, Dichotomocladium, Dinemasporium sp., Diplodia, Fusarium, Gliocladium, Malbranchea, Meripilus Trametes, Nectria, Nectria, Penicillium, Phanerochaete, Rhizomucor, Rhizopus, Streptomyces, Subulispora, Syncephalastrum, Thaminidium, Thermoasc ⁇ s, Thermomyces, Trametes, Trichophaea and Valsaria.
  • the alpha-amylases catalytic domain may also be derived from a bacteria, e.g., Bacillus.
  • the alpha-amylases amino acid sequence selected is derived from any species selected from the group consisting of Absidia cristata, Acremonium sp., Aspergillus niger, Aspergillus kawachii, Aspergillus oryzae, Coniochaeta sp., Coniochaeta sp., Cryptosporiopsis sp., Dichotomocladium hesseltinei, Dinemasporium sp., Diplodia sp., Fusarium sp., Gliocladium sp., Malbranchea sp., Meripilus giganteus, Nectria sp., Nectria sp., Penicillium sp., Phanerochaete chrysosporium, Rhizomucor pusillus, Rhizopus oryzae, Stereum sp.
  • Absidia cristata Acremonium s
  • Streptomyces thermocyaneoviolaceus Streptomyces limosus, Subulispora procurvata, Syncephalastrum racemosum, Thaminidium elegans, Thermoascus aurantiacus, Thermoascus sp., Thermomyces lanuginosus, Trametes corrugata, Trametes sp., Trichophaea saccata, Valsaria rubricosa, Valsaria spartii and Bacillus flavothermus (Syn. Anoxybacillus contaminans).
  • the hybrid comprises an alpha-amylase amino acid sequence selected from the group consisting of the alpha-amylase catalytic modules listed in table 1 or 2.
  • the hybrid comprises an alpha-amylase amino acid sequence selected from the group consisting of the alpha-amylases from Aspergillus niger (SEQ ID NO: 2), Aspergillus oryzae (SEQ ID NO: 4 and SEQ ID NO: 6), Trichophaea saccata (SEQ ID NO: 8), Subulispora procurvata (SEQ ID NO: 10), Valsaria rubricosa (SEQ ID NO: 12), Thermomyces lanuginosus (SEQ ID NO: 14), Acremonium sp. (SEQ ID NO: 16), Malbranchea sp.
  • SEQ ID NO: 2 Aspergillus niger
  • SEQ ID NO: 4 and SEQ ID NO: 6 Trichophaea saccata
  • Subulispora procurvata SEQ ID NO: 10
  • Valsaria rubricosa SEQ ID NO: 12
  • Thermomyces lanuginosus SEQ ID NO: 14
  • SEQ ID NO: 18 Rhizomucor pusillus
  • SEQ ID NO: 20 Dichotomocladium hesseltinei
  • SEQ ID NO: 24 Meripilus giganteus
  • SEQ ID NO: 24 Stereum sp. AMY1179
  • SEQ ID NO: 26 Trametes sp.
  • SEQ ID NO: 28 Coriolus censors
  • SEQ ID NO: 30 Dinemasporium sp.
  • SEQ ID NO: 34 Cryptosporiopsis sp.
  • Coniochaeta sp. SEQ ID NO: 36
  • Diplodia sp. SEQ ID NO: 38
  • SEQ ID NO: 40 Gliocladium sp.
  • SEQ ID NO: 42 Streptomyces thermocyaneoviolaceus
  • SEQ ID NO: 44 Thermoascus sp. Il
  • SEQ ID NO: 111 Coniochaeta sp.
  • SEQ ID NO: 113 Nectria sp.
  • SEQ ID NO: 115 Fusarium sp.
  • Trametes corrugata SEQ ID NO: 119
  • SEQ ID NO: 121 Valsaria spartii (SEQ ID NO: 123), Thermoascus aurantiacus (SEQ ID NO: 125), Phanerochaete chrysosporium (SEQ ID NO: 127), Rhizopus oryzae (SEQ ID NO: 129), Thaminidium elegans (SEQ ID NO: 131), Absidia cristata (SEQ ID NO: 133), Syncephalastrum racemosum (SEQ ID NO: 135) and Streptomyces limosus (SEQ ID NO: 155).
  • hybrids comprising a alpha-amylase amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO:
  • the hybrid enzyme has a alpha-amylase sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111 , SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO:
  • hybrids comprising a alpha-amylases amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 , SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO:
  • hybrids comprising a alpha-amylase encoded by a DNA sequence hybridizing under low, medium, midium/high, high and/or very high stringency to any DNA sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3,
  • SEQ ID NO: 114 SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122,
  • the linker sequence may be any suitable linker sequence, e.g., a linker sequence derived from an alpha-amylase or a glucoamylase.
  • the linker may be a bond, or a short linking group comprising from about 2 to about 100 carbon atoms, in particular of from 2 to 40 carbon atoms.
  • the linker is preferably a sequence of from about 2 to about 100 amino acid residues, more preferably of from 4 to 40 amino acid residues, such as from 6 to 15 amino acid residues.
  • the hybrids comprising a linker sequence derived from any species selected from the group consisting of Acremonium, Coniochaeta, Coniochaeta, Meripilus, Pachykytospora, Penicillium, Sublispora, Trametes, Trichophaea, Valsaria, Athelia, Aspergillus, Trametes and Leucopaxillus.
  • the linker may also be derived from a bacterium, e.g., from a strain within Bacillus sp.
  • linker is derived from a species selected from the group consisting of Acremonium sp., Coniochaeta sp., Coniochaeta sp., Meripilus giganteus, Penicillium sp., Sublispora provurvata, Trametes corrugata, Trichophaea saccata, Valsaria rubricosa, Valsario spartii, Aspergillus kawachii, Aspergillus niger, Athelia rolfsii, Leucopaxillus gigantus, Pachykytospora papayracea, Trametes cingulata and Bacillus flavothermus.
  • the hybrid comprises a linker amino acid sequence selected from the group consisting of the linkers listed in table 1 or 2.
  • the linker is a linker from a glucoamylase selected from the group consisting of Pachykytospora papayracea (SEQ ID NO: 46), Trametes cingulata (SEQ ID NO: 48), Leucopaxillus gigantus (SEQ ID NO: 50), Athelia rolfsii (SEQ ID NO: 68), Aspergillus kawachii (SEQ ID NO: 70), Aspergillus niger (SEQ ID NO: 72) or a linker from an alpha-amylase selected from the group consisting of Sublispora provurvata (SEQ ID NO: 54), Valsaria rubricosa (SEQ ID NO: 56), Acremonium sp.
  • a glucoamylase selected from the group consisting of Pachykytospora papayracea (SEQ ID NO: 46), Trametes cingulata (SEQ ID NO: 48), Leucopaxillus gigantus (SEQ
  • SEQ ID NO: 58 Meripilus giganteus
  • SEQ ID NO: 60 Meripilus giganteus
  • Bacillus flavothermus SEQ ID NO: 62, SEQ ID NO: 64 or SEQ ID NO: 66
  • Coniochaeta sp. AM603 SEQ ID NO: 74
  • Coniochaeta sp. SEQ ID NO: 145
  • Trametes corrugata SEQ ID NO: 147
  • Valsario spartii SEQ ID NO: 149
  • Penicillium sp. SEQ ID NO: 151
  • Trichophaea saccata SEQ ID NO: 52.
  • linker amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149 and SEQ ID NO: 151.
  • the hybrid enzyme has a linker sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149 and SEQ ID NO: 151 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • hybrids comprising a linker sequence encoded by a DNA sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51 , SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71 , SEQ ID NO: 73, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, and SEQ ID NO: 150.
  • hybrids comprising a linker sequence encoded by a DNA sequence hybridizing under high, medium or low stringency to any DNA sequence selected from the group consisting SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51 , SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61 , SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71 , SEQ ID NO: 73, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, and SEQ ID NO: 150.
  • the linker originating from the CBM source is used, e.g., when using the CBM from A. rolfsii glucoamylase the linker sequence from the A. rolfsii glucoamylase is used in the hybrid as well.
  • a carbohydrate-binding module or as often referred to, a carbohydrate- binding domain (CBM) is a polypeptide amino acid sequence which binds preferentially to a poly- or oligosaccharide (carbohydrate), frequently - but not necessarily exclusively - to a water-insoluble (including crystalline) form thereof.
  • CBMs derived from starch degrading enzymes are often referred to as starch-binding modules or SBMs (CBMs which may occur in certain amylolytic enzymes, such as certain glucoamylases (GA), or in enzymes such as cyclodextrin glucanotransferases, or in alpha- amylases).
  • CBMs cellulose-binding modules
  • CBMs from cellulolytic enzymes
  • CBMs chitin-binding modules
  • CBMs which typically occur in chitinases
  • xylan-binding modules CBMs which typically occur in xylanases
  • mannan-binding modules CBMs which typically occur in mannanases
  • SBMs are often referred to as SBDs (Starch Binding Domains).
  • CBMs are found as integral parts of large polypeptides or proteins consisting of two or more polypeptide amino acid sequence regions, especially in hydrolytic enzymes (hydrolases) which typically comprise a catalytic module containing the active site for substrate hydrolysis and a carbohydrate-binding module (CBM) for binding to the carbohydrate substrate in question.
  • hydrolytic enzymes hydrolytic enzymes
  • Such enzymes can comprise more than one catalytic module and one, two or three CBMs and optionally further comprise one or more polypeptide amino acid sequence regions linking the CBM(s) with the catalytic module(s), a region of the latter type usually being denoted a "linker".
  • hydrolytic enzymes comprising a CBM - some of which have already been mentioned above - are cellulases, xylanases, mannanases, arabinofuranosidases, acetylesterases and chitinases.
  • CBMs have also been found in algae, e.g., in the red alga Porphyra purpurea in the form of a non-hydrolytic polysaccharide-binding protein.
  • proteins/polypeptides in which CBMs occur e.g., enzymes, typically hydrolytic enzymes
  • a CBM may be located at the N or C terminus or at an internal position.
  • That part of a polypeptide or protein (e.g., hydrolytic enzyme) which constitutes a CBM per se typically consists of more than about 30 and less than about 250 amino acid residues.
  • the "Carbohydrate-Binding Module of Family 20" or a CBM-20 module is in the context of this invention defined as a sequence of approximately 100 amino acids having at least 45% homology to the Carbohydrate-Binding Module (CBM) of the polypeptide disclosed in figure 1 by Joergensen et al. (1997) in Biotechnol. Lett. 19:1027-1031.
  • the CBM comprises the last 102 amino acids of the polypeptide, i.e., the subsequence from amino acid 582 to amino acid 683.
  • Examples of enzymes which comprise a CBM suitable for use in the context of the invention are alpha-amylases, maltogenic alpha-amylases, cellulases, xylanases, mannanases, arabinofuranosidases, acetylesterases and chitinases.
  • Further CBMs of interest in relation to the present invention include CBMs deriving from glucoamylases (EC 3.2.1.3) or from CGTases (EC 2.4.1.19).
  • CBMs deriving from fungal, bacterial or plant sources will generally be suitable for use in the hybrid of the invention.
  • Preferred are CBMs of fungal origin.
  • techniques suitable for isolating the relevant genes are well known in the art.
  • hybrids comprising a CBM of Carbohydrate-Binding Module Family 20, 21 or 25.
  • CBMs of Carbohydrate-Binding Module Family 20 suitable for the invention may be derived from glucoamylases of Aspergillus awamori (SWISSPROT Q12537), Aspergillus kawachii (SWISSPROT P23176), Aspergillus niger (SWISSPROT P04064), Aspergillus oryzae (SWISSPROT P36914), from alpha-amylases of Aspergillus kawachii (EMBL:#AB008370), Aspergillus nidulans (NCBI AAF17100.1), from beta-amylases of Bacillus cereus (SWISSPROT P36924), or from CGTases of Bacillus circulans fSWISSPROT P43379).
  • CBM from the alpha-amylase of Aspergillus kawachii (EMBL:#AB008370) as well as CBMs having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the CBM of the alpha-amylase of Aspergillus kawachii (EMBL:#AB008370).
  • Further preferred CBMs include the CBMs of the glucoamylase from Hormoconis sp. such as from Hormoconis resinae (Syn.
  • Creosote fungus or Amorphotheca resinae such as the CBM of SWISSPROT:Q03045. from Lentinula sp. such as from Lentinula edodes (shiitake mushroom) such as the CBM of SPTREMBL:Q9P4C5, from Neurospora sp. such as from Neurospora crassa such as the CBM of SWISSPROT:P14804, from Talaromyces sp. such as from Talaromyces byssochlamydioides, from Geosmithia sp. such as from Geosmithia cylindrospora, from Scorias sp.
  • the hybrid comprises a CBM which is derived from any family or species selected from the group consisting of Acremonium, Aspergillus, Athelia, Coniochaeta, Cryptosporiopsis, Dichotomocladium, Dinemasporium, Diplodia, Gliocladium, Leucopaxillus, Malbranchea, Meripilus, Nectria, Pachykytospora, Penicillium, Rhizomucor, Rhizomucor pusillus, Streptomyces, Subulispora, Thermomyces, Trametes, Trichophaea saccata and Valsaria.
  • CBM which is derived from any family or species selected from the group consisting of Acremonium, Aspergillus, Athelia, Coniochaeta, Cryptosporiopsis, Dichotomocladium, Dinemasporium, Diplodia, Gliocladium, Leucopaxillus, Malbranchea, Meripilus, Ne
  • the CBM may also be derived from a plant, e.g., from corn (e.g., Zea mays) or a bacterial, e.g., Bacillus. More preferably the hybrid comprises a CBM derived from any species selected from the group consisting of Acremonium sp., Aspergillus kawachii, Aspergillus niger,Aspergillus oryzae, Athelia rolfsii, Bacillus flavothermus, Coniochaeta sp., Cryptosporiopsis sp., Dichotomocladium hesseltinei, Dinemasporium sp., Diplodia sp., Gliocladium sp., Leucopaxillus gigantus, Malbranchea sp, Meripilus giganteus, Nectria sp., Pachykytospora papayracea, Penicillium sp., Rhizomucor pusillus
  • the hybrid comprises a CBM amino acid sequence selected from the group consisting of the CBMs listed in table 1 or 2.
  • the hybrid comprises a CBM from a glucoamylase selected from the group consisting of the Pachykytospora papayracea (SEQ ID NO: 76), Trametes cingulata (SEQ ID NO: 78), Leucopaxillus gigantus (SEQ ID NO: 80), Athelia rolfsii (SEQ ID NO: 92), Aspergillus kawachii (SEQ ID NO: 94), Aspergillus niger (SEQ ID NO: 96) or from a alpha- amylase selected from the group consisting of Trichopheraea saccata (SEQ ID NO: 52), Subulispora provurvata (SEQ ID NO: 82), Valsaria rubricosa (SEQ ID NO: 84), Acremonium sp.
  • a glucoamylase selected from the group consisting of the Pachykytospora papayracea (SEQ ID NO: 76), Trametes cing
  • SEQ ID NO: 86 Meripilus giganteus
  • SEQ ID NO: 88 Meripilus giganteus
  • Bacillus flavothermus SEQ ID NO: 90
  • Coniochaeta sp. SEQ ID NO: 98
  • Zea mays SEQ ID NO: 109
  • Coniochaeta sp. SEQ ID NO: 137
  • Trametes corrugata SEQ ID NO: 139
  • Valsaho spartii SEQ ID NO: 141)
  • Penicillium sp. SEQ ID NO: 143.
  • the hybrid enzyme has a CBM sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO:
  • CBMs of Carbohydrate-Binding Module Family 20, 21 or 25 may be found at URL: http://afmb.cnrs-mrs.fr/ ⁇ cazy/CAZY/index.html).
  • a nucleotide sequence encoding the substrate-binding (carbohydrate-binding) region may then be manipulated in a variety of ways to fuse it to a DNA sequence encoding the polypeptide of interest.
  • the DNA fragment encoding the carbohydrate-binding amino acid sequence and the DNA encoding the polypeptide of interest are then ligated with or without a linker.
  • the resulting ligated DNA may then be manipulated in a variety of ways to achieve expression.
  • the polypeptide comprises a CDM derived from Athelia rolfsii, Pachykytospora papayracea, Valsaria rubricosa or M ⁇ ripilus giganteus.
  • the polypeptide comprises an alpha-amylase sequence derived from the A. oryzae acid alpha-amylase (SEQ ID NO: 4), Preferably the wherein said A. oryzae amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of A128P, K138V, S141 N, Q143A, D144S, Y155W, E156D, D157N, N244E, M246L, G446D, D448S and N450D. Most preferably the polypeptide comprises an catalytic domain having the amino acid sequence shown in SEQ ID NO: 6. In a preferred embodiment the polypeptide further comprises a CBM derived from A.
  • the polypeptide further comprises a CBM having the amino acid sequence shown in SEQ ID NO: 92.
  • the polypeptide has the amino acid sequence shown in SEQ ID NO: 100 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the afore mentioned amino acid sequence.
  • polypeptide comprises a catalytic module derived from the Rhizomucor pusillus alpha-amylase and/or a CBM derived from A. rolfsii.
  • polypeptide has the amino acid sequence shown in SEQ ID NO: 101 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the afore mentioned amino acid sequence.
  • the polypeptide comprises a catalytic module derived from the Meripilus giganteus alpha-amylase and/or a CBM derived from A. rolfsii.
  • the polypeptide has the amino acid sequence shown in SEQ ID NO: 102 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the afore mentioned amino acid sequence.
  • polypeptide has an amino acid sequence which differs from any the amino acid sequence amino acid sequences shown in SEQ ID NO: 100, SEQ ID NO: 101 and SEQ ID NO: 102 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
  • Other preferred embodiments of the polypeptides of the invention are shown in table 3,
  • the polypeptide comprises a catalytic domain having at least 75% homology to the A. oryzae catalytic domain (SEQ ID NO: 6) and a CBM having at least 75% homology to a CBM selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 52, SEQ . ID NO: 92, SEQ ID NO: 52, and SEQ ID NO: 90.
  • the polypeptide comprises the A.
  • oryzae catalytic domain (SEQ ID NO: 6) and a CBM selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 52, SEQ ID NO: 92, SEQ ID NO: 52, SEQ ID NO: 90, SEQ ID NO: 90 and SEQ ID NO: 90.
  • the polypeptide comprises a CBM having at least 75% homology to the A. rolfsii glucoamylase CBM (SEQ ID NO: 92) and a catalytic domain having at least 75% homology to a catalytic domain selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 155, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 123, SEQ ID NO: 125,
  • the polypeptide comprises the A. rolfsii glucoamylase CBM (SEQ ID NO: 92) and a catalytic domain selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 155, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111 , SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 121 , SEQ ID NO: 127, SEQ ID NO: 129
  • the polypeptide comprises a CBM having at least 75% homology the Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145 and a catalytic domain having at least 75% homology to a CBM selected from the group consisting of the Acremonium sp. alpha-amylase CBM in SEQ ID NO: 16, the Rhizomucor pusillus alpha-amylase CBM in SEQ ID NO: 20 and the Meripilus giganteus alpha-amylase CBM in SEQ ID NO: 24.
  • the polypeptide comprises the Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145 and a CBM selected from the group consisting of the Acremonium sp. alpha-amylase CBM in SEQ ID NO: 16, the Rhizomucor pusillus alpha-amylase CBM in SEQ ID . NO: 20 and the Meripilus giganteus alpha-amylase CBM in SEQ ID NO: 24.
  • the polypeptide comprises a catalytic domain having at least 75% homology to the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM having at least 75% homology to a CBM selected from the group consisting of Aspergillus kawachii glucoamylase CBM SEQ ID NO: 94 and the Aspergillus niger glucoamylase CBM in SEQ ID NO: 96.
  • the polypeptide comprises the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM selected from the group consisting of Aspergillus kawachii glucoamylase CBM SEQ ID NO: 94 and the Aspergillus niger glucoamylase CBM in SEQ ID NO: 96.
  • the polypeptide comprises a catalytic domain having at least 75% homology to the Meripilus giganteus alpha-amylase catalytic domain (SEQ ID NO: 24) and a CBM having at least 75% homology to a CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109.
  • SEQ ID NO: 24 Meripilus giganteus alpha-amylase catalytic domain
  • CBM having at least 75% homology to a CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109
  • the polypeptide comprises the Meripilus giganteus alpha-amylase catalytic domain (SEQ ID NO: 24) and a CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109.
  • SEQ ID NO: 24 Meripilus giganteus alpha-amylase catalytic domain
  • CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109.
  • the polypeptide comprises a catalytic domain having at least 75% homology to the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM having at least 75% homology to a CBM selected from the group consisting of the A. rolfsii glucoamylase CBM in SEQ ID NO: 92 and the Zea mays CBM in SEQ ID NO: 109, the Coniochaeta sp.
  • the polypeptide comprises the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM selected from the group consisting of the A.
  • the polypeptide is selected from the group consisting of V001 , V002, V003, V004, V005, V006, V007, V008, V009, V010, V011 , V012, V013, V014, V015, V016, V017, V018, V019, V021 , V022, V023, V024, V025, V026, V027, V028, V029, V030, V031 , V032, V033, V034, V035, V036, V037, V038, V039, V040, V041 , V042, V043, V047, V048, V049, V050, V051 , V052, V054, V055, V057, V059, V060, V061 , V063, V064, V065, V066, V067, V068 and V069.
  • Expression vectors which may comprise a DNA sequence encoding the polypeptide, a promoter, a signal peptide sequence and transcriptional and translational stop signals.
  • the various DNA and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the DNA sequence encoding the polypeptide at such sites.
  • the DNA sequence of the present invention may be expressed by inserting the DNA sequence or a DNA construct comprising the sequence into an appropriate vector for expression.
  • the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression and possibly secretion.
  • the recombinant expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the DNA sequence.
  • the choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.
  • the vectors may be linear or closed circular plasmids.
  • the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, a cosmid or an artificial chromosome.
  • the vector may contain any means for assuring self-replication.
  • the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
  • the vectors of the present invention preferably contain one or more selectable markers, which permit easy selection of transformed cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs and the like.
  • selectable markers for use in a filamentous fungus host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphor-transferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species.
  • amdS acetamidase
  • argB ornithine carbamoyltransferase
  • bar phosphinothricin acetyltransferase
  • hygB hygromycin phosphor-trans
  • amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus.
  • selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.
  • the vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.
  • the vectors of the present invention may be integrated into the host cell genome when introduced into a host cell.
  • the vector may rely on the DNA sequence encoding the polypeptide of interest or any other element of the vector for stable integration of the vector into the genome by homologous or none homologous recombination.
  • the vector may contain additional DNA sequences for directing integration by homologous recombination into the genome of the host cell. The additional DNA sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s).
  • the integrational elements should preferably contain a sufficient number of DNAs, such as 100 to 1 ,500 base pairs, preferably 400 to 1 ,500 base pairs, and most preferably 800 to 1 ,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination.
  • the integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell.
  • the integrational elements may be non-encoding or encoding DNA sequences.
  • the vector may be integrated into the genome of the host cell by non-homologous recombination.
  • These DNA sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
  • the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
  • the episomal replicating the AMA1 plasmid vector disclosed in WO 00/24883 may be used.
  • More than one copy of a DNA sequence encoding a polypeptide of interest may be inserted into the host cell to amplify expression of the DNA sequence.
  • Stable amplification of the DNA sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome using methods well known in the art and selecting for transformants.
  • the host cell of the invention is advantageously used as a host cell in the recombinant production of the polypeptide, e.g., a hybrid enzyme, a wild- type enzyme or a genetically modified wild-type enzyme.
  • the cell may be transformed with an expression vector.
  • the cell may be transformed with the DNA construct of the invention encoding the the polypeptide, e.g., a hybrid enzyme, a wild type enzyme or a genetically modified wild type enzyme, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. Integration of the DNA construct into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination.
  • the host cell may be any appropriate prokaryotic or eukaryotic cell, e.g., a bacterial cell, a filamentous fungus cell, a yeast, a plant cell or a mammalian cell.
  • the filamentous fungus includes all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al. In,
  • the filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic.
  • the filamentous fungus host cell is a cell of a species of, but not limited to a cell selected from the group consisting of a strain belonging to a species of Aspergillus, preferably Aspergillus oryzae, Aspergillus niger, Aspergillus awamori, Aspergillus kawachii, or a strain of Bacillus, or a strain of Fusarium, such as a strain of Fusarium oxysporium, Fusarium graminearum (in the perfect state named
  • Gribberella zeae previously Sphaeria zeae, synonym with Gibberella roseum and Gibberella roseum f. sp. cerealis), or Fusarium sulphureum (in the prefect state named Gibberella puricaris, synonym with Fusarium trichothecioides, Fusarium bactridioides, Fusarium sambucium, Fusarium roseum, and Fusarium roseum var. graminearum), Fusarium cerealis (synonym with Fusarium crookwellense), or Fusarium venenatum.
  • the filamentous fungus host cell may be a wild type filamentous fungus host cell or a variant, a mutant or a genetically modified filamentous fungus host cell.
  • the host cell is a protease deficient or protease minus strain.
  • Aspergillus strains such as Aspergillus niger strains, genetically modified to disrupt or reduce expression of glucoamyiase, acid-stable alpha- amylase, alpha-1,6 transglucosidase, and protease activities.
  • Filamentous fungus host cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known in the art. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023, EP 184 438, and Yelton et al. 1984, Proceedings of the National Academy of Sciences USA 81 :1470-1474. A suitable method of transforming Fusarium species is described by Malardier et al. 1989, Gene 78:147-156 or U.S. Patent No. 6,060,305.
  • Isolating and cloning a DNA sequence encoding a parent alpha-amylase The techniques used to isolate or clone a DNA sequence encoding a polypeptide of interest are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof.
  • the cloning of the DNA sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., lnnis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York.
  • Other DNA amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and DNA sequence-based amplification (NASBA) may be used.
  • LCR ligase chain reaction
  • LAT ligated activated transcription
  • NASBA DNA sequence-based amplification
  • the DNA sequence encoding a parent alpha-amylase may be isolated from any cell or microorganism producing the alpha-amylase in question, using various methods well known in the art.
  • a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the alpha-amylase to be studied.
  • labeled oligonucleotide probes may be synthesized and used to identify alpha-amylase-encoding clones from a genomic library prepared from the organism in question.
  • a labelled oligonucleotide probe containing sequences homologous to another known alpha-amylase gene could be used as a probe to identify alpha-amylase-encoding clones, using hybridization and washing conditions of very low to very high stringency.
  • Yet another method for identifying alpha-amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming alpha-amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for alpha-amylase (i.e., maltose), thereby allowing clones expressing the alpha-amylase to be identified.
  • an expression vector such as a plasmid
  • transforming alpha-amylase-negative bacteria with the resulting genomic DNA library
  • the DNA sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g., the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al. (1984), EMBO J. 3, p. 801-805.
  • the phosphoroamidite method oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.
  • the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques.
  • the DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in U.S. Patent No. 4,683,202 or R. K. Saiki et al. (1988), Science 239, 1988, pp. 487-491.
  • the present invention relates, inter alia, to an isolated DNA sequence comprising a DNA sequence encoding a polypeptide, e.g., a hybrid enzyme, a wild type enzyme or a genetically modified wild type enzyme comprising an amino acid sequence of a catalytic module having alpha-amylase activity and an amino acid sequence of a carbohydrate- binding module, wherein the catalytic module is of fungal origin.
  • a polypeptide e.g., a hybrid enzyme, a wild type enzyme or a genetically modified wild type enzyme comprising an amino acid sequence of a catalytic module having alpha-amylase activity and an amino acid sequence of a carbohydrate- binding module, wherein the catalytic module is of fungal origin.
  • isolated DNA sequence refers to a DNA sequence, which is essentially free of other DNA sequences, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis.
  • an isolated DNA sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the DNA sequence from its natural location to a different site where it will be reproduced.
  • the cloning procedures may involve excision and isolation of a desired DNA fragment comprising the DNA sequence encoding the polypeptide of interest, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the DNA sequence will be replicated.
  • An isolated DNA sequence may be manipulated in a variety of ways to provide for expression of the polypeptide of interest. Manipulation of the DNA sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying DNA sequences utilizing recombinant DNA methods are well known in the art.
  • the present invention relates, inter alia, to a DNA construct comprising a DNA sequence encoding a polypeptide, e.g., a hybrid enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module or a wild type enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module.
  • a hybrid enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module
  • a hybrid enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module
  • a wild type enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-
  • DNA construct is defined herein as a DNA molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of DNA, which are combined and juxtaposed in a manner, which would not otherwise exist in nature.
  • DNA construct is synonymous with the term expression cassette when the DNA construct contains all the control sequences required for expression of a coding sequence of the present invention.
  • mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
  • a single-stranded gap of DNA, the alpha-amylase- encoding sequence is created in a vector carrying the alpha-amylase gene.
  • the synthetic nucleotide, bearing the desired mutation is annealed to a homologous portion of the single- stranded DNA.
  • the remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase.
  • the random mutagenesis may be advantageously localized to a part of the parent alpha-amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.
  • the localized or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art.
  • the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g., by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.
  • the performance in a starch degradation process of a wild type or hybrid enzyme comprising a carbohydrate-binding module (“CBM”) and an alpha-amylase catalytic module may be improved through protein engineering, such as by site directed mutagenesis, by localized random mutagenesis, by synthetically preparing a new variant of the parent wild type enzyme or parent hybrid enzyme, or by any other suitable protein engineering techniques.
  • the variants may be produced using conventional protein engineering techniques.
  • the nucleotide sequence to be introduced into the DNA of the host cell may be integrated in nucleic acid constructs comprising the nucleotide sequence operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
  • a nucleotide sequence encoding a polypeptide may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleotide sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleotide sequences utilizing recombinant DNA methods are well known in the art.
  • the control sequence may be an appropriate promoter sequence, a nucleotide sequence which is recognized by a host cell for expression of the nucleotide sequence.
  • the promoter sequence contains transcriptional control sequences, which mediate the expression of the polypeptide.
  • the promoter may be any nucleotide sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
  • Suitable promoters for directing the transcription of the nucleic acid constructs of the present invention are the promoters obtained from the E. coli lac operon, Streptomyces coelicolor ag a rase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylB genes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75: 3727-3731), as well as the tac promoter (DeBoer et al.
  • promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha- amylase, Aspergillus niger or Aspergillus awamori glucoamylase ⁇ glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for
  • useful promoters are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase.
  • ENO-1 Saccharomyces cerevisiae enolase
  • GAL1 Saccharomyces cerevisiae galactokinase
  • ADH2/GAP Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase
  • Saccharomyces cerevisiae 3-phosphoglycerate kinase Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8: 423
  • the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
  • Preferred terminators for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.
  • Preferred terminators for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC 1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.
  • the control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell.
  • the leader sequence is operably linked to the 5' terminus of the nucleotide sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.
  • Preferred leaders for filamentous fungal host cells are obtained from the genes for
  • Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, and Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).
  • ENO-1 Saccharomyces cerevisiae enolase
  • Saccharomyces cerevisiae 3-phosphoglycerate kinase Saccharomyces cerevisiae alpha-factor
  • Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase ADH2/GAP
  • the control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleotide sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.
  • Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase.
  • the control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway.
  • the 5' end of the coding sequence of the nucleotide sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide.
  • the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence.
  • the foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region.
  • the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide.
  • any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.
  • Effective signal peptide coding regions for bacterial host cells are the signal peptide coding regions obtained from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral proteases (nprT, nprS, nprM), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
  • Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.
  • Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
  • the control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide.
  • the resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases).
  • a propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide.
  • the propeptide coding region may be obtained from the genes for Bacillus subtilis alkaline protease ⁇ aprE), Bacillus subtilis neutral protease (nprT), Saccharomyces cerevisiae alpha-factor, Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophila laccase (WO 95/33836).
  • the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.
  • regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell.
  • regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
  • Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems.
  • yeast the ADH2 system or GAL1 system may be used.
  • filamentous fungi the TAKA alpha-amylase promoter, Aspergillus niger glucoamylase promoter, and Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences.
  • Other examples of regulatory sequences are those which allow for gene amplification.
  • these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals.
  • the nucleotide sequence encoding the polypeptide would be operably linked with the regulatory sequence.
  • nucleotide and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleotide sequence encoding the polypeptide at such sites.
  • the nucleotide sequence of the present invention may be expressed by inserting the nucleotide sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression.
  • the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
  • the recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleotide sequence.
  • the choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.
  • the vectors may be linear or closed circular plasmids.
  • the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • a vector which exists as an extrachromosomal entity the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • the vector may contain any means for assuring self-replication.
  • the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.
  • the vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
  • Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
  • Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), as well as equivalents thereof.
  • Preferred for use in an Aspergillus cell are the amdS and pyrG genes of Aspergillus nidulans or Aspergillus oryzae and the bar gene of Streptomyces
  • the vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
  • the vector may rely on the nucleotide sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.
  • the vector may contain additional nucleotide sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleotide sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s).
  • the integrational elements should preferably contain a sufficient number of nucleotides, such as 100 to 1 ,500 base pairs, preferably 400 to 1 ,500 base pairs, and most preferably 800 to 1 ,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination.
  • the integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell.
  • the integrational elements may be non-encoding or encoding nucleotide sequences.
  • the vector may be integrated into the genome of the host cell by non-homologous recombination.
  • the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
  • origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E. coli, and pUB110, pE194, pTA1060, and pAMISI permitting replication in Bacillus.
  • origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1 , ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.
  • the origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75: 1433). More than one copy of a nucleotide sequence of the present invention may be inserted into the host cell to increase production of the gene product.
  • An increase in the copy number of the nucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleotide sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleotide sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.
  • the procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).
  • the present invention also relates to recombinant fermenting fungus, or a host cell comprising the nucleic acid construct of the invention, which are advantageously used in the recombinant production of the polypeptides on site.
  • a vector comprising a nucleotide sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier.
  • the host cell is a fungal cell.
  • "Fungi" as used herein includes the phyla Ascomycota,
  • the fungal host cell is a filamentous fungal cell.
  • Filamentous fungi include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra).
  • the filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic.
  • the filamentous fungal host cell is a cell of a thermophilic or thermo tolerant fungi such as a species within Ascomycotina, Basidiomycotina, Zygomycota or Chytridiomycota, in particular a species within the group consisting of Chaetomium, Thermoascus, Malbranchea, or Thielavia, such as Thielavia terrestris, or Trichophaea. Even more preferably the host cell is a strain of Trichophaea saccata or Humicola, such as H.insolens.
  • Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81: 1470-1474. Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M.
  • a DNA sequence encoding a polypeptide of interest such as a hybrid enzyme or a variant of a wild type enzyme or a hybrid of the present invention, may be transformed and expressed in transgenic plants as described below.
  • the transgenic plant can be dicotyledonous or monocotyledonous, for short a dicot or a monocot.
  • monocot plants are grasses, such as meadow grass (blue grass, Poa), forage grass such as Festuca, Lolium, temperate grass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum and maize (corn).
  • dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, oil seed rape and the closely related model organism Arabidopsis thaliana.
  • plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems.
  • specific plant cell compartments such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes and cytoplasm are considered to be a plant part.
  • any plant cell, whatever the tissue origin, is considered to be a plant part.
  • plant parts such as specific tissues and cells isolated to facilitate the utilisation of the invention are also considered plant parts, e.g., embryos, endosperms, aleurone and seeds coats.
  • the transgenic plant or plant cell expressing the polypeptide of interest may be constructed in accordance with methods known in the art.
  • the plant or plant cell is constructed by incorporating one or more expression constructs encoding the polypeptide of interest into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.
  • the expression construct is a DNA construct which comprises a gene encoding the polypeptide of interest in operable association with appropriate regulatory sequences required for expression of the gene in the plant or plant part of choice.
  • the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used).
  • the choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences is determined, e.g., on the basis of when, where and how the enzyme is desired to be expressed.
  • the expression of the gene encoding the enzyme of the invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific cell compartment, tissue or plant part such as seeds or leaves.
  • Regulatory sequences are, e.g., described by Tague et al, Plant Phys., 86, 506, 1988.
  • the maize ubiquitin 1 and the rice actin 1 promoter may be used (Franck et al. 1980. Cell 21 : 285-294, Christensen AH, Sharrock RA and Quail 1992. Maize polyubiquitin genes: structure, thermal perturbation of expression and transcript splicing, and promoter activity following transfer to protoplasts by electroporation. Plant Mo. Biol. 18, 675-689.; Zhang W, McElroy D. and Wu R 1991 , Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell 3, 1155-1165).
  • Organ-specific promoters may, e.g., be a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990. Annu. Rev. Genet. 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994, Plant MoI. Biol. 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin or albumin promoter from rice (Wu et al., Plant and Cell Physiology Vol. 39, No. 8 pp.
  • the promoter may be a leaf specific promoter such as the rbcs promoter from rice or tomato (Kyozuka et al., Plant Physiology, Vol. 102, No. 3, pp. 991-1000 (1993), the chlorella virus adenine methyltransferase gene promoter (Mitra, A. and Higgins, DW, Plant Molecular Biology, Vol. 26, No. 1 , pp. 85-93 (1994), or the aldP gene promoter from rice (Kagaya et al., Molecular and General Genetics, Vol. 248, No. 6, pp.
  • the promoter may inducible by abiotic treatments such as temperature, drought or alterations in salinity or induced by exogenously applied substances that activate the promoter, e.g., ethanol, oestrogens, plant hormones like ethylene, abscisic acid and gibberellic acid and heavy metals.
  • a promoter enhancer element may be used to achieve higher expression of the enzyme in the plant.
  • the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding the enzyme.
  • Xu et al. op cit disclose the use of the first intron of the rice actin 1 gene to enhance expression.
  • the selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.
  • the DNA construct is incorporated into the plant genome according to conventional techniques known in the art, including ⁇ ojoibactem/m-mediated transformation, virus- mediated transformation, micro injection, particle bombardment, biolistic transformation, and electroporation (Gasser et al, Science, 244, 1293; Potrykus, Bio/Techn. 8, 535, 1990;
  • Agrobacterium tumefaciens mediated gene transfer is the method of choice for generating transgenic dicots (for review Hooykas & Schilperoort, 1992, Plant MoI. Biol., 19: 15-38), and can also be used for transforming monocots, although other transformation methods often are used for these plants.
  • the method of choice for generating transgenic monocots supplementing the Agrobacterium approach is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, Plant J., 2: 275-281; Shimamoto, 1994, Curr. Opin.
  • the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well-known in the art.
  • the transformation procedure is designed for the selective elimination of selection genes either during regeneration or in the following generations by using, e.g., co- transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.
  • the polypeptide of the first, second and/or third aspect may be used in a process for liquefying starch, wherein a gelatinized or granular starch substrate is treated in aqueous medium with the hybrid enzyme.
  • the polypeptide of the first, second and/or third aspect may also be used in a process for saccharification of a liquefied starch substrate.
  • a preferred use is in a fermentation process wherein a starch substrate is liquefied and/or saccharified in the presence of the polypeptide of the first, second and/or third aspect to produce glucose and/or maltose suitable for conversion into a fermentation product by a fermenting organism, preferably a yeast.
  • Such fermentation processes include a process for producing ethanol for fuel or drinking ethanol (portable alcohol), a process for producing a beverage, a process for producing desired organic compounds, such as citric acid, itaconic acid, lactic acid, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta lactone, or sodium erythorbate; ketones; amino acids, such as glutamic acid (sodium monoglutaminate), but also more complex compounds such as antibiotics, such as penicillin, tetracyclin; enzymes; vitamins, such as riboflavin, B12, beta-carotene; hormones, which are difficult to produce synthetically.
  • desired organic compounds such as citric acid, itaconic acid, lactic acid, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta lactone, or sodium erythorbate
  • ketones amino acids, such as glutamic acid (sodium mono
  • the starch to be processed may be a highly refined starch quality, preferably at least 90%, at least 95%, at least 97% or at least 99.5% pure or it may be a more crude starch containing material comprising milled whole grain including non-starch fractions such as germ residues and fibres.
  • the raw material such as whole grain, is milled in order to open up the structure and allowing for further processing.
  • Two milling processes are preferred according to the invention: wet and dry milling. Also corn grits, and preferably milled corn grits may be applied.
  • Dry milled grain will in addition to starch comprise significant amounts of non-starch carbohydrate compounds.
  • a heterogeneous material is processed by jet cooking often only a partial gelatinization of the starch is achieved.
  • the polypeptides of the invention have a high activity towards ungelatinized starch the polypeptides are advantageously applied in a process comprising liquefaction and/or saccharification jet cooked dry milled starch.
  • the need for glucoamylase during the saccharification step is greatly reduced.
  • This allows saccharification to be performed at very low levels of glucoamylase activity and preferably glucoamylase activity is either absent or if present, then present in an amount of no more than or even less than 0.5 AGU/g DS, more preferably no more than or even less than 0.4 AGU/g DS, even more preferably no more than or even less than 0.3 AGU/g DS, and most preferably less than 0.1 AGU, such as no more than or even less than 0.05 AGU/g DS of starch substrate.
  • the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate.
  • the glucoamylase may preferably be derived from a strain within Aspergillus sp., Talaromyces sp., Pachykytospora sp.
  • the polypeptide of the first aspect may be dosed in amounts of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate.
  • the polypeptide of the first aspect may be dosed in amounts of 0.05 to 10.0 AFAU/g DS, preferably 0.1 to 5.0 AFAU/g DS, more preferably from 0.25 to 2.5 AFAU/g DS starch.
  • the process may comprise; a) contacting a starch substrate with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect; b) incubating said starch substrate with said polypeptide for a time and at a temperature sufficient to achieve conversion of at least 90%, or at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% w/w of said starch substrate into fermentable sugars; c) fermenting to produce a fermentation product, d) optionally recovering the fermentation product.
  • an enzyme having glucoamylase activity is either absent or present in an amount from 0.001 to 2.0 AGU/g DS, from 0.01 to 1.5 AGU/g DS, from 0.05 to 1 ,0 AGU/g DS, from 0.01 to 0.5 AGU/g DS.
  • the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 AGU/g DS, more preferably no more than or even less than 0.4 AGU/g DS, even more preferably no more than or even less than 0.3 AGU/g DS, and most preferably no more than or even less than 0.1 AGU, such as no more than or even less than 0.05 AGU/g DS of starch substrate.
  • the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate.
  • a, b, c, and/or d may be performed separately or simultaneously.
  • the process may comprise; a) contacting a starch substrate with a yeast cell transformed to express a polypeptide comprising a catalytic module having alpha- amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first and/or second aspect; b) incubating said starch substrate with said yeast for a time and at a temperature sufficient to achieve conversion of at least 90% w/w of said starch substrate into fermentable sugars; c) fermenting to produce ethanol; d) optionally recovering ethanol.
  • the steps a, b, and c may performed separately or simultaneously.
  • the process comprising hydrolysis of a slurry of gelatinized or granular starch, in particular hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below the initial gelatinization temperature of said granular starch.
  • a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first aspect
  • the starch may be contacted with an enzyme selected from the group consisting of; a fungal alpha-amylase (EC 3.2.1.1), a beta-amylase (E.C. 3.2.1.2), and a glucoamylase (E. C.3.2.1.3).
  • a bacterial alpha-amylase or a debranching enzyme such as an isoamylase (E.C. 3.2.1.68) or a pullulanases (E.C. 3.2.1.41) may be added.
  • a bacterial alpha-amylase is an alpha-amylase as defined in WO 99/19467 on page 3, line 18 to page 6, line 27.
  • the process is conducted at a temperature below the initial gelatinization temperature.
  • the temperature at which the processes are conducted is at least 30 0 C, at least 31 0 C, at least 32°C, at least 33°C, at least 34°C, at least 35 0 C, at least 36°C, at least 37°C, at least 38°C, at least 39°C, at least 40°C, at least 41 0 C, at least 42°C, at least 43°C, at least 44°C, at least 45°C, at least 46°C, at least 47°C, at least 48°C, at least 49 0 C, at least 50 0 C, at least 51 °C, at least 52°C, at least 53 0 C, at least 54°C, at least 55°C, at least 56 0 C, at least 57°C, at least 58 0 C, at least 59°C, or preferably at least 60 0 C.
  • the pH at which the process is conducted may in be in the range of 3.0 to 7.0, preferably from 3.5 to 6.0, or more preferably from 4.0-5.0.
  • the process comprises fermentation, e.g with a yeast to produce ethanol, e.g., at a temperature around 32 0 C, such as from 30 to 35 0 C.
  • the process comprises simultaneous saccharification and fermentation, e.g with a yeast to produce ethanol, or another suitable fermentation organism to produce a desired organic compound, such as at a temperature from 30 to 35 0 C, e.g., at around 32 0 C.
  • the ethanol content reaches at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15% such as at least 16% ethanol.
  • the starch slurry to be used in any of the above aspects may have 20-55% dry solids granular starch, preferably 25-40% dry solids granular starch, more preferably 30-35% dry solids granular starch.
  • the polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or preferably at least 99% of the dry solids of the granular starch is converted into a soluble starch hydrolysate.
  • the polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module
  • the polypeptide of the first aspect at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least
  • the polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module e.g, the polypeptide of the first aspect
  • a process for liquefaction, saccharification of a gelatinized starch e.g., but not limited to gelatinization by jet cooking.
  • the process may comprise fermentation to produce a fermentation product, e.g., ethanol.
  • Such a process for producing ethanol from starch-containing material by fermentation comprises: (i) liquefying said starch-containing material with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect; (ii) saccharifying the liquefied mash obtained; (iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism.
  • the process further comprises recovery of the ethanol.
  • the saccharification and fermentation may be carried out as a simultaneous saccharification and fermentation process (SSF process). During the fermentation the ethanol content reaches at least 7%, at least 8%, at least 9%, at least 10% such as at least 11 %, at least 12%, at least 13%, at least 14%, at least 15% such as at least 16% ethanol.
  • SSF process simultaneous saccharification and fermentation process
  • the starch to be processed in the processes of the above aspects may in particular be obtained from tubers, roots, stems, legumes, cereals or whole grain. More specifically the granular starch may be obtained from corns, cobs, wheat, barley, rye, milo, sago, cassava, tapioca, sorghum, rice, peas, bean, banana or potatoes. Specially contemplated are both waxy and non-waxy types of corn and barley.
  • the invention also relates to a composition comprising the polypeptide of the first and/or second aspect.
  • the composition comprises a polypeptide of the first aspect which polypeptide is selected from the group consisting of V001, V002, V003, V004, V005, V006, V007, V008, V009, V010, V011 , V012, V013, V014, V015, V016, V017, V018, V019, V021 , V022, V023, V024, V025, V026, V027, V028, V029, V030, V031 , V032, V033, V034, V035, V036, V037, V038, V039, V040, V041 , V042, V043, V047, V048, V049, V050, V051 , V052, V054, V055, V057, V059, V060, V061 , V063, V064, V065, V
  • the composition may further comprise an enzyme selected from the group comprising of; a fungal alpha-amylase (EC 3.2.1.1), a beta-amylase (E.G. 3.2.1.2), a glucoamylase (E.C.3.2.1.3) and a pullulanases (E.G. 3.2.1.41).
  • the glucoamylase may preferably be derived from a strain of Aspergillus sp., such as Aspergillus niger, or from a strain of Talaromyces sp. and in particular derived from Talaromyces leycettanus such as the glucoamylase disclosed in U.S. patent no. Re.
  • glucoamylases such as the glucoamylases disclosed in U.S. Patent No. 4,587,215 and more preferably derived from Talaromyces emersonii. Most preferably the glucoamylase is derived from Talaromyces emersonii strain CBS 793.97 and/or having the sequence disclosed as SEQ ID NO: 7 in WO 99/28448. Further preferred is a glucoamylase which has an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or even at least 95% homology to the aforementioned amino acid sequence.
  • a commercial Talaromyces glucoamylase preparation is supplied by Novozymes A/S as Spirizyme Fuel.
  • polypeptides having glucoamylase activity and having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or even at least 95% homology with amino acids for mature polypeptide amino acids 1 to 556 of SEQ ID NO: 2 in U.S. Patent Application No. 60/650,612.
  • composition described above may be used for liquefying and/or saccharifying a gelatinized or a granular starch, as well as a partly gelatinized starch.
  • a partly gelatinized starch is a starch which to some extent is gelatinized, i.e., wherein part of the starch has irreversibly swelled and gelatininized and part of the starch is still present in a granular state.
  • composition described above may preferably comprise acid alpha-amylase present in an amount of 0.01 to 10 AFAU/g DS, preferably 0.1 to 5 AFAU/g DS, more preferably 0.5 to 3 AFAU/AGU, and most preferably 0.3 to 2 AFAU/g DS.
  • the composition may be applied in any of the starch processes described above.
  • AFAU Acid Fungal Alpha-amylase Units
  • 1 AFAU is defined as the amount of enzyme which degrades 5.260 mg starch dry matter per hour under the below mentioned standard conditions.
  • Acid alpha-amylase i.e., acid stable alpha-amylase, an endo-alpha-amylase (1,4- alpha-D-glucan-glucano-hydrolase, E. C. 3.2.1.1) hydrolyzes alpha-1 ,4-glucosidic bonds in the inner regions of the starch molecule to form dextrins and oligosaccharides with different chain lengths.
  • the intensity of color formed with iodine is directly proportional to the concentration of starch.
  • Amylase activity is determined using reverse colorimetry as a reduction in the concentration of starch under the specified analytical conditions.
  • Iodine (I2) 0.03 g/L
  • Glucoamylase activity may be measured in AmyloGlucosidase Units (AGU).
  • AGU is defined as the amount of enzyme, which hydrolyzes 1 micromole maltose per minute under the standard conditions 37°C, pH 4.3, substrate: maltose 23.2 mM, buffer: acetate 0.1 M, reaction time 5 minutes.
  • An autoanalyzer system may be used. Mutarotase is added to the glucose dehydrogenase reagent so that any alpha-D-glucose present is turned into beta-D-glucose. Glucose dehydrogenase reacts specifically with beta-D-glucose in the reaction mentioned above, forming NADH which is determined using a photometer at 340 nm as a measure of the original glucose concentration.
  • Enzyme working range 0.5-4.0 AGU/mL
  • Buffer phosphate 0.12 M; 0.15 M NaCI pH: 7.60 ⁇ 0.05
  • E. coli DH12S (available from Gibco BRL) was used for yeast plasmid rescue.
  • pl_A1 is a S. cerevisiae and E. coli shuttle vector under the control of TPI promoter, constructed from pJC039 described in WO 01/92502.
  • the acid Aspergillus niger alpha- amylase signal sequence, the acid Aspergillus niger alpha-amylase gene (SEQ ID NO: 1) and the partial Athelia rolfsii glucoamylase gene sequence comprising the linker (SEQ ID NO: 67) and the CBM (SEQ ID NO: 91) has been inserted.
  • the full sequence of the plasmid is given in SEQ ID NO: 103.
  • the alpha-amylase gene is the sequence from 5029 to 6468, the linker is the sequence from 6469 to 6501 and the CBM is the sequence from 6502 to 6795.
  • the vector was used for alpha-amylase CBM hybrid construction. Saccharomyces cerevisiae YNG318: MATa Dpep4[cir+] ura3-52, Ieu2-D2, his 4-539 was used for alpha-amylase variants expression. It is described in J. Biol. Chem. 272 (15), pp 9720-9727, 1997.
  • the solution is sterilized using a filter of a pore size of 0.20 micrometer.
  • YPD Bacto peptone 20 g/I, yeast extract 10 g/I, 20% glucose 100 ml/l.
  • PEG/LiAc solution 40% PEG4000 50 ml, 5 M Lithium Acetate 1 ml
  • Yeast transformation was carried out by lithium acetate method. Mix 0.5 microL of vector (digested by restriction endnucleases) and 1 microL of PCR fragments. Thaw
  • YNG318 competent cells on ice. Mix 100 microL of the cells, the DNA mixture and 10 microL of carrier DNA (Clontech) in 12 ml polypropylene tubes (Falcon 2059). Add 0.6ml PEG/LiAc solution and mix gently. Incubate for 30 min at 3O 0 C, and 200 rpm. Incubate for 30 min at
  • E. coli transformation for DNA sequencing was carried out by electroporation (BIO- RAD Gene Pulser).
  • DNA Plasmids were prepared by alkaline method (Molecular Cloning, Cold Spring Harbor) or with the Qiagen ® Plasmid Kit. DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit. PCR was performed using a PTC-200 DNA Engine. The ABI PRISMTM 310 Genetic Analyzer was used for determination of all DNA sequences.
  • Example 1 Construction of the nucleic acid sequence V019, encoding Rhizomucor pusillus alpha amylases and Athelia rolfsii glucoamylase CBM
  • Vector pl_A1 was digested with the appropriate restriction endonuclease to cut out the region encoding A. niger alpha-amylase catalytic domain.
  • the Rhizomucor pusillus alpha-amylase gene was amplified by PCR using the primers P001 (SEQ ID NO: 104) and P002 (SEQ ID NO: 105), the amplified fragment is shown as SEQ ID NO: 19.
  • DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit.
  • the resulting purified fragments were mixed with the vector digest.
  • the mixed solution was introduced into Saccharomyces cerevisiae to construct the expression plasmid pl_AV019 by in vivo recombination.
  • Example 2 Construction of the nucleic acid sequence V022, encoding Meripilus giganteus alpha amylase and Athelia rolfsii glucoamylase CBM
  • the Meripilus giganteus alpha-amylase gene was amplified by PCR using the primers P003 (SEQ ID NO: 106) and P004 (SEQ ID NO: 107).
  • DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit.
  • the resulting purified fragments and the appropriate restriction endonuclease digested vector pl_A1 to cut out the region encoding A. niger alpha-amylase catalytic domain were mixed.
  • the mixed solution was introduced into Saccharomyces cerevisiae to construct the expression plasmid pl_AV022 by in vivo recombination.
  • Example 3 Expression of amylases with CBM in Aspergillus oryzae
  • the constructs comprising the alpha amylase genes with CBM described in examples 1 and 2 were used to construct expression vectors, pAspV019 and pAspV022, respectively.
  • the two plasmids, pAspV019 and pAspV022, consist of an expression cassette based on the Aspergillus niger neutral amylase Il promoter fused to the Aspergillus nidulans those phosphate isomerase non translated leader sequence (Pna2/tpi) and the Aspergillus niger amyloglycosidase terminator (Tamg).
  • the expression plasmids pAspV019 and pAspV022 were transformed into Aspergillus as described in Lassen et al. (2001), Applied and Environmental Micorbiology, 67, 4701-4707. Transformants expressing V019 and V022, were isolated, purified and cultivated in shake flasks. The culture broths from fermentations of Aspergillus oryzae expressing amylase with CBM were purified by affinity purification (Biochem. J. (2003) 372, 905-910).
  • Polypeptides of the invention were produced; a selection of catalytic domains were fused to the linker-CBM region of Athelia rolfsii glucoamylase, and a selection of CBM regions were attached to the C003 Aspergillus oryzae catalytic domain (a Fungamyl PE variant).
  • the CBM+linker from Trichophaea saccata alpha-amylase is located at N- terminal, it was inserted between SP288 signal and the Aspergillus oryzae catalytic domain.
  • the other CBMs were all C-terminally placed.
  • the variant V008 comprised both a C-terminally placed linker and CBM region of
  • Athelia rolfsii glucoamylase and an N-terminally placed linker+CBM from Trichophaea saccata alpha-amylase from Trichophaea saccata alpha-amylase.
  • CBM variants of the Aspergillus oryzae alpha-amylase and catalytic domain variants of the Athelia rolfsii glucoamylaseCBM are listed in tables 3 and 4 respectively.
  • Other produced polypeptides of the invention are listed in tables 5 and 6.
  • the variants have improved activity on starch, especially on granular starch.
  • the performance of the polypeptide V019 was evaluated in mini-scale fermentations with different dosages of Talaromyces emersonii glucoamylase.
  • Starch substrate 583.3g of ground corn was added to 912.2 g tap water. This mixture was supplemented with 4.5 ml of a 1 g/L penicillin solution. The pH of this slurry was adjusted to 5.0 with 40% H 2 SO 4 . DS level was determined in duplicate to be 34.2 ⁇ 0.8%. Approximately 5 g of this slurry was added to 20 ml vials. Each vial was dosed with the appropriate amount of enzyme followed by addition of 200 microL yeast propagate/5 g slurry.
  • Substrates for saccharification were prepared by dissolving a DE 11 maltodextrin prepared from corn starch liquefied with thermostable bacterial alpha-amylase (LIQUOZYME XTM, Novozymes A/S) in Milli-QTM water, and adjusting the dry solid matter content (DS) to 30%.
  • the saccharification experiments were carried out in sealed 2 ml glass vials at 6O 0 C and initial pH of 4.3 under continuous stirring. Two different dosages of CBM alpha-amylase V019 or V022 were applied on top of a standard treatment with Talaromyces emersonii glucoamylase 0.35 AGU/g DS and A. niger acid alpha-amylase 0.04 AFAU/g DS.
  • V022 were dosed on top according to the table.
  • Raw starch SSF treatments were evaluated in mini-scale fermentations.
  • a 35% DS granular starch slurry was obtained from mixing 41O g finely ground corn, 590 ml tap water,
  • A-AMG is an Aspergillus niger glucoamylase composition.
  • A-AMG is a Talaromyces emersonii glucoamylase composition.
  • the strains have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. ⁇ 1.14 and 35 U. S. C. ⁇ 122.
  • the deposits represent a substantially pure culture of the deposited strain.
  • the deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Jellies, Jams, And Syrups (AREA)

Abstract

The present invention relates to polypeptides comprising a carbohydrate-binding module amino acid sequence and an alpha-amylase amino acid sequence as well as to the application of such polypeptides.

Description

ENZYMES FOR STARCH PROCESSING
CROSS-REFERENCE TO SEQUENCE LISTING AND DEPOSITED MICROORGANISMS
The present application contains information in the form of a sequence listing, which is appended to the application and also submitted on a data carrier accompanying this application. In addition, the present application refers to deposited microorganisms. The contents of the data carrier and the deposited microorganisms are fully incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates to polypeptides comprising a carbohydrate-binding module ("CBM") and an alpha-amylase catalytic domain. Furthermore, the invention relates
~ to wild type alpha-amylases polypeptides comprising useful alpha-amylase catalytic domains and/or CBMs as well as to the catalytic domain sequences and/or CBM sequences. The invention also relates to the use of such polypeptides in a starch liquefaction process in which starch is degraded to smaller oligo- and/or polysaccharide fragments.
BACKGROUND OF THE INVENTION
A large number of enzymes and processes have been described for converting starch to starch hydrolysates, such as maltose, glucose or specialty syrups, either for use as sweeteners or as precursors for other saccharides such as fructose. Glucose may also be fermented to ethanol or other fermentation products, such as citric acid, monosodium glutamate, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta lactone, or sodium erythorbate, itaconic acid, lactic acid, gluconic acid; ketones; amino acids, glutamic acid (sodium monoglutaminate), penicillin, tetracyclin; enzymes; vitamins, such as riboflavin, B12, beta-carotene or hormones.
Starch is a high molecular-weight polymer consisting of chains of glucose units. It usually consists of about 80% amylopectin and 20% amylose. Amylopectin is a branched polysaccharide in which linear chains of alpha-1,4 D-glucose residues are joined by alpha- 1 ,6 glucosidic linkages.
Amylose is a linear polysaccharide built up of D-glucopyranose units linked together by alpha-1 ,4 glucosidic linkages. In the case of converting starch into a soluble starch hydrolysate, the starch is depolymerized. The conventional depolymerization process consists of a gelatinization step and two consecutive process steps, namely a liquefaction process and a saccharification process. Granular starch consists of microscopic granules, which are insoluble in water at room temperature. When an aqueous starch slurry is heated, the granules swell and eventually burst, dispersing the starch molecules into the solution. During this "gelatinization" process there is a dramatic increase in viscosity. As the solids level is 30-40% in a typical industrial process, the starch has to be thinned or "liquefied" so that it can be handled. This reduction in viscosity is today mostly obtained by enzymatic degradation. During the liquefaction step, the long-chained starch is degraded into smaller branched and linear units (maltodextrins) by an alpha-amylase. The liquefaction process is typically carried out at about 105-1100C for about 5 to 10 minutes followed by about 1-2 hours at about 95°C. The temperature is then lowered to 600C, a glucoamylase (also known as GA or AMG) or a beta- amylase and optionally a debranching enzyme, such as an isoamylase or a pullulanase are added, and the saccharification process proceeds for about 24 to 72 hours.
It will be apparent from the above discussion that the conventional starch conversion process is very energy consuming due to the different requirements in terms of temperature during the various steps. It is thus desirable to be able to select and/or design the enzymes used in the process so that the overall process can be performed without having to gelatinize the starch. Such "raw starch" processes are U.S. Patent Nos. 4,591 ,560, 4,727,026, and 4,009,074, EP Patent No. 0171218 and Danish patent application PA 2003 00949. The present invention discloses polypeptides designed for, inter alia, such processes and comprising an amino acid sequence of a CBM and an amino acid sequence of a starch degrading enzyme. Hybrid enzymes are the subject of WO 9814601 , WO0077165, and PCT/US2004/020499
SUMMARY OF THE INVENTION The present inventor have surprisingly discovered that by adding a carbohydrate- binding module (CBM) to certain alpha-amylases the activity and specificity can be altered thereby increasing the efficacy of various starch degrading processes, e.g., comprising degradation of raw, e.g., ungelatinized starch and/or gelatinized starch. Also by exchanging one CBM by another the activity and specificity can be altered. Such hybrids consisting of a polypeptide having alpha-amylase activity and a carbohydrate binding module, primarily having affinity for starch, have the advantage over existing alpha-amylases that by selecting a catalytic domain with desire properties eg. the pH profile, the temperature profile, the oxidation resistance, the calcium stability, the substrate affinity or the product profile can be combined with a carbohydrate binding module with stronger or weaker binding affinities, e.g., specific affinities for amylose, specific affinities for amylopectin or affinities for specific structure in the carbohydrate. Thus the invention relates to hybrids having altered properties relative to the alpha-amylase without the CBM and/or relative to prior art amylases, such as having increased stability and/or activity at low pH, e.g., at pH below 4, such as at 3.5, increased activity towards granular starch, and/or increased degradation of granular starch at low pH even in the absence of glucoamylase or at low glucoamylase levels, and/or with altered product profile.
Due to the superior hydrolysis activity of these polypeptide the overall starch conversion process can be performed without having to gelatinize the starch, i.e., the polypeptides hydrolyses granular starch in a raw starch process as well as fully or partially gelatinized starch in a traditional starch process. Accordingly the invention provides in a first aspect a polypeptide comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module, wherein said second amino acid sequence has at least 60% homology to any amino acid sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 109, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141 and SEQ ID NO: 143.
In a second aspect the invention provides a polypeptide having alpha-amylase activity, selected from the group consisting of: (a) a polypeptide having an amino acid sequence which has at least 75% homology with amino acids for the mature polypeptide selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, as amino acids 1-471 in SEQ ID NO: 18, as amino acids 1-450 in SEQ ID NO: 20, as amino acids 1-445 in SEQ ID NO: 22, as amino acids 1-498 in SEQ ID NO: 26, as amino acids 18-513 in SEQ ID NO: 28, as amino acids 1-507 in SEQ ID NO: 30, as amino acids 1-481 in SEQ ID NO: 32, as amino acids 1-495 in SEQ ID NO: 34, as amino acids 1-477 in SEQ ID NO: 38, as amino acids 1-449 in SEQ ID NO: 42, as amino acids 1-442 in SEQ ID NO: 115, as amino acids 1- 441 in SEQ ID NO: 117, as amino acids 1-477 in SEQ ID NO: 125, as amino acids 1-446 in SEQ ID NO: 131 , as amino acids 41-481 in SEQ ID NO: 157, as amino acids 22-626 in SEQ ID NO: 159, as amino acids 24-630 in SEQ ID NO: 161 , as amino acids 27-602 in SEQ ID NO: 163, as amino acids 21-643 in SEQ ID NO: 165, as amino acids 29-566 in SEQ ID NO: 167, as amino acids 22-613 in SEQ ID NO: 169, as amino acids 21-463 in SEQ ID NO: 171 , as amino acids 21-587 in SEQ ID NO: 173, as amino acids 30-773 in SEQ ID NO: 175, as amino acids 22-586 in SEQ ID NO: 177, as amino acids 20-582 in SEQ ID NO: 179, (b) a polypeptide which is encoded by a nucleotide sequence (i) which hybridizes under at least low stringency conditions with nucleotides 1-1326 in SEQ ID NO: 13, nucleotides 1-1413 in SEQ ID NO: 17, nucleotides 1-1350 in SEQ ID NO: 19, nucleotides 1-1338 in SEQ ID NO: 21 , nucleotides 1-1494 in SEQ ID NO: 25, nucleotides 52-1539 in SEQ ID NO: 27, nucleotides 1-1521 in SEQ ID NO: 29, nucleotides 1-1443 in SEQ ID NO: 31 , nucleotides 1- 1485 in SEQ ID NO: 33, nucleotides 1-1431 in SEQ ID NO: 37, nucleotides 1-1347 in SEQ ID NO: 41 , nucleotides 1-1326 in SEQ ID NO: 114, nucleotides 1-1323 in SEQ ID NO: 116, nucleotides 1-1431 in SEQ ID NO: 124, nucleotides 1-1338 in SEQ ID NO: 130, nucleotides 121-1443 in SEQ ID NO: 156, nucleotides 64-1878 in SEQ ID NO: 158, nucleotides 70-1890 in SEQ ID NO: 160, nucleotides 79-1806 in SEQ ID NO: 162, nucleotides 61-1929 in SEQ ID NO: 164, nucleotides 85-1701 in SEQ ID NO: 166, nucleotides 64-1842 in SEQ ID NO: 168, nucleotides 61-1389 in SEQ ID NO: 170, nucleotides 61-1764 in SEQ ID NO: 172, nucleotides 61-2322 in SEQ ID NO: 174, nucleotides 64-1761 in SEQ ID NO: 176, nucleotides 58-1749 in SEQ ID NO: 178, or (ii) which hybridizes under at least medium stringency conditions with the cDNA sequence contained in the polynucleotides shown as nucleotides 1-1326 in SEQ ID NO: 13, as nucleotides 1-1413 in SEQ ID NO: 17, as nucleotides 1-1350 in SEQ ID NO: 19, as nucleotides 1-1338 in SEQ ID NO: 21 , as nucleotides 1-1494 in SEQ ID NO: 25, as nucleotides 52-1539 in SEQ ID NO: 27, as nucleotides 1-1521 in SEQ ID NO: 29, as nucleotides 1-1443 in SEQ ID NO: 31 , as nucleotides 1-1485 in SEQ ID NO: 33, as nucleotides 1-1431 in SEQ ID NO: 37, as nucleotides 1-1347 in SEQ ID NO: 41 , as nucleotides 1-1326 in SEQ ID NO: 114, as nucleotides 1-1323 in SEQ ID NO: 116, as nucleotides 1-1431 in SEQ ID NO: 124, as nucleotides 1-1338 in SEQ ID NO: 130, as nucleotides 121-1443 in SEQ ID NO: 156, as nucleotides 64-1878 in SEQ ID NO: 158, as nucleotides 70-1890 in SEQ ID NO: 160, as nucleotides 79-1806 in SEQ ID NO: 162, as nucleotides 61-1929 in SEQ ID NO: 164, as nucleotides 85-1701 in SEQ ID NO: 166, as nucleotides 64-1842 in SEQ ID NO: 168, as nucleotides 61-1389 in SEQ ID NO: 170, as nucleotides 61-1764 in SEQ ID NO: 172, as nucleotides 61-2322 in SEQ ID NO: 174, as nucleotides 64-1761 in SEQ ID NO: 176, as nucleotides 58-1749 in SEQ ID NO: 178, or (iii) a complementary strand of (i) or (ii); and (c) a variant comprising a conservative substitution, deletion, and/or insertion of one or more amino acids in an acid amino sequence selected from the group consisting of amino acids 1- 441 in SEQ ID NO: 14, amino acids 1-471 in SEQ ID NO: 18, amino acids 1-450 in SEQ ID NO: 20, amino acids 1-445 in SEQ ID NO: 22, amino acids 1-498 in SEQ ID NO: 26, amino acids 18-513 in SEQ ID NO: 28, amino acids 1-507 in SEQ ID NO: 30, amino acids 1-481 in SEQ ID NO: 32, amino acids 1-495 in SEQ ID NO: 34, amino acids 1-477 in SEQ ID NO: 38, amino acids 1-449 in SEQ ID NO: 42, amino acids 1-442 in SEQ ID NO: 115, amino acids 1- 441 in SEQ ID NO: 117, amino acids 1-477 in SEQ ID NO: 125, amino acids 1-446 in SEQ ID NO: 131 , amino acids 41-481 in SEQ ID NO: 157, amino acids 22-626 in SEQ ID NO: 159, amino acids 24-630 in SEQ ID NO: 161, amino acids 27-602 in SEQ ID NO: 163, amino acids 21-643 in SEQ ID NO: 165, amino acids 29-566 in SEQ ID NO: 167, amino acids 22- 613 in SEQ ID NO: 169, amino acids 21-463 in SEQ ID NO: 171, amino acids 21-587 in SEQ ID NO: 173, amino acids 30-773 in SEQ ID NO: 175, amino acids 22-586 in SEQ ID NO: 177 and amino acids 20-582 in SEQ ID NO: 179. In a second aspect the invention provides a polypeptide having carbohydrate-binding affinity, selected from the group consisting of: (a) i) a polypeptide comprising an amino acid sequence which has at least 60% homology with a sequence selected from the group consisting of amino acids 529-626 of SEQ ID NO: 159, amino acids 533-630 of SEQ ID NO: 161 , amino acids 508-602 of SEQ ID NO: 163, amino acids 540-643 of SEQ ID NO: 165, amino acids 502-566 of SEQ ID NO: 167, amino acids 513-613 of SEQ ID NO: 169, 492-587 of SEQ ID NO: 173, amino acids 30-287 of SEQ ID NO: 175, amino acids 487-586 of SEQ ID NO: 177 and amino acids 482-582 of SEQ ID NO: 179; (b) a polypeptide which is encoded by a nucleotide sequence which hybridizes under low stringency conditions with a polynucleotide probe selected from the group consisting of (i) the complementary strand of a sequence selected from the group consisting of nucleotides 1585-1878 in SEQ ID NO: 158, nucleotides 1597-1890 in SEQ ID NO: 160, nucleotides 1522-1806 in SEQ ID NO: 162, nucleotides 1618-1929 in SEQ ID NO: 164, nucleotides 1504-1701 in SEQ ID NO: 166, nucleotides 1537-1842 in SEQ ID NO: 168, nucleotides 1474-1764 in SEQ ID NO: 172, nucleotides 61-861 in SEQ ID NO: 174, nucleotides 1459-1761 in SEQ ID NO: 176 and nucleotides 1444-1749 in SEQ ID NO: 178, (c) a fragment of (a) or (b) that has carbohydrate binding affinity.
In other aspects the invention provides uses of the polypeptide of the first, second and/or third aspect for saccharification, in a process comprising fermentation, in a starch conversion process, in a process for producing oligosaccharides, e.g., a process for producing maltodextrins or glucose and/or fructose syrups, in a process for producing fuel or drinking ethanol, for producing a beverage, and/or in a fermentation process for producing organic compounds, such as citric acid, ascorbic acid, lysine, glutamic acid.
In a further aspect the invention provides a composition comprising the polypeptide of the first, second and/or third aspect. In a further aspect the invention provides a process for saccharifying starch, wherein a starch is treated with the polypeptide of the first, second and/or third aspect.
In a further aspect the invention provides a process comprising; a) contacting a starch with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first, second and/or third aspect; b) incubating said starch with said polypeptide; c) fermenting to produce a fermentation product, d) optionally recovering the fermentation product, wherein an enzyme having glucoamylase activity is either absent or present in an amount of less than 0.5 AGU/g DS of starch substrate and wherein step a, b, c, and/or d may be performed separately or simultaneously.
In a further aspect the invention provides a process comprising; a) contacting a starch substrate with a yeast cell transformed to express a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first and/or second aspect; b) holding said starch substrate with said yeast; c) fermenting to produce ethanol; d) optionally recovering ethanol, wherein steps a), b), and c) are performed separately or simultaneously. In a preferred embodiment comprise holding the substrate with said yeast for a time and at a temperature sufficient to achieve conversion of at least 90% w/w of said starch substrate into fermentable sugars.
In a further aspect the invention provides a process of producing ethanol from starch- containing material by fermentation, said process comprises: (i) liquefying said starch- containing material with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first and/or second aspect; (ii) saccharifying the liquefied mash obtained; (iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism and optionally comprising recovery of the ethanol.
In further aspects the invention provides a DNA sequence encoding a polypeptide according to the first, second and/or third aspect, a DNA construct comprising said DNA sequence, a recombinant expression vector which carries said DNA construct, a host cell which is transformed with said DNA construct or said vector, said host cell, which is a microorganism, in particular a bacterium or a fungal cell, a yeast or a plant cell.
DETAILED DESCRIPTION OF THE INVENTION
The term "granular starch" is understood as raw uncooked starch, i.e., starch that has not been subjected to a gelatinization. Starch is formed in plants as tiny granules insoluble in water. These granules are preserved in starches at temperatures below the initial gelatinization temperature. When put in cold water, the grains may absorb a small amount of the liquid. Up to 500C to 700C the swelling is reversible, the degree of reversibility being dependent upon the particular starch. With higher temperatures an irreversible swelling called gelatinization begins.
The term "initial gelatinization temperature" is understood as the lowest temperature at which gelatinization of the starch commences. Starch heated in water begins to gelatinize between 50°C and 75"C; the exact temperature of gelatinization depends on the specific starch and can readily be determined by the skilled artisan. Thus, the initial gelatinization temperature may vary according to the plant species, to the particular variety of the plant species as well as with the growth conditions. In the context of this invention the initial gelatinization temperature of a given starch is the temperature at which birefringence is lost in 5% of the starch granules using the method described by Gorinstein. S. and Lii. C, Starch/Starke, Vol. 44 (12) pp. 461-466 (1992).
The term "soluble starch hydrolysate" is understood as the soluble products of the processes of the invention and may comprise mono-, di-, and oligosaccharides, such as glucose, maltose, maltodextrins, cyclodextrins and any mixture of these. Preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97% or at least 98% of the dry solids of the granular starch is converted into a soluble starch hydrolysate.
The term polypeptide "homology" is understood as the degree of identity between two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, 443-453. The following settings for amino acid sequence comparison are used: GAP creation penalty of 3.0 and GAP extension penalty of 0.1. The relevant part of the amino acid sequence for the homology determination is the mature polypeptide, i.e., without the signal peptide. Suitable experimental conditions for determining hybridization at low, medium, or high stringency between a nucleotide probe and a homologous DNA or RNA sequence involves presoaking of the filter containing the DNA fragments or RNA to hybridize in 5 x SSC (Sodium chloride/Sodium citrate, Sambrook et al. 1989) for 10 min, and prehybridization of the filter in a solution of 5 x SSC, 5 x Denhardt's solution (Sambrook et al. 1989), 0.5% SDS and 100 micrograms/ml of denatured sonicated salmon sperm DNA (Sambrook et al. 1989), followed by hybridization in the same solution containing a concentration of 10ng/ml of a random-primed (Feinberg, A. P. and Vogelstein, B. (1983) Anal. Biochem. 132:6-13), 32P- dCTP-labeled (specific activity > 1 x 109 cpm/microgram) probe for 12 hours at about 450C. The filter is then washed twice for 30 minutes in 2 x SSC, 0.5% SDS at about 55°C (low stringency), more preferably at about 600C (medium stringency), still more preferably at about 650C (medium/high stringency), even more preferably at about 700C (high stringency), and even more preferably at about 75°C (very high stringency).
Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using an x-ray film. Polypeptides
The polypeptide of the invention may be a hybrid enzyme or the polypeptide may be a wild type enzyme which already comprises a catalytic module having alpha-amylase activity and a carbohydrate-binding module. The polypeptide of the invention may also be a variant of such a wild type enzyme. The hybrid may be produced by fusion of a first DNA sequence encoding a first amino acid sequences and a second DNA sequence encoding a second amino acid sequences, or the hybrid may be produced as a completely synthetic gene based on knowledge of the amino acid sequences of suitable CBMs, linkers and catalytic domains. The terms "hybrid enzyme" or "hybrid polypeptide" is used herein to characterize those of the polypeptides of the invention that comprises a first amino acid sequence comprising at least one catalytic module having alpha-amylase activity and a second amino acid sequence comprising at least one carbohydrate-binding module wherein the first and the second are derived from different sources. The term "source" being understood as, e.g., but not limited to a parent enzyme, e.g., an amylase or glucoamylase, or other catalytic activity comprising a suitable catalytic module and/or a suitable CBM and/or a suitable linker.
The Enzyme classification numbers (EC numbers) are in accordance with the Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. Academic Press Inc., 1992. Polypeptides as referred to herein include species comprising an amino acid sequence of an alpha-amylase enzyme (EC 3.2.1.1) linked (i.e., covalently bound) to an amino acid sequence comprising a carbohydrate-binding module (CBM).
CBM-containing hybrid enzymes, as well as detailed descriptions of the preparation and purification thereof, are known in the art [see, e.g., WO 90/00609, WO 94/24158 and WO 95/16782, as well as Greenwood et al. Biotechnology and Bioenqineerinq 44 (1994) pp. 1295- 1305]. They may, e.g., be prepared by transforming into a host cell a DNA construct comprising at least a fragment of DNA encoding the carbohydrate-binding module ligated, with or without a linker, to a DNA sequence encoding the polypeptide of interest, and growing the transformed host cell to express the fused gene. The CBM in a polypeptide of the invention may be positioned C-terminally, N-terminally or internally in polypeptide. In an embodiment a polypeptide may comprise more than one CBM, e.g., two CBMs; one positioned C-terminally, the other N-terminally or the two CBMs in tandem positioned C-terminally, N-terminally or internally. However, polypeptides with more than two CBMs are equally contemplated. Alpha-amylases of the invention
The invention relates to alpha-amylase polypeptides useful as donors (parent amylases) of CBMs, linkers and/or catalytic modules. The polypeptide of the invention may be a wild type alpha-amylase enzyme (EC 3.2.1.1) or the polypeptide may also be a variant of such a wild type enzyme. Furthermore the polypeptide of the invention may be a fragment of such an enzyme, e.g., such as a catalytic domain, i.e., a fragment having alpha-amylase activity but which is separated from a CBM if such is present in the wild-type enzyme, or such as a CBM, i.e., a fragment having a carbohydrate binding module. It may also be a hybrid enzyme comprising a fragment of such an alpha-amylase enzyme, e.g., comprising a catalytic domain, a linker and/or a CBM derived from an alpha-amylase enzyme of the invention.
Furthermore, the polypeptide of the invention may be a fragment of such an enzyme, e.g., a fragment which still comprises a functional catalytic domain as well as a CBM if such is present in the wild type enzyme, or, e.g., a fragment of a wild-type enzyme, which wild-type enzyme does not comprise a CBM, and wherein said fragment comprises a functional catalytic domain.
Alpha-amylase enzymes: The invention relates to novel polypeptides comprising a carbohydrate-binding module ("CBM") and aving alpha-amylase activity. Such polypeptides may be derived from any organism, preferred are those of fungal or bacterial origin.
The alpha-amylases of the invention include alpha-amylases obtainable from a species within a genus selected from the list consisting of Absidia, Acremonium, Coniochaeta, Coriolus, Cryptosporiopsis, Dichotomocladium, Dinemasporium, Diplodia, Fusarium, Gliocladium, Malbranchea, Meripilus, Necteria, Penicillium, Rhizomucor, Stereum, Streptomyces, Subulispora, Syncephalastrum, Thamindium, Thermoascus, Thermomyces, Trametes, Trichophaea and Valsaria. The alpha-amylase may be derived from any genus, species or sequence listed in table 1.
Preferably the alpha-amylase is derived from any species selected from the group consisting of Thermomyces lanuginosus; in particular a polypeptide having the amino acids 1-441 in SEQ ID NO: 14, Malbranchea sp.; in particular a polypeptide having the amino acids 1-471 in SEQ ID NO: 18, Rhizomucor pusillus; in particular a polypeptide having the amino acids 1-450 in SEQ ID NO: 20, Dichotomocladium hesseltinei; in particular a polypeptide having the amino acids 1-445 in SEQ ID NO: 22, Stereum sp.; in particular a polypeptide having the amino acids 1-498 in SEQ ID NO: 26, Trametes sp.; in particular a polypeptide having the amino acids 18-513 in SEQ ID NO: 28, Coriolus consors; in particular a polypeptide having the amino acids 1-507 in SEQ ID NO: 30, Dinemasporium sp.; in particular a polypeptide having the amino acids 1-481 in SEQ ID NO: 32, Cryptosporiopsis sp.; in particular a polypeptide having the amino acids 1-495 in SEQ ID NO: 34, Diplodia sp.; in particular a polypeptide having the amino acids 1-477 in SEQ ID NO: 38, Gliocladium sp.; in particular a polypeptide having the amino acids 1-449 in SEQ ID NO: 42, Nectria sp.; in particular a polypeptide having the amino acids 1-442 in SEQ ID NO: 115, Fusarium sp.; in particular a polypeptide having the amino acids 1-441 in SEQ ID NO: 117, Thermoascus auranticus; in particular a polypeptide having the amino acids 1-477 in SEQ ID NO: 125, Thamindium elegans; in particular a polypeptide having the amino acids 1-446 in SEQ ID NO: 131, Absidia cristata; in particular a polypeptide having the amino acids 41-481 in SEQ ID NO: 157, Acremonium sp.; in particular a polypeptide having the amino acids 22-626 in SEQ ID NO: 159, Coniochaeta sp.; in particular a polypeptide having the amino acids 24-630 in SEQ ID NO: 161, Meripilus giganteus; in particular a polypeptide having the amino acids 27-602 in SEQ ID NO: 163, Penicillium sp.; in particular a polypeptide having the amino acids 21-643 in SEQ ID NO: 165, Streptomyces limosus; in particular a polypeptide having the amino acids 29-566 in SEQ ID NO: 167, Subulispora procurvata; in particular a polypeptide having the amino acids 22-613 in SEQ ID NO: 169, Syncephalastrum racemosum; in particular a polypeptide having the amino acids 21-463 in SEQ ID NO: 171, Trametes currugata; in particular a polypeptide having the amino acids 21-587 in SEQ ID NO: 173, Trichophaea saccata; in particular a polypeptide having the amino acids 30-773 in SEQ ID NO: 175, Valsaria rubricosa; in particular a polypeptide having the amino acids 22- 586 in SEQ ID NO: 177 and Valsaria spartii; in particular a polypeptide having the amino acids 20-582 in SEQ ID NO: 179.
Also preferred are alpha-amylase amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or even at least 98% homology to the mature peptide of any of the aforementioned polypeptides. In another preferred embodiment the alpha-amylase amino acid sequence have an amino acid sequence which differs from any of the aforementioned amino acid sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are alpha-amylase amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or even at least 98% homology to any sequence selected from the group consisting of the polynucleotides shown as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 154 and SEQ ID NO: 156. SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 , SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 41 , SEQ ID NO: 114, SEQ ID NO:
116, SEQ ID NO: 124, SEQ ID NO: 130, SEQ ID NO: 156, SEQ ID NO: 158, SEQ ID NO:
160, SEQ ID NO: 162, SEQ ID NO: 164, SEQ ID NO: 166, SEQ ID NO: 168, SEQ ID NO:
170, SEQ ID NO: 172, SEQ ID NO: 174, SEQ ID NO: 176 and SEQ ID NO: 178. Further preferred is any alpha-amylase amino acid sequence encoded by a DNA sequence which hybridizes under low, medium, midium/high, high and/or very high stringency to any of the aforementioned alpha-amylase DNA sequences. Also preferred are DNA sequences encoding an alpha-amylase amino acid sequence and having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or even 100% homology any of the aforementioned alpha-amylase DNA sequences.
Alpha-amylase catalytic domains: In one embodiment the invention relates to catalytic domains derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity, such as catalytic domains derived from a polypeptide selected from the alpha-amyiases shown in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 115, SEQ ID NO:
117, SEQ ID NO: 125, SEQ ID NO: 131 , SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO:
161 , SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO:
171 , SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177 and SEQ ID NO: 179. Preferred are the catalytic domains shown in the amino acids 1-441 in SEQ ID NO: 14, the amino acids 1-471 in SEQ ID NO: 18, the amino acids 1-450 in SEQ ID NO: 20, the amino acids 1- 445 in SEQ ID NO: 22, the amino acids 1-498 in SEQ ID NO: 26, the amino acids 18-513 in SEQ ID NO: 28, the amino acids 1-507 in SEQ ID NO: 30, the amino acids 1-481 in SEQ ID NO: 32, the amino acids 1-495 in SEQ ID NO: 34, the amino acids 1-477 in SEQ ID NO: 38, the amino acids 1-449 in SEQ ID NO: 42, the amino acids 1-442 in SEQ ID NO: 115, the amino acids 1-441 in SEQ ID NO: 117, the amino acids 1-477 in SEQ ID NO: 125, the amino acids 1-446 in SEQ ID NO: 131 , the amino acids 41-481 in SEQ ID NO: 157, the amino acids 22-502 in SEQ ID NO: 159, the amino acids 24-499 in SEQ ID NO: 161 , the amino acids 27-492 in SEQ ID NO: 163, the amino acids 21-496 in SEQ ID NO: 165, the amino acids 29-501 in SEQ ID NO: 167, the amino acids 22-487 in SEQ ID NO: 169, the amino acids 21-463 in SEQ ID NO: 171 , the amino acids 21-477 in SEQ ID NO: 173, the amino acids 288-773 in SEQ ID NO: 175, the amino acids 22-471 in SEQ ID NO: 177 and the amino acids 20-470 in SEQ ID NO: 179. Also preferred are catalytic domain sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned catalytic domain sequences. In another preferred embodiment the catalytic domain sequence have an amino acid sequence which differs from any of the aforementioned catalytic domain sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position. Also preferred are catalytic domain amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of the polynucleotides shown as the nucleotides 1-1326 in SEQ ID NO: 13, nucleotides 1-1413 in SEQ ID NO: 17, nucleotides 1-1350 in SEQ ID NO: 19, nucleotides 1-1338 in SEQ ID NO: 21 , nucleotides 1-1494 in SEQ ID NO: 25, nucleotides 52-1539 in SEQ ID NO: 27, nucleotides 1-1521 in SEQ ID NO: 29, nucleotides 1-1443 in SEQ ID NO: 31 , nucleotides 1-1485 in SEQ ID NO: 33, nucleotides 1-1431 in SEQ ID NO: 37, nucleotides 1-1347 in SEQ ID NO: 41 , nucleotides 1-1326 in SEQ ID NO: 114, nucleotides 1-1323 in SEQ ID NO: 116, nucleotides 1-1431 in SEQ ID NO: 124, nucleotides 1-1338 in SEQ ID NO: 130, nucleotides 121-1443 in SEQ ID NO: 156, nucleotides 64-1506 in SEQ ID NO: 158, nucleotides 70-1497 in SEQ ID NO: 160, nucleotides 79-1476 in SEQ ID NO: 162, nucleotides 61-1488 in SEQ ID NO: 164, nucleotides 85-1503 in SEQ ID NO: 166, nucleotides 64-1461 in SEQ ID NO: 168, nucleotides 61-1389 in SEQ ID NO: 170, nucleotides 61-1431 in SEQ ID NO: 172, nucleotides 862-2322 in SEQ ID NO: 174, nucleotides 64-1413 in SEQ ID NO: 176 and nucleotides 58-1410 in SEQ ID NO: 178. Further preferred is any catalytic domain amino acid sequence encoded by a DNA sequence hybridizing under low, medium, medium/high, high and/or very high stringency to any of the aforementioned DNA sequences. Also preferred are DNA sequences encoding a catalytic domain amino acid sequence and having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or even 100% homology any of the aforementioned catalytic domain DNA sequences.
Linker sequences: In one embodiment the invention relates to linker sequences derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity. Preferred are a linker amino acid sequences selected from the group consisting of the shown as amino acids 503-528 in SEQ ID NO: 159, amino acids 500-532 in SEQ ID NO: 161 , amino acids 493-507 in SEQ ID NO: 163, amino acids 497-539 in SEQ ID NO: 165, amino acids 488-512 in SEQ ID NO: 169 in 478-491 in SEQ ID NO: 173, amino acids 472-486 in SEQ ID NO: 177 and amino acids 471-481 in SEQ ID NO: 179. Also preferred are linker amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned linker sequences. In another preferred embodiment the linker sequence have an amino acid sequence which differs from any of the aforementioned linker sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position. Carbohvdrate-bindinα modules: In one embodiment the invention relates to CBMs derived from polypeptides comprising a carbohydrate-binding module ("CBM") and an having alpha-amylase activity, said CBM derived from a polypeptide selected from the alpha- amylases shown in SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 125, SEQ ID NO: 131 , SEQ ID NO: 157, SEQ ID NO: 159, SEQ ID NO: 161 , SEQ ID NO: 163, SEQ ID NO: 165, SEQ ID NO: 167, SEQ ID NO: 169, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 177 and SEQ ID NO: 179. Preferred are a CBM amino acid sequence selected from the group consisting of the sequence having the amino acids 529-626 in SEQ ID NO: 159, the amino acids 533-630 in SEQ ID NO: 161 , the amino acids 508-602 in SEQ ID NO: 163, the amino acids 540-643 in SEQ ID NO: 165, the amino acids 502-566 in SEQ ID NO: 167, the amino acids 513-613 in SEQ ID NO: 169, the amino acids 492-587 in SEQ ID NO: 173, the amino acids 30-287 in SEQ ID NO: 175, the amino acids 487-586 in SEQ ID NO: 177 and the amino acids 482-582 in SEQ ID NO: 179. Also preferred are CBM amino acid sequences having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the aforementioned CBM amino acid sequences. In another preferred embodiment the CBM sequence have an amino acid sequence which differs from any of the aforementioned CBM sequences in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are a CBM amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of the polynucleotides shown as nucleotides 1585-1878 in SEQ ID NO: 158, nucleotides 1597- 1890 in SEQ ID NO: 160, nucleotides 1522-1806 in SEQ ID NO: 162, nucleotides 1618-1929 in SEQ ID NO: 164, nucleotides 1504-1701 in SEQ ID NO: 166, nucleotides 1537-1842 in SEQ ID NO: 168, nucleotides 1474-1764 in SEQ ID NO: 172, nucleotides 61-861 in SEQ ID NO: 174, nucleotides 1459-1761 in SEQ ID NO: 176 and nucleotides 1444-1749 in SEQ ID NO: 178. SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ JD NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 154 and SEQ ID NO: 156. Further preferred is any CBM amino acid sequence encoded by a DNA sequence hybridizing under low, medium, medium/high, high and/or very high stringency to the complementary DNA sequence of any of the aforementioned CBM DNA sequences. Also preferred are DNA sequences encoding a CBM amino acid sequence and having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or even 100% homology any of the aforementioned CBM DNA sequences.
The DNA sequences shown as nucleotides 1504-1701 in SEQ ID NO: 166 and nucleotides 61-861 in SEQ ID NO: 174 and the encoded amino acid sequences comprise in addition to the CBD also a linker sequence. Table 1
Figure imgf000015_0001
Figure imgf000016_0001
The alpha-amylase polypeptides may be applied in starch degradation processes and/or used as donors of catalytic domain and/or CBM for a hybrid polypeptide. A preferred polypeptide of the invention, e.g., a hybrid polypeptide, comprises a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module, wherein said second amino acid sequence has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of amino acids 529-626 in SEQ ID NO: 159, the amino acids 533-630 in SEQ ID NO: 161 , the amino acids 508-602 in SEQ ID NO: 163, the amino acids 540-643 in SEQ ID NO: 165, the amino acids 502-566 in SEQ ID NO: 167, the amino acids 513-613 in SEQ ID NO: 169, the amino acids 492-587 in SEQ ID NO: 173, the amino acids 30-287 in SEQ ID NO: 175, the amino acids 487-586 in SEQ ID NO: 177 and the amino acids 482-582 in SEQ ID NO: 179. Further preferred are polypeptides, e.g., hybrid polypeptides, wherein said first amino acid sequence has at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, the amino acids 1-471 in SEQ ID NO: 18, the amino acids 1-450 in SEQ ID NO: 20, the amino acids 1-445 in SEQ ID NO: 22, the amino acids 1- 498 in SEQ ID NO: 26, the amino acids 18-513 in SEQ ID NO: 28, the amino acids 1-507 in SEQ ID NO: 30, the amino acids 1-481 in SEQ ID NO: 32, the amino acids 1-495 in SEQ ID NO: 34, the amino acids 1-477 in SEQ ID NO: 38, the amino acids 1-449 in SEQ ID NO: 42, the amino acids 1-442 in SEQ ID NO: 115, the amino acids 1-441 in SEQ ID NO: 117, the amino acids 1-477 in SEQ ID NO: 125, the amino acids 1-446 in SEQ ID NO: 131 , the amino acids 41-481 in SEQ ID NO: 157, the amino acids 22-502 in SEQ ID NO: 159, the amino acids 24-499 in SEQ ID NO: 161 , the amino acids 27-492 in SEQ ID NO: 163, the amino acids 21-496 in SEQ ID NO: 165, the amino acids 29-501 in SEQ ID NO: 167, the amino acids 22-487 in SEQ ID NO: 169, the amino acids 21-463 in SEQ ID NO: 171 , the amino acids 21-477 in SEQ ID NO: 173, the amino acids 288-773 in SEQ ID NO: 175, the amino acids 22-471 in SEQ ID NO: 177 and the amino acids 20-470 in SEQ ID NO: 179. Also preferred are polypeptides, e.g., hybrid polypeptides, wherein a linker sequence is present in a position between said first and said second amino acid sequence, said linker sequence having at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, such as at least 95% homology to any amino acid sequence selected from the group consisting of as amino acids 503-528 in SEQ ID NO: 159, amino acids 500-532 in SEQ ID NO: 161, amino acids 493-507 in SEQ ID NO: 163, amino acids 497-539 in SEQ ID NO: 165, amino acids 488-512 in SEQ ID NO: 169 in 478-491 in SEQ ID NO: 173, amino acids 472-486 in SEQ ID NO: 177 and amino acids 471-481 in SEQ ID NO: 179.
Alpha-amylase sequence
Catalytic domains, i.e., alpha-amylase catalytic domains (in particular acid stable alpha- amylases), which are appropriate for construction of polypeptides of the types of the present invention may be derived from any organism, preferred are those of fungal or bacterial origin. Preferably the alpha-amylase is a wild type enzyme. More preferably the alpha-amylase is a variant alpha-amylases comprising amino acid modifications leading to increased activity, increased protein stability at low pH, and/or at high pH, increased stability towards calcium depletion, and/or increased stability at elevated temperature.
Relevant alpha-amylases for use in a hybrid of the invention include alpha-amylases obtainable from a species selected from the list consisting of Absidia, Acremonium, Aspergillus, Coniochaeta, Coniochaeta, Cryptosporiopsis, Dichotomocladium, Dinemasporium sp., Diplodia, Fusarium, Gliocladium, Malbranchea, Meripilus Trametes, Nectria, Nectria, Penicillium, Phanerochaete, Rhizomucor, Rhizopus, Streptomyces, Subulispora, Syncephalastrum, Thaminidium, Thermoascυs, Thermomyces, Trametes, Trichophaea and Valsaria. The alpha-amylases catalytic domain may also be derived from a bacteria, e.g., Bacillus.
Preferably the alpha-amylases amino acid sequence selected is derived from any species selected from the group consisting of Absidia cristata, Acremonium sp., Aspergillus niger, Aspergillus kawachii, Aspergillus oryzae, Coniochaeta sp., Coniochaeta sp., Cryptosporiopsis sp., Dichotomocladium hesseltinei, Dinemasporium sp., Diplodia sp., Fusarium sp., Gliocladium sp., Malbranchea sp., Meripilus giganteus, Nectria sp., Nectria sp., Penicillium sp., Phanerochaete chrysosporium, Rhizomucor pusillus, Rhizopus oryzae, Stereum sp. Streptomyces thermocyaneoviolaceus, Streptomyces limosus, Subulispora procurvata, Syncephalastrum racemosum, Thaminidium elegans, Thermoascus aurantiacus, Thermoascus sp., Thermomyces lanuginosus, Trametes corrugata, Trametes sp., Trichophaea saccata, Valsaria rubricosa, Valsaria spartii and Bacillus flavothermus (Syn. Anoxybacillus contaminans).
Preferably the hybrid comprises an alpha-amylase amino acid sequence selected from the group consisting of the alpha-amylase catalytic modules listed in table 1 or 2.
Most preferably the hybrid comprises an alpha-amylase amino acid sequence selected from the group consisting of the alpha-amylases from Aspergillus niger (SEQ ID NO: 2), Aspergillus oryzae (SEQ ID NO: 4 and SEQ ID NO: 6), Trichophaea saccata (SEQ ID NO: 8), Subulispora procurvata (SEQ ID NO: 10), Valsaria rubricosa (SEQ ID NO: 12), Thermomyces lanuginosus (SEQ ID NO: 14), Acremonium sp. (SEQ ID NO: 16), Malbranchea sp. (SEQ ID NO: 18), Rhizomucor pusillus (SEQ ID NO: 20), Dichotomocladium hesseltinei (SEQ ID NO: 22), Meripilus giganteus (SEQ ID NO: 24), Stereum sp. AMY1179 (SEQ ID NO: 26), Trametes sp. (SEQ ID NO: 28), Coriolus censors (SEQ ID NO: 30), Dinemasporium sp. (SEQ ID NO: 32), Cryptosporiopsis sp. (SEQ ID NO: 34), Coniochaeta sp. (SEQ ID NO: 36), Diplodia sp. (SEQ ID NO: 38), Nectria sp. (SEQ ID NO: 40), Gliocladium sp. (SEQ ID NO: 42), Streptomyces thermocyaneoviolaceus (SEQ ID NO: 44), Thermoascus sp. Il (SEQ ID NO: 111), Coniochaeta sp. (SEQ ID NO: 113), Nectria sp. (SEQ ID NO: 115), Fusarium sp. (SEQ ID NO: 117), Trametes corrugata (SEQ ID NO: 119), Penicillium sp. (SEQ ID NO: 121), Valsaria spartii (SEQ ID NO: 123), Thermoascus aurantiacus (SEQ ID NO: 125), Phanerochaete chrysosporium (SEQ ID NO: 127), Rhizopus oryzae (SEQ ID NO: 129), Thaminidium elegans (SEQ ID NO: 131), Absidia cristata (SEQ ID NO: 133), Syncephalastrum racemosum (SEQ ID NO: 135) and Streptomyces limosus (SEQ ID NO: 155).
Also preferred for the invention are hybrids comprising a alpha-amylase amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121 , SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135 and SEQ ID NO: 155.
In another preferred embodiment the hybrid enzyme has a alpha-amylase sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111 , SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131 , SEQ ID NO: 133, SEQ ID NO: 135 and SEQ ID NO: 155 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are hybrids comprising a alpha-amylases amino acid sequence encoded by a DNA sequence having at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 , SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122, SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134 and SEQ ID NO: 154.
Further preferred are hybrids comprising a alpha-amylase encoded by a DNA sequence hybridizing under low, medium, midium/high, high and/or very high stringency to any DNA sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 3,
SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 , SEQ ID NO: 13, SEQ ID NO:
15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ
ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31 , SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41 , SEQ ID NO: 43, SEQ ID NO: 110, SEQ ID NO: 112,
SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120, SEQ ID NO: 122,
SEQ ID NO: 124, SEQ ID NO: 126, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132,
SEQ ID NO: 134 and SEQ ID NO: 154.
Linker sequence
The linker sequence may be any suitable linker sequence, e.g., a linker sequence derived from an alpha-amylase or a glucoamylase. The linker may be a bond, or a short linking group comprising from about 2 to about 100 carbon atoms, in particular of from 2 to 40 carbon atoms. However, the linker is preferably a sequence of from about 2 to about 100 amino acid residues, more preferably of from 4 to 40 amino acid residues, such as from 6 to 15 amino acid residues.
Preferably the hybrids comprising a linker sequence derived from any species selected from the group consisting of Acremonium, Coniochaeta, Coniochaeta, Meripilus, Pachykytospora, Penicillium, Sublispora, Trametes, Trichophaea, Valsaria, Athelia, Aspergillus, Trametes and Leucopaxillus. The linker may also be derived from a bacterium, e.g., from a strain within Bacillus sp. More the preferably linker is derived from a species selected from the group consisting of Acremonium sp., Coniochaeta sp., Coniochaeta sp., Meripilus giganteus, Penicillium sp., Sublispora provurvata, Trametes corrugata, Trichophaea saccata, Valsaria rubricosa, Valsario spartii, Aspergillus kawachii, Aspergillus niger, Athelia rolfsii, Leucopaxillus gigantus, Pachykytospora papayracea, Trametes cingulata and Bacillus flavothermus.
Preferably the hybrid comprises a linker amino acid sequence selected from the group consisting of the linkers listed in table 1 or 2.
More preferably the linker is a linker from a glucoamylase selected from the group consisting of Pachykytospora papayracea (SEQ ID NO: 46), Trametes cingulata (SEQ ID NO: 48), Leucopaxillus gigantus (SEQ ID NO: 50), Athelia rolfsii (SEQ ID NO: 68), Aspergillus kawachii (SEQ ID NO: 70), Aspergillus niger (SEQ ID NO: 72) or a linker from an alpha-amylase selected from the group consisting of Sublispora provurvata (SEQ ID NO: 54), Valsaria rubricosa (SEQ ID NO: 56), Acremonium sp. (SEQ ID NO: 58), Meripilus giganteus (SEQ ID NO: 60), Bacillus flavothermus (SEQ ID NO: 62, SEQ ID NO: 64 or SEQ ID NO: 66), Coniochaeta sp. AM603 (SEQ ID NO: 74), Coniochaeta sp. (SEQ ID NO: 145), Trametes corrugata (SEQ ID NO: 147), Valsario spartii (SEQ ID NO: 149), Penicillium sp. (SEQ ID NO: 151), Trichophaea saccata (SEQ ID NO: 52).
Also preferred for the invention is any linker amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149 and SEQ ID NO: 151. In another preferred embodiment the hybrid enzyme has a linker sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149 and SEQ ID NO: 151 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are the hybrids comprising a linker sequence encoded by a DNA sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51 , SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71 , SEQ ID NO: 73, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, and SEQ ID NO: 150.
Further preferred are the hybrids comprising a linker sequence encoded by a DNA sequence hybridizing under high, medium or low stringency to any DNA sequence selected from the group consisting SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51 , SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61 , SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71 , SEQ ID NO: 73, SEQ ID NO: 144, SEQ ID NO: 146, SEQ ID NO: 148, and SEQ ID NO: 150. In preferred embodiments the linker originating from the CBM source is used, e.g., when using the CBM from A. rolfsii glucoamylase the linker sequence from the A. rolfsii glucoamylase is used in the hybrid as well.
Carbohydrate-binding modules
A carbohydrate-binding module (CBM), or as often referred to, a carbohydrate- binding domain (CBM), is a polypeptide amino acid sequence which binds preferentially to a poly- or oligosaccharide (carbohydrate), frequently - but not necessarily exclusively - to a water-insoluble (including crystalline) form thereof. CBMs derived from starch degrading enzymes are often referred to as starch-binding modules or SBMs (CBMs which may occur in certain amylolytic enzymes, such as certain glucoamylases (GA), or in enzymes such as cyclodextrin glucanotransferases, or in alpha- amylases). Likewise, other sub-classes of CBMs would embrace, e.g., cellulose-binding modules (CBMs from cellulolytic enzymes), chitin-binding modules (CBMs which typically occur in chitinases), xylan-binding modules (CBMs which typically occur in xylanases), mannan-binding modules (CBMs which typically occur in mannanases). SBMs are often referred to as SBDs (Starch Binding Domains).
CBMs are found as integral parts of large polypeptides or proteins consisting of two or more polypeptide amino acid sequence regions, especially in hydrolytic enzymes (hydrolases) which typically comprise a catalytic module containing the active site for substrate hydrolysis and a carbohydrate-binding module (CBM) for binding to the carbohydrate substrate in question. Such enzymes can comprise more than one catalytic module and one, two or three CBMs and optionally further comprise one or more polypeptide amino acid sequence regions linking the CBM(s) with the catalytic module(s), a region of the latter type usually being denoted a "linker". Examples of hydrolytic enzymes comprising a CBM - some of which have already been mentioned above - are cellulases, xylanases, mannanases, arabinofuranosidases, acetylesterases and chitinases. CBMs have also been found in algae, e.g., in the red alga Porphyra purpurea in the form of a non-hydrolytic polysaccharide-binding protein. In proteins/polypeptides in which CBMs occur (e.g., enzymes, typically hydrolytic enzymes), a CBM may be located at the N or C terminus or at an internal position.
That part of a polypeptide or protein (e.g., hydrolytic enzyme) which constitutes a CBM per se typically consists of more than about 30 and less than about 250 amino acid residues. The "Carbohydrate-Binding Module of Family 20" or a CBM-20 module is in the context of this invention defined as a sequence of approximately 100 amino acids having at least 45% homology to the Carbohydrate-Binding Module (CBM) of the polypeptide disclosed in figure 1 by Joergensen et al. (1997) in Biotechnol. Lett. 19:1027-1031. The CBM comprises the last 102 amino acids of the polypeptide, i.e., the subsequence from amino acid 582 to amino acid 683. The numbering of Glycoside Hydrolase Families applied in this disclosure follows the concept of Coutinho, P.M. & Henrissat, B. (1999) CAZy - Carbohydrate-Active Enzymes server at URL: http://afmb.cnrs-mrs.fr/~cazv/CAZY/index.html or alternatively Coutinho, P.M. & Henrissat, B. 1999; The modular structure of cellulases and other carbohydrate-active enzymes: an integrated database approach. In "Genetics, Biochemistry and Ecology of Cellulose Degradation", K. Ohmiya, K. Hayashi, K. Sakka, Y. Kobayashi, S. Karita and T. Kimura eds., Uni Publishers Co., Tokyo, pp. 15-23 and Bourne, Y. Se Henrissat, B. 2001 ; Glycoside hydrolases and glycosyltransferases: families and functional modules, Current Opinion in Structural Biology 11 :593-600.
Examples of enzymes which comprise a CBM suitable for use in the context of the invention are alpha-amylases, maltogenic alpha-amylases, cellulases, xylanases, mannanases, arabinofuranosidases, acetylesterases and chitinases. Further CBMs of interest in relation to the present invention include CBMs deriving from glucoamylases (EC 3.2.1.3) or from CGTases (EC 2.4.1.19).
CBMs deriving from fungal, bacterial or plant sources will generally be suitable for use in the hybrid of the invention. Preferred are CBMs of fungal origin. In this connection, techniques suitable for isolating the relevant genes are well known in the art.
Preferred are hybrids comprising a CBM of Carbohydrate-Binding Module Family 20, 21 or 25. CBMs of Carbohydrate-Binding Module Family 20 suitable for the invention may be derived from glucoamylases of Aspergillus awamori (SWISSPROT Q12537), Aspergillus kawachii (SWISSPROT P23176), Aspergillus niger (SWISSPROT P04064), Aspergillus oryzae (SWISSPROT P36914), from alpha-amylases of Aspergillus kawachii (EMBL:#AB008370), Aspergillus nidulans (NCBI AAF17100.1), from beta-amylases of Bacillus cereus (SWISSPROT P36924), or from CGTases of Bacillus circulans fSWISSPROT P43379). Preferred is a CBM from the alpha-amylase of Aspergillus kawachii (EMBL:#AB008370) as well as CBMs having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the CBM of the alpha-amylase of Aspergillus kawachii (EMBL:#AB008370). Further preferred CBMs include the CBMs of the glucoamylase from Hormoconis sp. such as from Hormoconis resinae (Syn. Creosote fungus or Amorphotheca resinae) such as the CBM of SWISSPROT:Q03045. from Lentinula sp. such as from Lentinula edodes (shiitake mushroom) such as the CBM of SPTREMBL:Q9P4C5, from Neurospora sp. such as from Neurospora crassa such as the CBM of SWISSPROT:P14804, from Talaromyces sp. such as from Talaromyces byssochlamydioides, from Geosmithia sp. such as from Geosmithia cylindrospora, from Scorias sp. such as from Scorias spongiosa, from Eupenicillium sp. such as from Eupenicillium ludwigii, from Aspergillus sp. such as from Aspergillus japonicus, from Penicillium sp. such as from Penicillium cf. miczynskii, from Thysanophora sp., and from Humicola sp. such as from Humicola grisea var. thermoidea such as the CBM of SPTREMBLQ12623.
Preferably the hybrid comprises a CBM which is derived from any family or species selected from the group consisting of Acremonium, Aspergillus, Athelia, Coniochaeta, Cryptosporiopsis, Dichotomocladium, Dinemasporium, Diplodia, Gliocladium, Leucopaxillus, Malbranchea, Meripilus, Nectria, Pachykytospora, Penicillium, Rhizomucor, Rhizomucor pusillus, Streptomyces, Subulispora, Thermomyces, Trametes, Trichophaea saccata and Valsaria. The CBM may also be derived from a plant, e.g., from corn (e.g., Zea mays) or a bacterial, e.g., Bacillus. More preferably the hybrid comprises a CBM derived from any species selected from the group consisting of Acremonium sp., Aspergillus kawachii, Aspergillus niger,Aspergillus oryzae, Athelia rolfsii, Bacillus flavothermus, Coniochaeta sp., Cryptosporiopsis sp., Dichotomocladium hesseltinei, Dinemasporium sp., Diplodia sp., Gliocladium sp., Leucopaxillus gigantus, Malbranchea sp, Meripilus giganteus, Nectria sp., Pachykytospora papayracea, Penicillium sp., Rhizomucor pusillus, Streptomyces thermocyaneoviolaceus, Streptomyces limosus, Subulispora provurvata, Thermomyces lanuginosus, Trametes cingulata, Trametes corrugata, Trichophaea saccata, Valsaria rubricosa, Valsaho spartii and Zea mays.
Preferably the hybrid comprises a CBM amino acid sequence selected from the group consisting of the CBMs listed in table 1 or 2.
Most preferably the hybrid comprises a CBM from a glucoamylase selected from the group consisting of the Pachykytospora papayracea (SEQ ID NO: 76), Trametes cingulata (SEQ ID NO: 78), Leucopaxillus gigantus (SEQ ID NO: 80), Athelia rolfsii (SEQ ID NO: 92), Aspergillus kawachii (SEQ ID NO: 94), Aspergillus niger (SEQ ID NO: 96) or from a alpha- amylase selected from the group consisting of Trichopheraea saccata (SEQ ID NO: 52), Subulispora provurvata (SEQ ID NO: 82), Valsaria rubricosa (SEQ ID NO: 84), Acremonium sp. (SEQ ID NO: 86), Meripilus giganteus (SEQ ID NO: 88), Bacillus flavothermus (SEQ ID NO: 90), Coniochaeta sp. (SEQ ID NO: 98), Zea mays (SEQ ID NO: 109), Coniochaeta sp. (SEQ ID NO: 137), Trametes corrugata (SEQ ID NO: 139), Valsaho spartii (SEQ ID NO: 141) and Penicillium sp. (SEQ ID NO: 143).
In another preferred embodiment the hybrid enzyme has a CBM sequence which differs from an amino acid sequences selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID
NO: 98, SEQ ID NO: 109, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141 and SEQ ID
NO: 143 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are any CBM encoded by a DNA sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence selected from the group consisting of SEQ ID NO: 75,
SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81 , SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91 , SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 108, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140 and SEQ ID NO: 142. Further preferred are any CBM encoded by a DNA sequence hybridizing under high, medium or low stringency to any DNA sequence selected from the group consisting of SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81 , SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91 , SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 97, SEQ ID NO: 108, SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 140 and SEQ ID NO: 142.
Further suitable CBMs of Carbohydrate-Binding Module Family 20, 21 or 25 may be found at URL: http://afmb.cnrs-mrs.fr/~cazy/CAZY/index.html). Once a nucleotide sequence encoding the substrate-binding (carbohydrate-binding) region has been identified, either as cDNA or chromosomal DNA, it may then be manipulated in a variety of ways to fuse it to a DNA sequence encoding the polypeptide of interest. The DNA fragment encoding the carbohydrate-binding amino acid sequence and the DNA encoding the polypeptide of interest are then ligated with or without a linker. The resulting ligated DNA may then be manipulated in a variety of ways to achieve expression.
Particular embodiments
In a preferred embodiment the polypeptide comprises a CDM derived from Athelia rolfsii, Pachykytospora papayracea, Valsaria rubricosa or Mθripilus giganteus. Preferred are any polypeptide comprising a CBM amino acid sequence selected from the group consisting of Athelia rolfsii glucoamylase (SEQ ID NO: 92), the Pachykytospora papayracea glucoamylase (SEQ ID NO: 76), the Valsaria rubricosa alpha-amylase (SEQ ID NO: 84) and the Meripilus giganteus alpha-amylase (SEQ ID NO: 88).
In yet a preferred embodiment the polypeptide comprises an alpha-amylase sequence derived from the A. oryzae acid alpha-amylase (SEQ ID NO: 4), Preferably the wherein said A. oryzae amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of A128P, K138V, S141 N, Q143A, D144S, Y155W, E156D, D157N, N244E, M246L, G446D, D448S and N450D. Most preferably the polypeptide comprises an catalytic domain having the amino acid sequence shown in SEQ ID NO: 6. In a preferred embodiment the polypeptide further comprises a CBM derived from A. rolfsii, Preferably the polypeptide further comprises a CBM having the amino acid sequence shown in SEQ ID NO: 92. Most preferably the polypeptide has the amino acid sequence shown in SEQ ID NO: 100 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the afore mentioned amino acid sequence. Also preferred is any polypeptide encoded by a DNA sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the DNA sequence shown in SEQ ID NO: 99.
In another preferred embodiment the polypeptide comprises a catalytic module derived from the Rhizomucor pusillus alpha-amylase and/or a CBM derived from A. rolfsii. In a particular preferred embodiment the polypeptide has the amino acid sequence shown in SEQ ID NO: 101 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any of the afore mentioned amino acid sequence.
In yet a preferred embodiment the polypeptide comprises a catalytic module derived from the Meripilus giganteus alpha-amylase and/or a CBM derived from A. rolfsii. In a particular preferred embodiment the polypeptide has the amino acid sequence shown in SEQ ID NO: 102 or the polypeptide has an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to the afore mentioned amino acid sequence. In yet another preferred embodiment the polypeptide has an amino acid sequence which differs from any the amino acid sequence amino acid sequences shown in SEQ ID NO: 100, SEQ ID NO: 101 and SEQ ID NO: 102 in no more than 10 positions, no more than 9 positions, no more than 8 positions, no more than 7 positions, no more than 6 positions, no more than 5 positions, no more than 4 positions, no more than 3 positions, no more than 2 positions, or even no more than 1 position.
Also preferred are any polypeptide encoded by a DNA sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or even at least 95% homology to any sequence DNA sequence encoding any the amino acid sequence amino acid sequences shown in SEQ ID NO: 100, SEQ ID NO: 101 and SEQ ID NO: 102. Further preferred are any CBM encoded by a DNA sequence which hybridizing under high, medium or low stringency to any DNA sequence encoding any of the amino acid sequence amino acid sequences shown in SEQ ID NO: 100, SEQ ID NO: 101 and SEQ ID NO: 102. Other preferred embodiments of the polypeptides of the invention are shown in table 3,
4, 5 and 6 in the examples section. Also preferred is any polypeptide having at least 70%, more preferred at least 80% and even more preferred at least 90% homology to any of the amino acid sequences of the polypeptides shown in tables 1 to 7. Further preferred is any polypeptide encoded by a DNA sequence which hybridizes at low, medium, or high stringency with DNA sequence encoding any of the amino acid sequences of the polypeptides shown in tables 1 to 7.
In a preferred embodiment the polypeptide comprises a catalytic domain having at least 75% homology to the A. oryzae catalytic domain (SEQ ID NO: 6) and a CBM having at least 75% homology to a CBM selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 52, SEQ . ID NO: 92, SEQ ID NO: 52, and SEQ ID NO: 90. In a more preferred embodiment the polypeptide comprises the A. oryzae catalytic domain (SEQ ID NO: 6) and a CBM selected from the group consisting of SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 88, SEQ ID NO: 52, SEQ ID NO: 92, SEQ ID NO: 52, SEQ ID NO: 90, SEQ ID NO: 90 and SEQ ID NO: 90.
In a preferred embodiment the polypeptide comprises a CBM having at least 75% homology to the A. rolfsii glucoamylase CBM (SEQ ID NO: 92) and a catalytic domain having at least 75% homology to a catalytic domain selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 155, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 121 , SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131 , SEQ ID NO: 133 and SEQ ID NO: 135. In a more preferred embodiment the polypeptide comprises the A. rolfsii glucoamylase CBM (SEQ ID NO: 92) and a catalytic domain selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 155, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111 , SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 121 , SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131 , SEQ ID NO: 133 and SEQ ID NO: 135.
In a preferred embodiment the polypeptide comprises a CBM having at least 75% homology the Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145 and a catalytic domain having at least 75% homology to a CBM selected from the group consisting of the Acremonium sp. alpha-amylase CBM in SEQ ID NO: 16, the Rhizomucor pusillus alpha-amylase CBM in SEQ ID NO: 20 and the Meripilus giganteus alpha-amylase CBM in SEQ ID NO: 24. In a more preferred embodiment the polypeptide comprises the Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145 and a CBM selected from the group consisting of the Acremonium sp. alpha-amylase CBM in SEQ ID NO: 16, the Rhizomucor pusillus alpha-amylase CBM in SEQ ID . NO: 20 and the Meripilus giganteus alpha-amylase CBM in SEQ ID NO: 24.
In a preferred embodiment the polypeptide comprises a catalytic domain having at least 75% homology to the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM having at least 75% homology to a CBM selected from the group consisting of Aspergillus kawachii glucoamylase CBM SEQ ID NO: 94 and the Aspergillus niger glucoamylase CBM in SEQ ID NO: 96. In a more preferred embodiment the polypeptide comprises the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM selected from the group consisting of Aspergillus kawachii glucoamylase CBM SEQ ID NO: 94 and the Aspergillus niger glucoamylase CBM in SEQ ID NO: 96.
In a preferred embodiment the polypeptide comprises a catalytic domain having at least 75% homology to the Meripilus giganteus alpha-amylase catalytic domain (SEQ ID NO: 24) and a CBM having at least 75% homology to a CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109. In a more preferred embodiment the polypeptide comprises the Meripilus giganteus alpha-amylase catalytic domain (SEQ ID NO: 24) and a CBM selected from the group consisting of Pachykytospora papayracea glucoamylase CBM in SEQ ID NO: 145, the Valsaria rubricosa alpha-amylase CBM SEQ ID NO: 84 in and the Zea mays CBM in SEQ ID NO: 109.
In a preferred embodiment the polypeptide comprises a catalytic domain having at least 75% homology to the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM having at least 75% homology to a CBM selected from the group consisting of the A. rolfsii glucoamylase CBM in SEQ ID NO: 92 and the Zea mays CBM in SEQ ID NO: 109, the Coniochaeta sp. alpha-amylase CBM in SEQ ID NO: 113, the Trametes corrugate alpha-amylase CBM in SEQ ID NO: 119, the Valsaha spartii alpha- amylase CBM in SEQ ID NO: 123, the Penicillium sp. alpha-amylase CBM in SEQ ID NO: 121 and the Meripulus giganteus alpha-amylase CBM in SEQ ID NO: 88. In a more preferred embodiment the polypeptide comprises the Rhizomucor pusillus alpha-amylase catalytic domain (SEQ ID NO: 20) and a CBM selected from the group consisting of the A. rolfsii glucoamylase CBM in SEQ ID NO: 92 and the Zea mays CBM in SEQ ID NO: 109, the Coniochaeta sp. alpha-amylase CBM in SEQ ID NO: 113, the Trametes corrugata alpha- amylase CBM in SEQ ID NO: 119, the Valsaha spartii alpha-amylase CBM in SEQ ID NO: 123, the Penicillium sp. alpha-amylase CBM in SEQ ID NO: 121 and the Meripulus giganteus alpha-amylase CBM in SEQ ID NO: 88.
In a particularly preferred embodiment the polypeptide is selected from the group consisting of V001 , V002, V003, V004, V005, V006, V007, V008, V009, V010, V011 , V012, V013, V014, V015, V016, V017, V018, V019, V021 , V022, V023, V024, V025, V026, V027, V028, V029, V030, V031 , V032, V033, V034, V035, V036, V037, V038, V039, V040, V041 , V042, V043, V047, V048, V049, V050, V051 , V052, V054, V055, V057, V059, V060, V061 , V063, V064, V065, V066, V067, V068 and V069.
Expression vectors The present invention also relates to recombinant expression vectors which may comprise a DNA sequence encoding the polypeptide, a promoter, a signal peptide sequence and transcriptional and translational stop signals. The various DNA and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the DNA sequence encoding the polypeptide at such sites. Alternatively, the DNA sequence of the present invention may be expressed by inserting the DNA sequence or a DNA construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression and possibly secretion.
The recombinant expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the DNA sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, a cosmid or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
Markers The vectors of the present invention preferably contain one or more selectable markers, which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs and the like.
Examples of selectable markers for use in a filamentous fungus host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphor-transferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species. Preferred for use in an Aspergillus cell are the amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus. Furthermore, selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.
The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.
The vectors of the present invention may be integrated into the host cell genome when introduced into a host cell. For integration, the vector may rely on the DNA sequence encoding the polypeptide of interest or any other element of the vector for stable integration of the vector into the genome by homologous or none homologous recombination. Alternatively, the vector may contain additional DNA sequences for directing integration by homologous recombination into the genome of the host cell. The additional DNA sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of DNAs, such as 100 to 1 ,500 base pairs, preferably 400 to 1 ,500 base pairs, and most preferably 800 to 1 ,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding DNA sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These DNA sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
The episomal replicating the AMA1 plasmid vector disclosed in WO 00/24883 may be used.
More than one copy of a DNA sequence encoding a polypeptide of interest may be inserted into the host cell to amplify expression of the DNA sequence. Stable amplification of the DNA sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome using methods well known in the art and selecting for transformants.
The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor, New York).
Host cells
The host cell of the invention, either comprising a DNA construct or an expression vector comprising the DNA sequence encoding the polypeptide, is advantageously used as a host cell in the recombinant production of the polypeptide, e.g., a hybrid enzyme, a wild- type enzyme or a genetically modified wild-type enzyme. The cell may be transformed with an expression vector. Alternatively, the cell may be transformed with the DNA construct of the invention encoding the the polypeptide, e.g., a hybrid enzyme, a wild type enzyme or a genetically modified wild type enzyme, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. Integration of the DNA construct into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination.
The host cell may be any appropriate prokaryotic or eukaryotic cell, e.g., a bacterial cell, a filamentous fungus cell, a yeast, a plant cell or a mammalian cell. In a preferred embodiment, the host cell is a filamentous fungus represented by the following groups of Ascomycota, include, e.g., Neurospora, Eupenicillium (=Penicillium), Emericella (^Aspergillus), Eurotium (=Aspergillus).
In a more preferred embodiment, the filamentous fungus includes all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al. In,
Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International,
University Press, Cambridge, UK. The filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic.
In an even more preferred embodiment, the filamentous fungus host cell is a cell of a species of, but not limited to a cell selected from the group consisting of a strain belonging to a species of Aspergillus, preferably Aspergillus oryzae, Aspergillus niger, Aspergillus awamori, Aspergillus kawachii, or a strain of Bacillus, or a strain of Fusarium, such as a strain of Fusarium oxysporium, Fusarium graminearum (in the perfect state named
Gribberella zeae, previously Sphaeria zeae, synonym with Gibberella roseum and Gibberella roseum f. sp. cerealis), or Fusarium sulphureum (in the prefect state named Gibberella puricaris, synonym with Fusarium trichothecioides, Fusarium bactridioides, Fusarium sambucium, Fusarium roseum, and Fusarium roseum var. graminearum), Fusarium cerealis (synonym with Fusarium crookwellense), or Fusarium venenatum.
In a most preferred embodiment, the filamentous fungus host cell is a cell of a strain belonging to a species of Aspergillus, preferably Aspergillus oryzae or Aspergillus niger.
The filamentous fungus host cell may be a wild type filamentous fungus host cell or a variant, a mutant or a genetically modified filamentous fungus host cell. In a preferred embodiment of the invention the host cell is a protease deficient or protease minus strain. Also specifically contemplated is Aspergillus strains, such as Aspergillus niger strains, genetically modified to disrupt or reduce expression of glucoamyiase, acid-stable alpha- amylase, alpha-1,6 transglucosidase, and protease activities.
Transformation of filamentous fungus host cells
Filamentous fungus host cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known in the art. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023, EP 184 438, and Yelton et al. 1984, Proceedings of the National Academy of Sciences USA 81 :1470-1474. A suitable method of transforming Fusarium species is described by Malardier et al. 1989, Gene 78:147-156 or U.S. Patent No. 6,060,305.
Isolating and cloning a DNA sequence encoding a parent alpha-amylase The techniques used to isolate or clone a DNA sequence encoding a polypeptide of interest are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the DNA sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., lnnis et al., 1990, PCR: A Guide to Methods and Application, Academic Press, New York. Other DNA amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and DNA sequence-based amplification (NASBA) may be used.
The DNA sequence encoding a parent alpha-amylase may be isolated from any cell or microorganism producing the alpha-amylase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the alpha-amylase to be studied. Then, if the amino acid sequence of the alpha-amylase is known, labeled oligonucleotide probes may be synthesized and used to identify alpha-amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known alpha-amylase gene could be used as a probe to identify alpha-amylase-encoding clones, using hybridization and washing conditions of very low to very high stringency.
Yet another method for identifying alpha-amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming alpha-amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for alpha-amylase (i.e., maltose), thereby allowing clones expressing the alpha-amylase to be identified.
Alternatively, the DNA sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g., the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p. 1859-1869, or the method described by Matthes et al. (1984), EMBO J. 3, p. 801-805. In the phosphoroamidite method, oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors. Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in U.S. Patent No. 4,683,202 or R. K. Saiki et al. (1988), Science 239, 1988, pp. 487-491.
Isolated DNA sequence
The present invention relates, inter alia, to an isolated DNA sequence comprising a DNA sequence encoding a polypeptide, e.g., a hybrid enzyme, a wild type enzyme or a genetically modified wild type enzyme comprising an amino acid sequence of a catalytic module having alpha-amylase activity and an amino acid sequence of a carbohydrate- binding module, wherein the catalytic module is of fungal origin.
The term "isolated DNA sequence" as used herein refers to a DNA sequence, which is essentially free of other DNA sequences, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably at least about 60% pure, even more preferably at least about 80% pure, and most preferably at least about 90% pure as determined by agarose electrophoresis.
For example, an isolated DNA sequence can be obtained by standard cloning procedures used in genetic engineering to relocate the DNA sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired DNA fragment comprising the DNA sequence encoding the polypeptide of interest, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the DNA sequence will be replicated. An isolated DNA sequence may be manipulated in a variety of ways to provide for expression of the polypeptide of interest. Manipulation of the DNA sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying DNA sequences utilizing recombinant DNA methods are well known in the art.
DNA construct
The present invention relates, inter alia, to a DNA construct comprising a DNA sequence encoding a polypeptide, e.g., a hybrid enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module or a wild type enzyme comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module. "DNA construct" is defined herein as a DNA molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of DNA, which are combined and juxtaposed in a manner, which would not otherwise exist in nature. The term DNA construct is synonymous with the term expression cassette when the DNA construct contains all the control sequences required for expression of a coding sequence of the present invention.
Site-directed mutagenesis
Once a parent alpha-amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites. In a specific method, a single-stranded gap of DNA, the alpha-amylase- encoding sequence, is created in a vector carrying the alpha-amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single- stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al. (1984), Biotechnology 2, p. 646-639. U.S. Patent No. 4,760,025 disclose the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.
Another method for introducing mutations into alpha-amylase-encoding DNA sequences is described in Nelson and Long, (1989), Analytical Biochemistry 180, p. 147-151. It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.
Localized random mutagenesis The random mutagenesis may be advantageously localized to a part of the parent alpha-amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme. The localized or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known in the art. Alternatively, the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g., by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.
Variants of hybrid or wild-type enzymes
The performance in a starch degradation process of a wild type or hybrid enzyme comprising a carbohydrate-binding module ("CBM") and an alpha-amylase catalytic module may be improved through protein engineering, such as by site directed mutagenesis, by localized random mutagenesis, by synthetically preparing a new variant of the parent wild type enzyme or parent hybrid enzyme, or by any other suitable protein engineering techniques. The variants may be produced using conventional protein engineering techniques.
Expression of the polypeptides in a host cell
The nucleotide sequence to be introduced into the DNA of the host cell may be integrated in nucleic acid constructs comprising the nucleotide sequence operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
A nucleotide sequence encoding a polypeptide may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleotide sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleotide sequences utilizing recombinant DNA methods are well known in the art.
The control sequence may be an appropriate promoter sequence, a nucleotide sequence which is recognized by a host cell for expression of the nucleotide sequence. The promoter sequence contains transcriptional control sequences, which mediate the expression of the polypeptide. The promoter may be any nucleotide sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the E. coli lac operon, Streptomyces coelicolor ag a rase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylB genes, and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75: 3727-3731), as well as the tac promoter (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.
Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha- amylase, Aspergillus niger or Aspergillus awamori glucoamylase {glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (WO 96/00787), as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for Aspergillus niger neutral alpha-amylase and Aspergillus oryzae triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.
In a yeast host, useful promoters are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8: 423-488.
The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
Preferred terminators for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.
Preferred terminators for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC 1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra. The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleotide sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.
Preferred leaders for filamentous fungal host cells are obtained from the genes for
Aspergillus oryzae TAKA amylase and Aspergillus nidulans those phosphate isomerase.
Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-factor, and Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).
The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleotide sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.
Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase.
Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Molecular Cellular Biology 15: 5983-5990.
The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleotide sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention. Effective signal peptide coding regions for bacterial host cells are the signal peptide coding regions obtained from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral proteases (nprT, nprS, nprM), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.
Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for Bacillus subtilis alkaline protease {aprE), Bacillus subtilis neutral protease (nprT), Saccharomyces cerevisiae alpha-factor, Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophila laccase (WO 95/33836).
Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.
It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, Aspergillus niger glucoamylase promoter, and Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleotide sequence encoding the polypeptide would be operably linked with the regulatory sequence.
The various nucleotide and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleotide sequence encoding the polypeptide at such sites. Alternatively, the nucleotide sequence of the present invention may be expressed by inserting the nucleotide sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleotide sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.
The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.
The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), as well as equivalents thereof. Preferred for use in an Aspergillus cell are the amdS and pyrG genes of Aspergillus nidulans or Aspergillus oryzae and the bar gene of Streptomyces hygroscopicus.
The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
For integration into the host cell genome, the vector may rely on the nucleotide sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleotide sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleotide sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleotides, such as 100 to 1 ,500 base pairs, preferably 400 to 1 ,500 base pairs, and most preferably 800 to 1 ,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleotide sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.
For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E. coli, and pUB110, pE194, pTA1060, and pAMISI permitting replication in Bacillus. Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1 , ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75: 1433). More than one copy of a nucleotide sequence of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the nucleotide sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the nucleotide sequence where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the nucleotide sequence, can be selected for by cultivating the cells in the presence of the appropriate selectable agent. The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).
Host Cells: The present invention also relates to recombinant fermenting fungus, or a host cell comprising the nucleic acid construct of the invention, which are advantageously used in the recombinant production of the polypeptides on site. A vector comprising a nucleotide sequence of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota,
Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra). In a more preferred embodiment, the fungal host cell is a filamentous fungal cell.
"Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic.
In a preferred embodiment, the filamentous fungal host cell is a cell of a thermophilic or thermo tolerant fungi such as a species within Ascomycotina, Basidiomycotina, Zygomycota or Chytridiomycota, in particular a species within the group consisting of Chaetomium, Thermoascus, Malbranchea, or Thielavia, such as Thielavia terrestris, or Trichophaea. Even more preferably the host cell is a strain of Trichophaea saccata or Humicola, such as H.insolens.
Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences USA 81: 1470-1474. Suitable methods for transforming Fusarium species are described by Malardier et al., 1989, Gene 78: 147-156 and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J.N. and Simon, M. I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume 194, pp 182-187, Academic Press, Inc., New York; lto et al., 1983, Journal of Bacteriology 153: 163; and Hinnen et al., 1978, Proceedings of the National Academy of Sciences USA 75: 1920. Expression of the enzymes in plants
A DNA sequence encoding a polypeptide of interest, such as a hybrid enzyme or a variant of a wild type enzyme or a hybrid of the present invention, may be transformed and expressed in transgenic plants as described below.
The transgenic plant can be dicotyledonous or monocotyledonous, for short a dicot or a monocot. Examples of monocot plants are grasses, such as meadow grass (blue grass, Poa), forage grass such as Festuca, Lolium, temperate grass, such as Agrostis, and cereals, e.g., wheat, oats, rye, barley, rice, sorghum and maize (corn). Examples of dicot plants are tobacco, legumes, such as lupins, potato, sugar beet, pea, bean and soybean, and cruciferous plants (family Brassicaceae), such as cauliflower, oil seed rape and the closely related model organism Arabidopsis thaliana.
Examples of plant parts are stem, callus, leaves, root, fruits, seeds, and tubers as well as the individual tissues comprising these parts, e.g., epidermis, mesophyll, parenchyme, vascular tissues, meristems. In the present context, also specific plant cell compartments, such as chloroplast, apoplast, mitochondria, vacuole, peroxisomes and cytoplasm are considered to be a plant part. Furthermore, any plant cell, whatever the tissue origin, is considered to be a plant part. Likewise, plant parts such as specific tissues and cells isolated to facilitate the utilisation of the invention are also considered plant parts, e.g., embryos, endosperms, aleurone and seeds coats.
Also included within the scope of the invention are the progeny of such plants, plant parts and plant cells.
The transgenic plant or plant cell expressing the polypeptide of interest may be constructed in accordance with methods known in the art. In short the plant or plant cell is constructed by incorporating one or more expression constructs encoding the polypeptide of interest into the plant host genome and propagating the resulting modified plant or plant cell into a transgenic plant or plant cell.
Conveniently, the expression construct is a DNA construct which comprises a gene encoding the polypeptide of interest in operable association with appropriate regulatory sequences required for expression of the gene in the plant or plant part of choice. Furthermore, the expression construct may comprise a selectable marker useful for identifying host cells into which the expression construct has been integrated and DNA sequences necessary for introduction of the construct into the plant in question (the latter depends on the DNA introduction method to be used). The choice of regulatory sequences, such as promoter and terminator sequences and optionally signal or transit sequences is determined, e.g., on the basis of when, where and how the enzyme is desired to be expressed. For instance, the expression of the gene encoding the enzyme of the invention may be constitutive or inducible, or may be developmental, stage or tissue specific, and the gene product may be targeted to a specific cell compartment, tissue or plant part such as seeds or leaves. Regulatory sequences are, e.g., described by Tague et al, Plant Phys., 86, 506, 1988.
For constitutive expression the 35S-CaMV, the maize ubiquitin 1 and the rice actin 1 promoter may be used (Franck et al. 1980. Cell 21 : 285-294, Christensen AH, Sharrock RA and Quail 1992. Maize polyubiquitin genes: structure, thermal perturbation of expression and transcript splicing, and promoter activity following transfer to protoplasts by electroporation. Plant Mo. Biol. 18, 675-689.; Zhang W, McElroy D. and Wu R 1991 , Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell 3, 1155-1165). Organ-specific promoters may, e.g., be a promoter from storage sink tissues such as seeds, potato tubers, and fruits (Edwards & Coruzzi, 1990. Annu. Rev. Genet. 24: 275-303), or from metabolic sink tissues such as meristems (Ito et al., 1994, Plant MoI. Biol. 24: 863-878), a seed specific promoter such as the glutelin, prolamin, globulin or albumin promoter from rice (Wu et al., Plant and Cell Physiology Vol. 39, No. 8 pp. 885-889 (1998)), a Vicia faba promoter from the legumin B4 and the unknown seed protein gene from Vicia faba described by Conrad U. et al, Journal of Plant Physiology Vol. 152, No. 6, pp. 708-711 (1998), a promoter from a seed oil body protein (Chen et al., Plant and Cell Physiology, Vol. 39, No. 9, pp. 935-941 (1998), the storage protein napA promoter from Brassica napus, or any other seed specific promoter known in the art, e.g., as described in WO 91/14772. Furthermore, the promoter may be a leaf specific promoter such as the rbcs promoter from rice or tomato (Kyozuka et al., Plant Physiology, Vol. 102, No. 3, pp. 991-1000 (1993), the chlorella virus adenine methyltransferase gene promoter (Mitra, A. and Higgins, DW, Plant Molecular Biology, Vol. 26, No. 1 , pp. 85-93 (1994), or the aldP gene promoter from rice (Kagaya et al., Molecular and General Genetics, Vol. 248, No. 6, pp. 668-674 (1995), or a wound inducible promoter such as the potato pin2 promoter (Xu et al, Plant Molecular Biology, Vol. 22, No. 4, pp. 573- 588 (1993). Likewise, the promoter may inducible by abiotic treatments such as temperature, drought or alterations in salinity or induced by exogenously applied substances that activate the promoter, e.g., ethanol, oestrogens, plant hormones like ethylene, abscisic acid and gibberellic acid and heavy metals.
A promoter enhancer element may be used to achieve higher expression of the enzyme in the plant. For instance, the promoter enhancer element may be an intron which is placed between the promoter and the nucleotide sequence encoding the enzyme. For instance, Xu et al. op cit disclose the use of the first intron of the rice actin 1 gene to enhance expression. The selectable marker gene and any other parts of the expression construct may be chosen from those available in the art.
The DNA construct is incorporated into the plant genome according to conventional techniques known in the art, including Λojoibactem/m-mediated transformation, virus- mediated transformation, micro injection, particle bombardment, biolistic transformation, and electroporation (Gasser et al, Science, 244, 1293; Potrykus, Bio/Techn. 8, 535, 1990;
Shimamoto et al, Nature, 338, 274, 1989).
Presently, Agrobacterium tumefaciens mediated gene transfer is the method of choice for generating transgenic dicots (for review Hooykas & Schilperoort, 1992, Plant MoI. Biol., 19: 15-38), and can also be used for transforming monocots, although other transformation methods often are used for these plants. Presently, the method of choice for generating transgenic monocots supplementing the Agrobacterium approach is particle bombardment (microscopic gold or tungsten particles coated with the transforming DNA) of embryonic calli or developing embryos (Christou, 1992, Plant J., 2: 275-281; Shimamoto, 1994, Curr. Opin. Biotechnol., 5: 158-162; Vasil et al., 1992, Bio/Technology 10: 667-674). An alternative method for transformation of monocots is based on protoplast transformation as described by Omirulleh S, et al., Plant Molecular Biology, Vol. 21, No. 3, pp. 415-428 (1993).
Following transformation, the transformants having incorporated the expression construct are selected and regenerated into whole plants according to methods well-known in the art. Often the transformation procedure is designed for the selective elimination of selection genes either during regeneration or in the following generations by using, e.g., co- transformation with two separate T-DNA constructs or site specific excision of the selection gene by a specific recombinase.
Starch processing
The polypeptide of the first, second and/or third aspect may be used in a process for liquefying starch, wherein a gelatinized or granular starch substrate is treated in aqueous medium with the hybrid enzyme. The polypeptide of the first, second and/or third aspect may also be used in a process for saccharification of a liquefied starch substrate. A preferred use is in a fermentation process wherein a starch substrate is liquefied and/or saccharified in the presence of the polypeptide of the first, second and/or third aspect to produce glucose and/or maltose suitable for conversion into a fermentation product by a fermenting organism, preferably a yeast. Such fermentation processes include a process for producing ethanol for fuel or drinking ethanol (portable alcohol), a process for producing a beverage, a process for producing desired organic compounds, such as citric acid, itaconic acid, lactic acid, gluconic acid, sodium gluconate, calcium gluconate, potassium gluconate, glucono delta lactone, or sodium erythorbate; ketones; amino acids, such as glutamic acid (sodium monoglutaminate), but also more complex compounds such as antibiotics, such as penicillin, tetracyclin; enzymes; vitamins, such as riboflavin, B12, beta-carotene; hormones, which are difficult to produce synthetically.
The starch to be processed may be a highly refined starch quality, preferably at least 90%, at least 95%, at least 97% or at least 99.5% pure or it may be a more crude starch containing material comprising milled whole grain including non-starch fractions such as germ residues and fibres. The raw material, such as whole grain, is milled in order to open up the structure and allowing for further processing. Two milling processes are preferred according to the invention: wet and dry milling. Also corn grits, and preferably milled corn grits may be applied.
Dry milled grain will in addition to starch comprise significant amounts of non-starch carbohydrate compounds. When such a heterogeneous material is processed by jet cooking often only a partial gelatinization of the starch is achieved. As the polypeptides of the invention have a high activity towards ungelatinized starch the polypeptides are advantageously applied in a process comprising liquefaction and/or saccharification jet cooked dry milled starch.
Furthermore, due to the superior hydrolysis activity of the polypeptide of the first aspect the need for glucoamylase during the saccharification step is greatly reduced. This allows saccharification to be performed at very low levels of glucoamylase activity and preferably glucoamylase activity is either absent or if present, then present in an amount of no more than or even less than 0.5 AGU/g DS, more preferably no more than or even less than 0.4 AGU/g DS, even more preferably no more than or even less than 0.3 AGU/g DS, and most preferably less than 0.1 AGU, such as no more than or even less than 0.05 AGU/g DS of starch substrate. Expressed in mg enzyme protein the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate. The glucoamylase may preferably be derived from a strain within Aspergillus sp., Talaromyces sp., Pachykytospora sp. or Trametes sp., more preferably from Aspergillus niger, Talaromyces emersonii, Trametes cingulata or Pachykytospora papyracea. Again due to the superior hydrolysis activity of the polypeptide of the first aspect the need for alpha-amylase in the liquefaction and/or saccharification step is greatly reduced. Expressed in mg enzyme protein the polypeptide of the first aspect may be dosed in amounts of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate. The polypeptide of the first aspect may be dosed in amounts of 0.05 to 10.0 AFAU/g DS, preferably 0.1 to 5.0 AFAU/g DS, more preferably from 0.25 to 2.5 AFAU/g DS starch. The process may comprise; a) contacting a starch substrate with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect; b) incubating said starch substrate with said polypeptide for a time and at a temperature sufficient to achieve conversion of at least 90%, or at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% w/w of said starch substrate into fermentable sugars; c) fermenting to produce a fermentation product, d) optionally recovering the fermentation product. During the process steps b) and/or c) an enzyme having glucoamylase activity is either absent or present in an amount from 0.001 to 2.0 AGU/g DS, from 0.01 to 1.5 AGU/g DS, from 0.05 to 1 ,0 AGU/g DS, from 0.01 to 0.5 AGU/g DS. Preferably the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 AGU/g DS, more preferably no more than or even less than 0.4 AGU/g DS, even more preferably no more than or even less than 0.3 AGU/g DS, and most preferably no more than or even less than 0.1 AGU, such as no more than or even less than 0.05 AGU/g DS of starch substrate. Expressed in mg enzyme protein the enzyme having glucoamylase activity is either absent or present in an in an amount of no more than or even less than 0.5 mg EP/g DS, more preferably no more than or even less than 0.4 mg EP/g DS, even more preferably no more than or even less than 0.3 mg EP/g DS, and most preferably no more than or even less than 0.1 mg EP/g DS, such as no more than or even less than 0.05 mg EP/g DS or no more than or even less than 0.02 mg EP/g DS of starch substrate. In the process step a, b, c, and/or d may be performed separately or simultaneously. In another aspect the process may comprise; a) contacting a starch substrate with a yeast cell transformed to express a polypeptide comprising a catalytic module having alpha- amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first and/or second aspect; b) incubating said starch substrate with said yeast for a time and at a temperature sufficient to achieve conversion of at least 90% w/w of said starch substrate into fermentable sugars; c) fermenting to produce ethanol; d) optionally recovering ethanol. The steps a, b, and c may performed separately or simultaneously. In yet another aspect the process comprising hydrolysis of a slurry of gelatinized or granular starch, in particular hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below the initial gelatinization temperature of said granular starch. In addition to being contacted with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g., the polypeptide of the first aspect, the starch may be contacted with an enzyme selected from the group consisting of; a fungal alpha-amylase (EC 3.2.1.1), a beta-amylase (E.C. 3.2.1.2), and a glucoamylase (E. C.3.2.1.3). In an embodiment further a bacterial alpha-amylase or a debranching enzyme, such as an isoamylase (E.C. 3.2.1.68) or a pullulanases (E.C. 3.2.1.41) may be added. In the context of the present invention a bacterial alpha-amylase is an alpha-amylase as defined in WO 99/19467 on page 3, line 18 to page 6, line 27.
In an embodiment the process is conducted at a temperature below the initial gelatinization temperature. Preferably the temperature at which the processes are conducted is at least 300C, at least 310C, at least 32°C, at least 33°C, at least 34°C, at least 350C, at least 36°C, at least 37°C, at least 38°C, at least 39°C, at least 40°C, at least 410C, at least 42°C, at least 43°C, at least 44°C, at least 45°C, at least 46°C, at least 47°C, at least 48°C, at least 490C, at least 500C, at least 51 °C, at least 52°C, at least 530C, at least 54°C, at least 55°C, at least 560C, at least 57°C, at least 580C, at least 59°C, or preferably at least 600C. The pH at which the process is conducted may in be in the range of 3.0 to 7.0, preferably from 3.5 to 6.0, or more preferably from 4.0-5.0. In a preferred embodiment the process comprises fermentation, e.g with a yeast to produce ethanol, e.g., at a temperature around 320C, such as from 30 to 350C.
In another preferred embodiment the process comprises simultaneous saccharification and fermentation, e.g with a yeast to produce ethanol, or another suitable fermentation organism to produce a desired organic compound, such as at a temperature from 30 to 350C, e.g., at around 320C.
In the above fermentation processes the ethanol content reaches at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15% such as at least 16% ethanol. The starch slurry to be used in any of the above aspects may have 20-55% dry solids granular starch, preferably 25-40% dry solids granular starch, more preferably 30-35% dry solids granular starch. After being contacted with the polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or preferably at least 99% of the dry solids of the granular starch is converted into a soluble starch hydrolysate.
In another preferred embodiment the polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect, is used in a process for liquefaction, saccharification of a gelatinized starch, e.g., but not limited to gelatinization by jet cooking. The process may comprise fermentation to produce a fermentation product, e.g., ethanol. Such a process for producing ethanol from starch-containing material by fermentation comprises: (i) liquefying said starch-containing material with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module, e.g, the polypeptide of the first aspect; (ii) saccharifying the liquefied mash obtained; (iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism. Optionally the process further comprises recovery of the ethanol. The saccharification and fermentation may be carried out as a simultaneous saccharification and fermentation process (SSF process). During the fermentation the ethanol content reaches at least 7%, at least 8%, at least 9%, at least 10% such as at least 11 %, at least 12%, at least 13%, at least 14%, at least 15% such as at least 16% ethanol.
The starch to be processed in the processes of the above aspects may in particular be obtained from tubers, roots, stems, legumes, cereals or whole grain. More specifically the granular starch may be obtained from corns, cobs, wheat, barley, rye, milo, sago, cassava, tapioca, sorghum, rice, peas, bean, banana or potatoes. Specially contemplated are both waxy and non-waxy types of corn and barley.
The invention also relates to a composition comprising the polypeptide of the first and/or second aspect. In a particularly preferred embodiment the composition comprises a polypeptide of the first aspect which polypeptide is selected from the group consisting of V001, V002, V003, V004, V005, V006, V007, V008, V009, V010, V011 , V012, V013, V014, V015, V016, V017, V018, V019, V021 , V022, V023, V024, V025, V026, V027, V028, V029, V030, V031 , V032, V033, V034, V035, V036, V037, V038, V039, V040, V041 , V042, V043, V047, V048, V049, V050, V051 , V052, V054, V055, V057, V059, V060, V061 , V063, V064, V065, V066, V067, V068 and V069. The composition may further comprise an enzyme selected from the group comprising of; a fungal alpha-amylase (EC 3.2.1.1), a beta-amylase (E.G. 3.2.1.2), a glucoamylase (E.C.3.2.1.3) and a pullulanases (E.G. 3.2.1.41). The glucoamylase may preferably be derived from a strain of Aspergillus sp., such as Aspergillus niger, or from a strain of Talaromyces sp. and in particular derived from Talaromyces leycettanus such as the glucoamylase disclosed in U.S. patent no. Re. 32,153, Talaromyces duponti and/or Talaromyces thermopiles such as the glucoamylases disclosed in U.S. Patent No. 4,587,215 and more preferably derived from Talaromyces emersonii. Most preferably the glucoamylase is derived from Talaromyces emersonii strain CBS 793.97 and/or having the sequence disclosed as SEQ ID NO: 7 in WO 99/28448. Further preferred is a glucoamylase which has an amino acid sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or even at least 95% homology to the aforementioned amino acid sequence. A commercial Talaromyces glucoamylase preparation is supplied by Novozymes A/S as Spirizyme Fuel.
Also preferred for a composition comprising the polypeptide of the first and/or second aspect and a glucoamylase are polypeptides having glucoamylase activity which are derived from a strain of the genus Trametes, preferably Trametes cingulata. Further preferred is polypeptides having glucoamylase activity and havering at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or even at least 95% homology with amino acids for mature polypeptide amino acids 1 to 575 of SEQ ID NO: 5 in U.S. Patent Application No. 60/650,612.
Also preferred for a composition comprising the polypeptide of the first and/or second aspect and a glucoamylase are polypeptides having glucoamylase activity which are derived from a strain of the genus Pachykytospora, preferably Pachykytospora papyracea or the E. coli strain deposited at DSMZ and given the no. DSM 17105. Further preferred are polypeptides having glucoamylase activity and having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or even at least 95% homology with amino acids for mature polypeptide amino acids 1 to 556 of SEQ ID NO: 2 in U.S. Patent Application No. 60/650,612.
The composition described above may be used for liquefying and/or saccharifying a gelatinized or a granular starch, as well as a partly gelatinized starch. A partly gelatinized starch is a starch which to some extent is gelatinized, i.e., wherein part of the starch has irreversibly swelled and gelatininized and part of the starch is still present in a granular state.
The composition described above may preferably comprise acid alpha-amylase present in an amount of 0.01 to 10 AFAU/g DS, preferably 0.1 to 5 AFAU/g DS, more preferably 0.5 to 3 AFAU/AGU, and most preferably 0.3 to 2 AFAU/g DS. The composition may be applied in any of the starch processes described above.
MATERIALS AND IVIETHODS Determination of acid alpha-amylase activity
When used according to the present invention the activity of any acid alpha-amylase may be measured in AFAU (Acid Fungal Alpha-amylase Units), which are determined relative to an enzyme standard. 1 AFAU is defined as the amount of enzyme which degrades 5.260 mg starch dry matter per hour under the below mentioned standard conditions.
Acid alpha-amylase, i.e., acid stable alpha-amylase, an endo-alpha-amylase (1,4- alpha-D-glucan-glucano-hydrolase, E. C. 3.2.1.1) hydrolyzes alpha-1 ,4-glucosidic bonds in the inner regions of the starch molecule to form dextrins and oligosaccharides with different chain lengths. The intensity of color formed with iodine is directly proportional to the concentration of starch. Amylase activity is determined using reverse colorimetry as a reduction in the concentration of starch under the specified analytical conditions.
ALPHA- AMYLASE
STARCH + IODINE n. pH25 > DEXTRINS + OLIGOSACCHARIDES
1 = 590 nm blue/violet t = 23 sec. decoloration
Standard conditions/reaction conditions:
Substrate: Soluble starch, approx. 0.17 g/L
Buffer: Citrate, approx. 0.03 M
Iodine (I2): 0.03 g/L
CaCI2: 1.85 mM pH: 2.50 ± 0.05
Incubation temperature: 400C
Reaction time: 23 seconds
Wavelength: 590 nm
Enzyme concentration: 0.025 AFAU/mL
Enzyme working range: 0.01-0.04 AFAU/mL
A folder EB-SM-0259.02/01 describing this analytical method in more detail is available upon request to Novozymes AJS, Denmark, which folder is hereby included by reference.
Glucoamylase activity
Glucoamylase activity may be measured in AmyloGlucosidase Units (AGU). The AGU is defined as the amount of enzyme, which hydrolyzes 1 micromole maltose per minute under the standard conditions 37°C, pH 4.3, substrate: maltose 23.2 mM, buffer: acetate 0.1 M, reaction time 5 minutes.
An autoanalyzer system may be used. Mutarotase is added to the glucose dehydrogenase reagent so that any alpha-D-glucose present is turned into beta-D-glucose. Glucose dehydrogenase reacts specifically with beta-D-glucose in the reaction mentioned above, forming NADH which is determined using a photometer at 340 nm as a measure of the original glucose concentration.
AMG incubation:
Substrate: maltose 23.2 mM
Buffer: acetate 0.1 M
Ph: 4.30 ± 0.05
Incubation 37°C ± 1 temperature:
Reaction time: 5 minutes
Enzyme working range: 0.5-4.0 AGU/mL
Color reaction:
GlucDH: 430 U/L
Mutarotase: 9 U/L
NAD: 0.21 mM
Buffer: phosphate 0.12 M; 0.15 M NaCI pH: 7.60 ± 0.05
Incubation temperature: 37°C ± 1
Reaction time: 5 minutes
Wavelength: 340 nm
A folder (EB-SM-0131.02/01) describing this analytical method in more detail is available on request from Novozymes A/S, Denmark, which folder is hereby included by reference.
Strains and plasmids
E. coli DH12S (available from Gibco BRL) was used for yeast plasmid rescue. pl_A1 is a S. cerevisiae and E. coli shuttle vector under the control of TPI promoter, constructed from pJC039 described in WO 01/92502. The acid Aspergillus niger alpha- amylase signal sequence, the acid Aspergillus niger alpha-amylase gene (SEQ ID NO: 1) and the partial Athelia rolfsii glucoamylase gene sequence comprising the linker (SEQ ID NO: 67) and the CBM (SEQ ID NO: 91) has been inserted. The full sequence of the plasmid is given in SEQ ID NO: 103. The alpha-amylase gene is the sequence from 5029 to 6468, the linker is the sequence from 6469 to 6501 and the CBM is the sequence from 6502 to 6795. The vector was used for alpha-amylase CBM hybrid construction. Saccharomyces cerevisiae YNG318: MATa Dpep4[cir+] ura3-52, Ieu2-D2, his 4-539 was used for alpha-amylase variants expression. It is described in J. Biol. Chem. 272 (15), pp 9720-9727, 1997.
Media and substrates
10X Basal solution: Yeast nitrogen base w/o amino acids (DIFCO) 66.8 g/I, succinate 100 g/l, NaOH 60 g/I.
SC-αlucose: 20% glucose (i.e., a final concentration of 2% = 2 g/100ml)) 100 ml/I, 5% threonine 4 ml/l, 1% tryptophaniO mi/I, 20% casamino acids 25 ml/1, 10 X basal solution 100 ml/l. The solution is sterilized using a filter of a pore size of 0.20 micrometer. Agar and H2O
(approx. 761 ml) is autoclaved together, and the separately sterilized SC-glucose solution added to the agar solution.
YPD: Bacto peptone 20 g/I, yeast extract 10 g/I, 20% glucose 100 ml/l.
PEG/LiAc solution: 40% PEG4000 50 ml, 5 M Lithium Acetate 1 ml
DNA manipulations
Unless otherwise stated, DNA manipulations and transformations were performed using standard methods of molecular biology as described in Sambrook et al. (1989)
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current Protocols in Molecular Biology", John Wiley and Sons,
1995; Harwood, C. R. and Cutting, S. M. (eds.).
Yeast transformation
Yeast transformation was carried out by lithium acetate method. Mix 0.5 microL of vector (digested by restriction endnucleases) and 1 microL of PCR fragments. Thaw
YNG318 competent cells on ice. Mix 100 microL of the cells, the DNA mixture and 10 microL of carrier DNA (Clontech) in 12 ml polypropylene tubes (Falcon 2059). Add 0.6ml PEG/LiAc solution and mix gently. Incubate for 30 min at 3O0C, and 200 rpm. Incubate for 30 min at
420C (heat shock). Transfer to an eppendorf tube and centrifuge for 5 sec. Remove the supernatant and resolve in 3 ml of YPD. Incubate the cell suspension for 45 min at 200 rpm at 3O0C. Pour the suspension to SC-glucose plates and incubate 3O0C for 3 days to make colonies. Yeast total DNA was extracted by the Robzyk and Kassir's method described in
Nucleic Acids Research, Vol. 20, No. 14 (1992) 3790. DNA sequencing
E. coli transformation for DNA sequencing was carried out by electroporation (BIO- RAD Gene Pulser). DNA Plasmids were prepared by alkaline method (Molecular Cloning, Cold Spring Harbor) or with the Qiagen® Plasmid Kit. DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit. PCR was performed using a PTC-200 DNA Engine. The ABI PRISM™ 310 Genetic Analyzer was used for determination of all DNA sequences.
Table 2
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Example 1: Construction of the nucleic acid sequence V019, encoding Rhizomucor pusillus alpha amylases and Athelia rolfsii glucoamylase CBM
Vector pl_A1 was digested with the appropriate restriction endonuclease to cut out the region encoding A. niger alpha-amylase catalytic domain. The Rhizomucor pusillus alpha-amylase gene was amplified by PCR using the primers P001 (SEQ ID NO: 104) and P002 (SEQ ID NO: 105), the amplified fragment is shown as SEQ ID NO: 19.
PCR reactior i system: Conditions:
38.9 micro L H2O 1 980C 10 sec
5 micro L 10 X reaction buffer 2 680C 90 sec
1 micro L Klen Taq LA (CLONTECH) 1-2 30 cycles
4 micro L 1O mM dNTPs 3 680C 10min
0.3micro L X 2100 pmole/micro L Primers
0.5 micro L Template DNA
DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit.
The resulting purified fragments were mixed with the vector digest. The mixed solution was introduced into Saccharomyces cerevisiae to construct the expression plasmid pl_AV019 by in vivo recombination.
Example 2: Construction of the nucleic acid sequence V022, encoding Meripilus giganteus alpha amylase and Athelia rolfsii glucoamylase CBM
The Meripilus giganteus alpha-amylase gene was amplified by PCR using the primers P003 (SEQ ID NO: 106) and P004 (SEQ ID NO: 107).
DNA fragments were recovered from agarose gel by the Qiagen gel extraction Kit. The resulting purified fragments and the appropriate restriction endonuclease digested vector pl_A1 to cut out the region encoding A. niger alpha-amylase catalytic domain were mixed. The mixed solution was introduced into Saccharomyces cerevisiae to construct the expression plasmid pl_AV022 by in vivo recombination. Example 3. Expression of amylases with CBM in Aspergillus oryzae
The constructs comprising the alpha amylase genes with CBM described in examples 1 and 2 were used to construct expression vectors, pAspV019 and pAspV022, respectively. The two plasmids, pAspV019 and pAspV022, consist of an expression cassette based on the Aspergillus niger neutral amylase Il promoter fused to the Aspergillus nidulans those phosphate isomerase non translated leader sequence (Pna2/tpi) and the Aspergillus niger amyloglycosidase terminator (Tamg). Also present on the plasmid was the Aspergillus selective marker amdS from Aspergillus nidulans enabling growth on acetamide as sole nitrogen source. The expression plasmids pAspV019 and pAspV022 were transformed into Aspergillus as described in Lassen et al. (2001), Applied and Environmental Micorbiology, 67, 4701-4707. Transformants expressing V019 and V022, were isolated, purified and cultivated in shake flasks. The culture broths from fermentations of Aspergillus oryzae expressing amylase with CBM were purified by affinity purification (Biochem. J. (2003) 372, 905-910).
Example 4. Amylases with CBM
Polypeptides of the invention were produced; a selection of catalytic domains were fused to the linker-CBM region of Athelia rolfsii glucoamylase, and a selection of CBM regions were attached to the C003 Aspergillus oryzae catalytic domain (a Fungamyl PE variant).
Because the CBM+linker from Trichophaea saccata alpha-amylase is located at N- terminal, it was inserted between SP288 signal and the Aspergillus oryzae catalytic domain. The other CBMs were all C-terminally placed. The variant V008 comprised both a C-terminally placed linker and CBM region of
Athelia rolfsii glucoamylase and an N-terminally placed linker+CBM from Trichophaea saccata alpha-amylase.
CBM variants of the Aspergillus oryzae alpha-amylase and catalytic domain variants of the Athelia rolfsii glucoamylaseCBM are listed in tables 3 and 4 respectively. Other produced polypeptides of the invention are listed in tables 5 and 6.
The variants have improved activity on starch, especially on granular starch. Table 3
Figure imgf000059_0001
Table 4
Figure imgf000059_0002
Figure imgf000060_0001
Figure imgf000060_0002
Figure imgf000061_0001
Table 6
Figure imgf000061_0002
Example 5
The performance of the polypeptide V019 was evaluated in mini-scale fermentations with different dosages of Talaromyces emersonii glucoamylase. Starch substrate, 583.3g of ground corn was added to 912.2 g tap water. This mixture was supplemented with 4.5 ml of a 1 g/L penicillin solution. The pH of this slurry was adjusted to 5.0 with 40% H2SO4. DS level was determined in duplicate to be 34.2 ± 0.8%. Approximately 5 g of this slurry was added to 20 ml vials. Each vial was dosed with the appropriate amount of enzyme followed by addition of 200 microL yeast propagate/5 g slurry. Actual dosages were based on the exact weight of corn slurry in each vial. Vials were incubated at 32°C. Fermentations were followed by measuring weight loss over time. At 70 hours the fermentations were stopped and prepared for HPLC analysis. The HPLC preparation consisted of stopping the reaction by addition of 50 microL of 40% H2SO4, centrifuging, and filtering through a 0.45 micrometer filter. Samples awaiting HPLC analysis were stored at 4°C.
Table 7
Figure imgf000062_0001
Example 6
Substrates for saccharification were prepared by dissolving a DE 11 maltodextrin prepared from corn starch liquefied with thermostable bacterial alpha-amylase (LIQUOZYME X™, Novozymes A/S) in Milli-Q™ water, and adjusting the dry solid matter content (DS) to 30%. The saccharification experiments were carried out in sealed 2 ml glass vials at 6O0C and initial pH of 4.3 under continuous stirring. Two different dosages of CBM alpha-amylase V019 or V022 were applied on top of a standard treatment with Talaromyces emersonii glucoamylase 0.35 AGU/g DS and A. niger acid alpha-amylase 0.04 AFAU/g DS.
Samples were taken at set intervals and heated in boiling water for 15 minutes to inactivate the enzymes. After cooling, the samples were diluted to 5% DS and filtered (Sartorius MINISART™ NML 0.2 micro-m), before being analysed by HPLC. The glucose levels as a % of total soluble carbohydrate are given in table 8 below.
Table 8
All treatments with Talaromyces emersonii glucoamylase 0.35 AGU/g DS and A. niger acid alpha-amylase 0.04 AFAU/g DS. Acid alpha-amylase variants V019 and
V022 were dosed on top according to the table.
DP1
Additional Acid alpha-amylase 24 h 48 h 7O h
Enzyme variant
AFAU/g DS
Control 0 81.5 90.2 93.1
V019 0.0875 95.7 96.2 95.6
0.1750 92.1 96.2 96.2
V022 0.0875 93.8 95.6 95.5
0.1750 92.9 95.9 96.0
Example 6
Raw starch SSF treatments were evaluated in mini-scale fermentations. A 35% DS granular starch slurry was obtained from mixing 41O g finely ground corn, 590 ml tap water,
3.0 mis 1 g/L penicillin and 1 g of urea. The slurry was adjusted to pH 4.5 using 5 N NaOH and samples of 5 g were distributed to 20 ml vials. The appropriate amount of enzymes was dosed and the vials were inoculated with yeast. Vials were incubated at 32°C. 9 replicate fermentations of each treatment were run. Three replicates were selected for 24 hours, 48 hours and 70 hours time point analysis. Vials were vortexed at 24, 48 and 70 hours. The time point analysis consisted of weighing the vials and prepping the sample for HPLC. For
HPLC the reaction was stopped by addition of 50 microL of 40% H2SO4, centrifuging, and filtering through a 0.45 urn filter. Samples awaiting HPLC analysis were stored at 4°C.
Example 6a
Enzymes and amounts used are shown in the table below. A-AMG is an Aspergillus niger glucoamylase composition.
Table 9
Raw starch SSF with Aspergillus niger glucoamylase and V019, enzyme dosage trial No % dose mg/gDS AGU/gDS AFAU/gDS
A-AMG V019 A-AMG V019 A-AMG V019
2 100% 0% 0.5 0 0.95 0
3 90% 10% 0.45 0.01 0.855 0.01
4 80% 20% 0.4 0.02 0.76 0.02
5 70% 30% 0.35 0.03 0.665 0.03
6 60% 40% 0.3 0.04 0.57 0.04
7 45% 55% 0.225 0.055 0.4275 0.055
8 30% 70% 0.15 0.07 0.285 0.07
9 15% 85% 0.075 0.085 0.1425 0.085
10 0% 100% 0 0.1 0 0.1
Good ethanol yield after 70 hours fermentation was observed in the range of 1.7-85.5 AGU/AFAU ratio of A. niger AMG to V019, indicating robust performance in a broad activity ratio range for the mixtures of A. niger AMG to V019.
Table 10
Raw starch SSF with Aspergillus niger glucoamylase and V019, results
Trial No AGU/gDS AFAU/gDS Ethanol Yield (g/i) AGU/AFAU
A-AMG V019 24hr 48hr 70hr Ratio
2 0.950 0.000 77.73 119.46 139.27 N/A
3 0.855 0.010 92.93 134.65 144.39 85.5
4 0.760 0.020 93.13 133.74 145.42 38.0
5 0.665 0.030 92.66 134.32 147.56 22.2
6 0.570 0.040 91.68 132.86 145.77 14.3
7 0.428 0.055 90.17 130.87 146.26 7.8
8 0.285 0.070 87.11 127.74 144.82 4.1
9 0.143 0.085 84.32 120.95 143.40 1.7
10 0.000 0.100 80.80 114.55 134.08 0.0 Example 6b
Enzymes and amounts used are shown in the table below. A-AMG is a Talaromyces emersonii glucoamylase composition.
Table 11
Raw starch SSF with Talaromyces emersonii glucoamylase and V019, enzyme dosages trial No % dose mg/gDS AGU/gDS AFAU/gDS
T-AMG V019 T-AMG V019 T-AMG V019
2 100% 0% 0.3 0 2.4 0
3 90% 10% 0.27 0.01 2.16 0.01
4 80% 20% 0.24 0.02 1.92 0.02
5 70% 30% 0.21 0.03 1.68 0.03
6 60% 40% 0.18 0.04 1.44 0.04
7 45% 55% 0.135 0.055 1.08 0.055
8 30% 70% 0.09 0.07 0.72 0.07
9 15% 85% 0.045 0.085 0.36 0.085
10 0% 100% 0 0.1 0 0.1
Good ethanol yield after 70 hours fermentation was observed in the range of 10-216 AGU/AFAU ratio of T. emersonii AMG to V019, indicating a broad activity ratio range for the mixtures of T. emersonii AMG to V019.
Table 12
Raw starch SSF with Talaromyces emersonii glucoamylase and V019, results trial No AGU/gDS AFAU/gDS Ethanol Yield (g/i) AGU/AFAU
Sp Fuel V019 24 hrs 48 hrs 70 hrs Ratio
2 2.4 0 60.07 91.77 113.17 N/A
3 2.16 0.01 89.00 129.36 142.91 216.0
4 1.92 0.02 91.02 132.07 147.18 96.0
5 1.68 0.03 93.31 133.75 148.19 56.0
6 1.44 0.04 93.71 134.16 146.84 36.0
7 1.08 0.055 92.83 131.53 141.80 19.6
8 0.72 0.07 91.25 125.48 139.25 10.3
9 0.36 0.085 86.14 124.22 137.38 4.2
10 0 0.1 80.63 115.00 132.08 0.0
Deposit of Biological Material
The following biological material has been deposited under the terms of the Budapest Treaty at Deutshe Sammmlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE, and given the following accession number:
Deposit Accession Number Date of Deposit Escherichia coli NN049798 DSM 17106 2 February 2005 Escherichia coli NN049797 DSM 17105 2 February 2005
The strains have been deposited under conditions that assure that access to the culture will be available during the pendency of this patent application to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under 37 C.F.R. §1.14 and 35 U. S. C. §122. The deposits represent a substantially pure culture of the deposited strain. The deposits are available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny are filed. However, it should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Claims

1. A polypeptide comprising a first amino acid sequence comprising a catalytic module having alpha-amylase activity and a second amino acid sequence comprising a carbohydrate-binding module, wherein said second amino acid sequence has at least 60% homology to any amino acid sequence selected from the group consisting of SEQ ID NO: 52, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 109, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141 and SEQ ID NO: 143.
2. The polypeptide of claim 1 , wherein said first amino acid sequence has at least 60% homology to any amino acid sequence selected from the group consisting of SEQ ID NO:02, SEQ ID NO:04, SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 111 , SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119, SEQ ID NO: 121 , SEQ ID NO: 123, SEQ ID NO: 125, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131 , SEQ ID NO: 133, SEQ ID NO: 135 and SEQ ID NO: 155.
3. The polypeptide of claim 1 or 2, wherein a linker sequence is present in a position between said first and said second amino acid sequence, said linker sequence having at least 60% homology to any amino acid sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 149, SEQ ID NO: 151 , and SEQ ID NO: 52.
4. The polypeptide of any of claims 1-3, wherein said first amino acid sequence has at least 60% homology to the amino acid sequence shown in SEQ ID NO: 4 and wherein said first amino acid sequence comprises one or more amino acid substitutions selected from the group consisting of A128P, K138V, S141 N, Q143A, D144S, Y155W, E156D, D157N, N244E, M246L, G446D, D448S and N450D.
5. The polypeptide of claim 4, wherein said polypeptide has the amino acid sequence shown in SEQ ID NO: 100 or a an amino acid sequence having at least 60% homology to amino acid sequence shown in SEQ ID NO: 100.
6. The polypeptide of any of claims 1-3, wherein said polypeptide has the amino acid sequence shown in SEQ ID NO: 101 or a an amino acid sequence having at least 60% homology to amino acid sequence shown in SEQ ID NO: 101.
7. The polypeptide of any of claims 1-3, wherein said polypeptide has the amino acid sequence shown in SEQ ID NO: 102 or a an amino acid sequence having at least 50% homology to amino acid sequence shown in SEQ ID NO: 102.
8. The polypeptide of any of claims 1-7, wherein the polypeptide is a hybrid.
9. A polypeptide having alpha-amylase activity, selected from the group consisting of:
(a) a polypeptide having an amino acid sequence which has at least 75% homology with amino acids for the mature polypeptide selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, as amino acids 1-471 in SEQ ID NO: 18, as amino acids 1-450 in SEQ ID NO: 20, as amino acids 1-445 in SEQ ID NO: 22, as amino acids 1- 498 in SEQ ID NO: 26, as amino acids 18-513 in SEQ ID NO: 28, as amino acids 1-507 in SEQ ID NO: 30, as amino acids 1-481 in SEQ ID NO: 32, as amino acids 1-495 in SEQ ID NO: 34, as amino acids 1-477 in SEQ ID NO: 38, as amino acids 1-449 in SEQ ID NO: 42, as amino acids 1-442 in SEQ ID NO: 115, as amino acids 1-441 in SEQ ID NO: 117, as amino acids 1-477 in SEQ ID NO: 125, as amino acids 1-446 in SEQ ID NO: 131 , as amino acids 41-481 in SEQ ID NO: 157, as amino acids 22-626 in SEQ ID NO: 159, as amino acids 24-630 in SEQ ID NO: 161 , as amino acids 27-602 in SEQ ID NO: 163, as amino acids 21- 643 in SEQ ID NO: 165, as amino acids 29-566 in SEQ ID NO: 167, as amino acids 22-613 in SEQ ID NO: 169, as amino acids 21-463 in SEQ ID NO: 171, as amino acids 21-587 in SEQ ID NO: 173, as amino acids 30-773 in SEQ ID NO: 175, as amino acids 22-586 in SEQ ID NO: 177, as amino acids 20-582 in SEQ ID NO: 179.
(b) a polypeptide which is encoded by a nucleotide sequence (i) which hybridizes under at least low stringency conditions with nucleotides 1-1326 in SEQ ID NO: 13, nucleotides 1-1413 in SEQ ID NO: 17, nucleotides 1-1350 in SEQ ID NO: 19, nucleotides 1- 1338 in SEQ ID NO: 21 , nucleotides 1-1494 in SEQ ID NO: 25, nucleotides 52-1539 in SEQ ID NO: 27, nucleotides 1-1521 in SEQ ID NO: 29, nucleotides 1-1443 in SEQ ID NO: 31 , nucleotides 1-1485 in SEQ ID NO: 33, nucleotides 1-1431 in SEQ ID NO: 37, nucleotides 1- 1347 in SEQ ID NO: 41 , nucleotides 1-1326 in SEQ ID NO: 114, nucleotides 1-1323 in SEQ ID NO: 116, nucleotides 1-1431 in SEQ ID NO: 124, nucleotides 1-1338 in SEQ ID NO: 130, nucleotides 121-1443 in SEQ ID NO: 156, nucleotides 64-1878 in SEQ ID NO: 158, nucleotides 70-1890 in SEQ ID NO: 160, nucleotides 79-1806 in SEQ ID NO: 162, nucleotides 61-1929 in SEQ ID NO: 164, nucleotides 85-1701 in SEQ ID NO: 166, nucleotides 64-1842 in SEQ ID NO: 168, nucleotides 61-1389 in SEQ ID NO: 170, nucleotides 61-1764 in SEQ ID NO: 172, nucleotides 61-2322 in SEQ ID NO: 174, nucleotides 64-1761 in SEQ ID NO: 176, nucleotides 58-1749 in SEQ ID NO: 178, or (ii) which hybridizes under at least medium stringency conditions with the cDNA sequence contained in the polynucleotides shown as nucleotides 1-1326 in SEQ ID NO: 13, as nucleotides 1-1413 in SEQ ID NO: 17, as nucleotides 1-1350 in SEQ ID NO: 19, as nucleotides 1-1338 in SEQ ID NO: 21 , as nucleotides 1-1494 in SEQ ID NO: 25, as nucleotides 52-1539 in SEQ ID NO: 27, as nucleotides 1-1521 in SEQ ID NO: 29, as nucleotides 1-1443 in SEQ ID NO: 31 , as nucleotides 1-1485 in SEQ ID NO: 33, as nucleotides 1-1431 in SEQ ID NO: 37, as nucleotides 1-1347 in SEQ ID NO: 41 , as nucleotides 1-1326 in SEQ ID NO: 114, as nucleotides 1-1323 in SEQ ID NO: 116, as nucleotides 1-1431 in SEQ ID NO: 124, as nucleotides 1-1338 in SEQ ID NO: 130, as nucleotides 121-1443 in SEQ ID NO: 156, as nucleotides 64-1878 in SEQ ID NO: 158, as nucleotides 70-1890 in SEQ ID NO: 160, as nucleotides 79-1806 in SEQ ID NO: 162, as nucleotides 61-1929 in SEQ ID NO: 164, as nucleotides 85-1701 in SEQ ID NO: 166, as nucleotides 64-1842 in SEQ ID NO: 168, as nucleotides 61-1389 in SEQ ID NO: 170, as nucleotides 61-1764 in SEQ ID NO: 172, as nucleotides 61-2322 in SEQ ID NO: 174, as nucleotides 64-1761 in SEQ ID NO: 176, as nucleotides 58-1749 in SEQ ID NO: 178, or (iii) a complementary strand of (i) or (ii); and (c) a variant comprising a conservative substitution, deletion, and/or insertion of one or more amino acids in an acid amino sequence selected from the group consisting of amino acids 1-441 in SEQ ID NO: 14, amino acids 1-471 in SEQ ID NO: 18, amino acids 1- 450 in SEQ ID NO: 20, amino acids 1-445 in SEQ ID NO: 22, amino acids 1-498 in SEQ ID NO: 26, amino acids 18-513 in SEQ ID NO: 28, amino acids 1-507 in SEQ ID NO: 30, amino acids 1-481 in SEQ ID NO: 32, amino acids 1-495 in SEQ ID NO: 34, amino acids 1-477 in SEQ ID NO: 38, amino acids 1-449 in SEQ ID NO: 42, amino acids 1-442 in SEQ ID NO: 115, amino acids 1-441 in SEQ ID NO: 117, amino acids 1-477 in SEQ ID NO: 125, amino acids 1-446 in SEQ ID NO: 131, amino acids 41-481 in SEQ ID NO: 157, amino acids 22- 626 in SEQ ID NO: 159, amino acids 24-630 in SEQ ID NO: 161 , amino acids 27-602 in SEQ ID NO: 163, amino acids 21-643 in SEQ ID NO: 165, amino acids 29-566 in SEQ ID NO: 167, amino acids 22-613 in SEQ ID NO: 169, amino acids 21-463 in SEQ ID NO: 171 , amino acids 21-587 in SEQ ID NO: 173, amino acids 30-773 in SEQ ID NO: 175, amino acids 22-586 in SEQ ID NO: 177 and amino acids 20-582 in SEQ ID NO: 179.
10. A polypeptide having carbohydrate-binding affinity, selected from the group consisting of:
(a) a polypeptide comprising an amino acid sequence which has at least 60% homology with a sequence selected from the group consisting of amino acids 529-626 of SEQ ID NO: 159, amino acids 533-630 of SEQ ID NO: 161 , amino acids 508-602 of SEQ ID NO: 163, amino acids 540-643 of SEQ ID NO: 165, amino acids 502-566 of SEQ ID NO: 167, amino acids 513-613 of SEQ ID NO: 169, 492-587 of SEQ ID NO: 173, amino acids 30- 287 of SEQ ID NO: 175, amino acids 487-586 of SEQ ID NO: 177, and amino acids 482-582 of SEQ ID NO: 179;
(b) a polypeptide which is encoded by a nucleotide sequence which hybridizes under low stringency conditions with a polynucleotide probe selected from the group consisting of the complementary strand of a sequence selected from the group consisting of nucleotides 1585-1878 in SEQ ID NO: 158, nucleotides 1597-1890 in SEQ ID NO: 160, nucleotides 1522-1806 in SEQ ID NO: 162, nucleotides 1618-1929 in SEQ ID NO: 164, nucleotides 1504-1701 in SEQ ID NO: 166, nucleotides 1537-1842 in SEQ ID NO: 168, nucleotides 1474-1764 in SEQ ID NO: 172, nucleotides 61-861 in SEQ ID NO: 174, nucleotides 1459-1761 in SEQ ID NO: 176, and nucleotides 1444-1749 in SEQ ID NO: 178;
(c) a fragment of (a) or (b) that has carbohydrate binding affinity.
11. The polypeptide of claim 10, wherein the carbohydrate-binding affinity is starch- binding affinity.
12. Use of a polypeptide according to any of claims 1-11 for liquefaction.
13. Use of a polypeptide according to any of claims 1-11 for saccharification.
14. Use of a polypeptide according to any of claims 1-11 for in a process comprising fermentation.
15. Use of a polypeptide according to any of claims 1-11 in a starch conversion process.
16. Use of a polypeptide according to any of claims 1-11 in a process for producing oligosaccharides.
17. Use of a polypeptide according to any of claims 1-11 in a process for producing maltodextrins or glucose syrups.
18. Use of a polypeptide according to any of claims 1-11 in a process for producing fuel or drinking ethanol.
19. Use of a polypeptide according to any of claims 1-11 in a process for producing a beverage.
20. Use of a polypeptide according to any of claims 1-11 in a fermentation process for producing organic compounds, such as citric acid, ascorbic acid, lysine, glutamic acid.
21. A composition comprising a polypeptide according to any of claims 1-11.
22. A process for saccharifying starch, wherein a starch is treated with the polypeptide according to any of claims 1-11.
23. The process according to claim 22, comprising converting starch into a syrup containing dextrose and/or maltose.
24. The process according to claim 22 or 23, wherein the starch is gelatinized or granular starch.
25. The process according to any of claims 22-24, wherein the saccharified starch is contacted with a fermenting organism to produce a fermentation product.
26. The process according to claim 24, wherein the fermenting organism is a yeast and the fermentation product is ethanol.
27. A process comprising:
(a) contacting a starch with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module;
(b) incubating said starch with said polypeptide; (c) fermenting to produce a fermentation product, d) optionally recovering the fermentation product, wherein an enzyme having glucoamylase activity is either absent or present in an amount of no more than or even less than 0.5 AGU/g DS, more preferably no more than or even less than 0.4 AGU/g DS, even more preferably no more than or even less than 0.3 AGU/g DS, and most preferably no more than or even less than 0.1 AGU, such as no more than or even less than 0.05 AGU/g DS of starch substrate and wherein step a, b, c, and/or d may be performed separately or simultaneously.
28. The process according to claim 27, wherein said polypeptide is a polypeptide according to any of claims 1 to 11.
29. A process comprising:
(a) contacting a starch substrate with a yeast cell transformed to express a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate-binding module; (b) holding said starch substrate with said yeast;
(c) fermenting to produce ethanol
(d) optionally recovering ethanol wherein steps a, b, and c are performed separately or simultaneously.
30. The process of claim 29; wherein the yeast cell is the yeast cell of claim 43.
31. A process of producing ethanol from starch-containing material by fermentation, said process comprises:
(i) liquefying said starch-containing material with a polypeptide comprising a catalytic module having alpha-amylase activity and a carbohydrate- binding module;
(ii) saccharifying the liquefied mash obtained;
(iii) fermenting the material obtained in step (ii) in the presence of a fermenting organism.
32. The process of claim 31 , wherein the polypeptide is a polypeptide according to any of claims 1-11.
33. The process according to claim 31 or 32, further comprising recovery of the ethanol.
34. The process according to any of claims 31-33, wherein the saccharification and fermentation is carried out as a simultaneous saccharification and fermentation process (SSF process).
35. The process according to any of claims 31-34; wherein the ethanol content during step iii reaches at least 7%, at least 8%, at least 9%, at least 10% such as at least 11%, at least 12%, at least 13%, at least 14%, at least 15% such as at least 16% ethanol.
36. The process according to any of claims 31-35, wherein the acid alpha-amylase is present in an amount of 0.01 to 10 AFAU/g DS, preferably 0.1 to 5 AFAU/g DS, especially
0.3 to 2 AFAU/g DS.
37. The process according to any of claims 31-36, wherein the acid alpha-amylase and glucoamylase is added in a ratio of between 0.1 to 10 AGU/AFAU, preferably 0.30 and 5 AFAU/AGU, especially 0.5 to 3 AFAU/AGU.
38. A DNA sequence encoding a polypeptide according to any of claims 1-11.
39. A DNA construct comprising a DNA sequence according to claim 38.
40. A recombinant expression vector which carries a DNA construct according to claim 39.
41. A host cell which is transformed with a DNA construct according to claim 39 or a vector according to claim 40.
42. The host cell according to claim 41 , which is a microorganism, in particular a bacterium or a fungal cell.
43. The host cell according to claim 41 or 42, which is a yeast.
44. The host cell according to claim 41 or 42, which is a strain from Aspergillus, in particular A. niger, a strain from Talaromyces, in particular Talaromyces emersonii or is a strain from Trichoderma.
45. The host cell according to claim 41, which is a plant cell.
46. A composition comprising the polypeptide according to any of claims 1-11.
47. The composition according to claim 46, said composition further comprising a glucoamylase.
48. The composition according to claim 46 or 47, wherein the glucoamylase is derived from a strain within Talaromyces sp., Aspergillus sp., Trametes sp.or Pachykytospora sp.
49. The composition according to any of claims 46-48, wherein the glucoamylase is derived from a species selected from the group consisting of Aspergillus niger, Talaromyces leycettanus, Talaromyces duponti, Talaromyces emersonii, Trametes cingulata and Pachykytospora papyracea.
50. Use of the composition according to any of claims 46-49 for liquefying and/or saccharifying a gelatinized, a partly gelatinized or a granular starch.
PCT/US2005/046725 2004-12-22 2005-12-22 Enzymes for starch processing WO2006069290A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN200580048598.0A CN101128580B (en) 2004-12-22 2005-12-22 For the enzyme of starch processing
DK05855308.2T DK1831385T3 (en) 2004-12-22 2005-12-22 Enzymes for starch processing
MX2007007030A MX2007007030A (en) 2004-12-22 2005-12-22 Enzymes for starch processing.
ES05855308.2T ES2543131T3 (en) 2004-12-22 2005-12-22 Enzymes for starch treatment
EP05855308.2A EP1831385B1 (en) 2004-12-22 2005-12-22 Enzymes for starch processing
AU2005319074A AU2005319074B2 (en) 2004-12-22 2005-12-22 Enzymes for starch processing
CA2592104A CA2592104C (en) 2004-12-22 2005-12-22 Enzymes for starch processing
JP2007548502A JP5452869B2 (en) 2004-12-22 2005-12-22 Starch processing method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63861404P 2004-12-22 2004-12-22
US60/638,614 2004-12-22
US65061205P 2005-02-07 2005-02-07
US60/650,612 2005-02-07

Publications (2)

Publication Number Publication Date
WO2006069290A2 true WO2006069290A2 (en) 2006-06-29
WO2006069290A3 WO2006069290A3 (en) 2007-05-31

Family

ID=36602341

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/046724 WO2006069289A2 (en) 2004-12-22 2005-12-22 Polypeptides having glucoamylase activity and polynucleotides encoding same
PCT/US2005/046725 WO2006069290A2 (en) 2004-12-22 2005-12-22 Enzymes for starch processing

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046724 WO2006069289A2 (en) 2004-12-22 2005-12-22 Polypeptides having glucoamylase activity and polynucleotides encoding same

Country Status (10)

Country Link
US (5) US20060148054A1 (en)
EP (3) EP2365068B1 (en)
JP (2) JP5160899B2 (en)
AR (1) AR051864A1 (en)
AU (2) AU2005319074B2 (en)
CA (2) CA2591745C (en)
DK (3) DK1831385T3 (en)
ES (3) ES2552635T3 (en)
MX (2) MX2007007107A (en)
WO (2) WO2006069289A2 (en)

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106533A1 (en) 2003-05-30 2004-12-09 Novozymes A/S Alcohol product processes
WO2007035730A2 (en) 2005-09-20 2007-03-29 Novozymes North America, Inc. Process of producing a fermentation product
WO2007076388A2 (en) 2005-12-22 2007-07-05 Novozymes North America, Inc. Processes for producing a fermentation product
WO2007109750A2 (en) 2006-03-22 2007-09-27 Novozymes North America, Inc. Fermentation processes
WO2008134259A1 (en) 2007-04-24 2008-11-06 Novozymes North America, Inc. Detoxifying pre-treated lignocellulose-containing materials
WO2009030728A2 (en) * 2007-09-05 2009-03-12 Novozymes A/S Enzyme compositions with stabilizing constituent
WO2009030713A1 (en) 2007-09-03 2009-03-12 Novozymes A/S Detoxifying and recycling of washing solution used in pretreatment of lignocellulose-containing materials
WO2009114403A1 (en) * 2008-03-11 2009-09-17 Danisco Us Inc., Genencor Division Use of rhizopus amylases in granular starch hydrolysis
WO2009140504A1 (en) * 2008-05-16 2009-11-19 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2010008841A2 (en) 2008-06-23 2010-01-21 Novozymes A/S Processes for producing fermentation products
WO2010039812A2 (en) 2008-09-30 2010-04-08 Novozymes North America, Inc. Improvement of enzymatic hydrolysis of pre-treated lignocellulose-containing material with distillers dried grains
WO2010059413A2 (en) 2008-11-20 2010-05-27 Novozymes, Inc. Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
WO2010078391A2 (en) 2008-12-30 2010-07-08 Novozymes North America, Inc. Improvement of enzymatic hydrolysis of pretreated lignocellulose-containing material with dissolved air flotation sludge
WO2010078392A2 (en) 2008-12-31 2010-07-08 Novozymes North America, Inc. Processes of producing fermentation products
WO2010088447A1 (en) * 2009-01-30 2010-08-05 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2011008785A2 (en) 2009-07-17 2011-01-20 Novozymes A/S A method of analyzing cellulose decay in cellulosic material hydrolysis
WO2011039324A1 (en) 2009-09-30 2011-04-07 Novozymes A/S Steamed bread preparation methods and steamed bread improving compositions
WO2011066576A1 (en) 2009-11-30 2011-06-03 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011066560A1 (en) * 2009-11-30 2011-06-03 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011068803A1 (en) * 2009-12-01 2011-06-09 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011087836A2 (en) 2009-12-22 2011-07-21 Novozymes A/S Pullulanase variants and uses thereof
WO2011100161A1 (en) 2010-02-09 2011-08-18 Novozymes North America, Inc. Addition of alpha - glucosidase and cobalt for producing fermentation products from starch
WO2011123505A1 (en) 2010-03-30 2011-10-06 Novozymes North America, Inc. Processes of producing a fermentation product
EP2336308A3 (en) * 2003-06-25 2011-11-09 Novozymes A/S Enzymes for starch processing
WO2011154529A1 (en) 2010-06-11 2011-12-15 Novozymes A/S Enzymatic flour correction
WO2012018775A1 (en) 2010-08-02 2012-02-09 Novozymes North America, Inc. Process of producing a fermentation product
WO2012064350A1 (en) * 2010-11-08 2012-05-18 Novozymes A/S Polypeptides Having Glucoamylase Activity and Polynucleotides Encoding Same
WO2012068047A2 (en) 2010-11-19 2012-05-24 Novozymes North America, Inc. Processes of producing a fermentation product
WO2012088303A2 (en) 2010-12-22 2012-06-28 Novozymes North America, Inc. Processes for producing fermentation products
WO2012109119A2 (en) 2011-02-07 2012-08-16 Novozymes North America, Inc. Process of producing a fermentation product
WO2013006756A2 (en) 2011-07-06 2013-01-10 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
WO2013016115A1 (en) 2011-07-22 2013-01-31 Novozymes North America, Inc. Processes for pretreating cellulosic material and improving hydrolysis thereof
WO2013029496A1 (en) 2011-08-26 2013-03-07 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2013036526A1 (en) 2011-09-06 2013-03-14 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2013034106A1 (en) 2011-09-09 2013-03-14 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2013053801A1 (en) 2011-10-11 2013-04-18 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2013055676A1 (en) 2011-10-11 2013-04-18 Novozymes North America, Inc. Processes for producing fermentation products
WO2013082486A1 (en) 2011-12-02 2013-06-06 Novozymes A/S Processes for producing fermentation products
WO2013096652A1 (en) 2011-12-21 2013-06-27 Novozymes, Inc. Methods for determining the degradation of a biomass material
WO2013148993A1 (en) 2012-03-30 2013-10-03 Novozymes North America, Inc. Processes of producing fermentation products
WO2014006140A1 (en) 2012-07-06 2014-01-09 Novozymes A/S Liquid enzyme composition and method for enzyme recovery
WO2014028436A1 (en) * 2012-08-16 2014-02-20 Danisco Us Inc. Method of using alpha-amylase from aspergillus clavatus and isoamylase for saccharification
WO2014027062A1 (en) 2012-08-17 2014-02-20 Novozymes A/S Thermostable asparaginase variants and polynucleotides encoding same
WO2014058572A1 (en) * 2012-10-10 2014-04-17 Danisco Us Inc. Method of using alpha-amylase from talaromyces emersonii for saccharification
WO2014085439A1 (en) 2012-11-30 2014-06-05 Novozymes A/S Processes for producing fermentation products
WO2014099653A1 (en) 2012-12-17 2014-06-26 Novozymes A/S Alpha-amylases and polynucleotides encoding same
EP2751131A1 (en) * 2011-09-30 2014-07-09 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2015007639A1 (en) 2013-07-17 2015-01-22 Novozymes A/S Pullulanase chimeras and polynucleotides encoding same
US8945889B2 (en) 2012-05-11 2015-02-03 Danisco Us Inc. Method of using alpha-amylase from Aspergillus clavatus for saccharification
WO2015031477A1 (en) 2013-08-30 2015-03-05 Novozymes A/S Enzyme composition and uses thereof
WO2015035914A1 (en) 2013-09-11 2015-03-19 Novozymes A/S Processes for producing fermentation products
WO2015143144A1 (en) 2014-03-19 2015-09-24 Novozymes A/S Method for enhancing activity of an x143 polypeptide
EP3000324A1 (en) 2014-09-29 2016-03-30 Puratos Improved cake batters
WO2016062875A2 (en) 2014-10-23 2016-04-28 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2016087445A1 (en) 2014-12-01 2016-06-09 Novozymes A/S Improved production of glucose syrups
US9416355B2 (en) 2010-01-04 2016-08-16 Novozymes North America, Inc. Alpha-amylase variants and polynucleotides encoding same
WO2016138437A1 (en) 2015-02-27 2016-09-01 Novozymes A/S Processes of producing ethanol using a fermenting organism
WO2016205127A1 (en) 2015-06-18 2016-12-22 Novozymes A/S Polypeptides having trehalase activity and the use thereof in process of producing fermentation products
WO2017015329A1 (en) 2015-07-23 2017-01-26 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
WO2017112540A1 (en) 2015-12-22 2017-06-29 Novozymes A/S Processes for producing fermentation products
US9909112B2 (en) 2011-09-30 2018-03-06 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2018098381A1 (en) 2016-11-23 2018-05-31 Novozymes A/S Improved yeast for ethanol production
CN108611339A (en) * 2018-05-11 2018-10-02 中国农业科学院饲料研究所 Glucoamylase TlGa15 and its gene and application
WO2018222990A1 (en) 2017-06-02 2018-12-06 Novozymes A/S Improved yeast for ethanol production
EP3415624A1 (en) 2014-01-22 2018-12-19 Novozymes A/S Pullulanase variants and polynucleotides encoding same
WO2019005755A1 (en) 2017-06-28 2019-01-03 Novozymes A/S Polypeptides having trehalase activity and polynucleotides encoding same
WO2019030165A1 (en) 2017-08-08 2019-02-14 Novozymes A/S Polypeptides having trehalase activity and the use thereof in process of producing fermentation products
CN109385413A (en) * 2018-10-09 2019-02-26 中国农业科学院饲料研究所 Glucoamylase TlGA1931 and its gene and application
WO2019148192A1 (en) 2018-01-29 2019-08-01 Novozymes A/S Microorganisms with improved nitrogen utilization for ethanol production
WO2019161227A1 (en) 2018-02-15 2019-08-22 Novozymes A/S Improved yeast for ethanol production
WO2019197318A1 (en) 2018-04-09 2019-10-17 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
EP2981170B1 (en) 2013-04-05 2019-11-13 Novozymes A/S Method of producing a baked product with alpha-amylase, lipase and phospholipase
WO2019231944A2 (en) 2018-05-31 2019-12-05 Novozymes A/S Processes for enhancing yeast growth and productivity
WO2020023411A1 (en) 2018-07-25 2020-01-30 Novozymes A/S Enzyme-expressing yeast for ethanol production
WO2020076697A1 (en) 2018-10-08 2020-04-16 Novozymes A/S Enzyme-expressing yeast for ethanol production
EP3712240A1 (en) 2014-02-07 2020-09-23 Novozymes A/S Compositions for producing glucose syrups
WO2020206058A1 (en) 2019-04-02 2020-10-08 Novozymes A/S Process for producing a fermentation product
WO2021021458A1 (en) 2019-07-26 2021-02-04 Novozymes A/S Microorganisms with improved nitrogen transport for ethanol production
WO2021026201A1 (en) 2019-08-05 2021-02-11 Novozymes A/S Enzyme blends and processes for producing a high protein feed ingredient from a whole stillage byproduct
WO2021055395A1 (en) 2019-09-16 2021-03-25 Novozymes A/S Polypeptides having beta-glucanase activity and polynucleotides encoding same
WO2021119304A1 (en) 2019-12-10 2021-06-17 Novozymes A/S Microorganism for improved pentose fermentation
WO2021163030A2 (en) 2020-02-10 2021-08-19 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2022090564A1 (en) 2020-11-02 2022-05-05 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2022261003A1 (en) 2021-06-07 2022-12-15 Novozymes A/S Engineered microorganism for improved ethanol fermentation
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
WO2024088549A1 (en) 2022-10-24 2024-05-02 Novozymes A/S Baking method with thermostable amg variant and alpha-amylase
WO2024088550A1 (en) 2022-10-24 2024-05-02 Novozymes A/S Baking method for pulse protein fortified bread employing thermostable amyloglucosidase variante (ec 3.2.1.3)
WO2024089126A1 (en) 2022-10-28 2024-05-02 Novozymes A/S A method for obtaining a plant-based food ingredient
WO2024137246A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Carbohydrate esterase family 1 (ce1) polypeptides having ferulic acid esterase and/or acetyl xylan esterase activity and polynucleotides encoding same
WO2024137248A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Compositions comprising arabinofuranosidases and a xylanase, and use thereof for increasing hemicellulosic fiber solubilization
WO2024137252A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Process for reducing syrup viscosity in the backend of a process for producing a fermentation product
WO2024137250A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Carbohydrate esterase family 3 (ce3) polypeptides having acetyl xylan esterase activity and polynucleotides encoding same
WO2024137704A2 (en) 2022-12-19 2024-06-27 Novozymes A/S Processes for producing fermentation products using fiber-degrading enzymes with engineered yeast

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069289A2 (en) * 2004-12-22 2006-06-29 Novozymes North America, Inc Polypeptides having glucoamylase activity and polynucleotides encoding same
US8841091B2 (en) 2004-12-22 2014-09-23 Novozymes Als Enzymes for starch processing
WO2006066582A1 (en) * 2004-12-22 2006-06-29 Novozymes A/S Fermentation product processes
US7871800B2 (en) 2006-04-19 2011-01-18 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
ATE448319T1 (en) * 2006-06-15 2009-11-15 Novozymes As METHOD FOR PRODUCING A STARCH HYDROLYZATE
CA2657998A1 (en) * 2006-06-22 2007-12-27 Novozymes A/S Preparation of dough and baked products
US20110099670A1 (en) * 2008-02-14 2011-04-28 Andries Jurriaan Koops Nucleotide sequences coding for cis-aconitic decarboxylase and use thereof
US8153006B1 (en) 2008-06-05 2012-04-10 Procorp Enterprises, Llc Anaerobic treatment process for ethanol production
ES2594438T3 (en) * 2008-08-20 2016-12-20 Novozymes A/S Processes to produce fermentation products
WO2010091221A1 (en) 2009-02-06 2010-08-12 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
JP5193905B2 (en) * 2009-03-04 2013-05-08 麒麟麦酒株式会社 Method for producing ethanol from cereal raw materials
WO2010124206A1 (en) 2009-04-24 2010-10-28 Novozymes North America, Inc. Antistaling process for flat bread
US20120088285A1 (en) 2009-07-07 2012-04-12 Novozymes A/S Process For Treating A Substrate With An Enzyme
WO2011092136A1 (en) 2010-01-29 2011-08-04 Novozymes A/S Biogas production process with enzymatic pre-treatment
DK2558484T3 (en) 2010-04-14 2016-03-29 Novozymes As Polypeptides having glucoamylase activity and polynucleotides encoding them
DK2585591T3 (en) 2010-06-25 2015-02-23 Novozymes As Polynucleotides with leader sequence function
EP2585602A1 (en) 2010-06-25 2013-05-01 Novozymes A/S Polynucleotides having promoter activity
CN103068989B (en) 2010-06-25 2015-09-09 诺维信公司 There are the polynucleotide of promoter activity
CN103298932B (en) 2010-11-08 2016-08-10 诺维信公司 There is the polypeptide of glucoamylase activity and encode the polynucleotide of this polypeptide
DK2646558T3 (en) 2010-11-30 2016-10-03 Novozymes Inc Promoters for expression of genes in a fungal cell
US8924138B2 (en) 2010-12-07 2014-12-30 Vnomics Corp. System and method for measuring and reducing vehicle fuel waste
EP2661499A1 (en) 2011-01-04 2013-11-13 Novozymes A/S Process for producing biogas from pectin and lignocellulose containing material
EP2527432A1 (en) 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
EP2527448A1 (en) 2011-05-23 2012-11-28 Novozymes A/S Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi
BR112013032543A2 (en) 2011-06-28 2017-01-17 Novozymes As biogas production process
US9567574B2 (en) 2011-09-09 2017-02-14 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US8697412B2 (en) 2011-11-28 2014-04-15 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2013083801A2 (en) 2011-12-09 2013-06-13 Novozymes A/S Biogas from substrates comprising animal manure and enzymes
WO2014028833A1 (en) 2012-08-17 2014-02-20 Novozymes A/S Methods for co-silencing expression of genes in filamentous fungal strains and uses thereof
US9879241B2 (en) 2012-09-07 2018-01-30 Novozymes A/S Glucoamylase variants and polynucleotides encoding same and uses thereof
CN103275952B (en) * 2012-12-23 2014-09-24 北京挑战生物技术有限公司 Middle temperature acidic amylase AMY-8 and gene and application thereof
WO2014177541A2 (en) 2013-04-30 2014-11-06 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2014177546A2 (en) * 2013-04-30 2014-11-06 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
HUE057274T2 (en) 2013-06-24 2022-04-28 Novozymes As Processes for recovering oil from fermentation product processes and processes for producing fermentation products
WO2015065871A1 (en) 2013-10-28 2015-05-07 Danisco Us Inc. Large scale genetically engineered active dry yeast
EP3129478B1 (en) 2014-04-10 2019-03-27 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
JP6277108B2 (en) * 2014-10-31 2018-02-07 日本ジフィー食品株式会社 Granular dry food and method for producing the same
WO2016196202A1 (en) 2015-05-29 2016-12-08 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
AU2016357263B2 (en) 2015-11-17 2019-07-18 Novozymes A/S Yeast strains suitable for saccharification and fermentation expressing glucoamylase and/or alpha-amylase
US11015212B2 (en) 2016-10-17 2021-05-25 Novozymes A/S Methods of reducing foam during ethanol fermentation
WO2018093285A1 (en) 2016-11-18 2018-05-24 Baltika Breweries - Part Of The Carlsberg Group Method of producing a grain malt and the malt product obtained in this way
US20190367952A1 (en) 2016-11-23 2019-12-05 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
WO2018102348A1 (en) 2016-11-29 2018-06-07 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
WO2019046232A1 (en) 2017-08-30 2019-03-07 Novozymes A/S Combined use of an endo-protease of the m35 family and an exo-protease of the s53 family in the fermentation of starch
CA3070730A1 (en) 2017-09-15 2019-03-21 Novozymes A/S Enzyme blends and processes for improving the nutritional quality of animal feed
WO2019070883A1 (en) 2017-10-04 2019-04-11 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
EP3701037A1 (en) 2017-10-23 2020-09-02 Novozymes A/S Processes for reducing lactic acid in a biofuel fermentation system
DE102017220757A1 (en) 2017-11-21 2019-05-23 Henkel Ag & Co. Kgaa Amylase and such containing detergent or cleaning agent
DE102018208445A1 (en) 2018-05-29 2019-12-05 Henkel Ag & Co. Kgaa Improved washing performance with a new alpha-amylase from Fomitopsis pinicola (Fpi)
DE102018208446A1 (en) 2018-05-29 2019-12-05 Henkel Ag & Co. Kgaa Improved washing performance with a new alpha-amylase from Fomes fomentarius (Ffo)
DE102018208444A1 (en) 2018-05-29 2019-12-05 Henkel Ag & Co. Kgaa Improved washing performance with a new alpha-amylase from Trametes hirsuta (Thi)
DE102018208443A1 (en) 2018-05-29 2019-12-05 Henkel Ag & Co. Kgaa Improved washing performance with a new alpha-amylase Irpex lacteus (IIa)
EP3806642A1 (en) 2018-06-12 2021-04-21 Novozymes A/S Less added sugar in baked products
BR112021000369A2 (en) 2018-07-11 2021-04-13 Novozymes A/S PROCESSES FOR PRODUCTION OF FERMENTATION PRODUCTS
BR112021014873A2 (en) 2019-01-31 2021-10-05 Novozymes A/S POLYPEPTIDE, COMBINATION OF ENZYMES, POLYNUCLEOTIDE, NUCLEIC ACID CONSTRUCTION OR RECOMBINANT EXPRESSION VECTOR, RECOMBINANT HOST CELL, METHOD OF PRODUCTION OF A POLYPEPTIDE, AND, PROCESS OF PRODUCTION OF A FERMENTATION PRODUCT
US20220154226A1 (en) 2019-03-18 2022-05-19 Novozymes A/S Polypeptides Having Pullulanase Activity Suitable For Use In Liquefaction
AU2020310162A1 (en) 2019-07-09 2022-02-03 International N&H Denmark Aps Fat coated particulate enzyme compositions
WO2021025872A1 (en) 2019-08-06 2021-02-11 Novozymes A/S Fusion proteins for improved enzyme expression
WO2021046073A1 (en) 2019-09-05 2021-03-11 Dupont Nutrition Biosciences Aps Feed composition
WO2021126966A1 (en) 2019-12-16 2021-06-24 Novozymes A/S Processes for producing fermentation products
AU2021372822A1 (en) 2020-11-02 2023-06-01 Novozymes A/S Baked and par-baked products with thermostable amg variants from penicillium
MX2024003691A (en) 2021-09-27 2024-06-26 Int N&H Denmark Aps Feed additive compositions and methods for using the same.
CN113875916A (en) * 2021-10-08 2022-01-04 内蒙古工业大学 Oat beverage and preparation method thereof
CN118176296A (en) 2021-11-04 2024-06-11 丹尼斯科美国公司 Recombinant yeast cells
CN118215740A (en) 2021-11-04 2024-06-18 丹尼斯科美国公司 Method and recombinant yeast cell for producing ethanol
CA3242135A1 (en) * 2021-12-24 2023-06-29 Zhongmei TANG Hybrid glucoamylases and methods of use thereof
WO2023213424A1 (en) 2022-05-04 2023-11-09 Novozymes A/S Brewing with thermostable amg variants
WO2023225510A1 (en) 2022-05-17 2023-11-23 Dupont Nutrition Biosciences Aps Feed additive comprising enzyme combinations
WO2024046594A1 (en) 2022-09-01 2024-03-07 Novozymes A/S Baking with thermostable amg glucosidase variants (ec 3.2.1.3) and low or no added emulsifier
WO2024046595A1 (en) 2022-09-01 2024-03-07 Novozymes A/S Baking with thermostable amyloglucosidase (amg) variants (ec 3.2.1.3) and low added sugar
WO2024118096A1 (en) 2022-11-30 2024-06-06 Novozymes A/S Baking at low-ph with thermostable glucoamylase variants

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009074A (en) 1975-03-13 1977-02-22 Cpc International Inc. Preparation of levulose from granular starch
EP0171218A2 (en) 1984-08-06 1986-02-12 Genencor, Inc. Enzymatic hydrolysis of granular starch directly to glucose
US4587215A (en) 1984-06-25 1986-05-06 Uop Inc. Highly thermostable amyloglucosidase
USRE32153E (en) 1978-09-01 1986-05-20 Cpc International Inc. Highly thermostable glucoamylaseand process for its production
US4591560A (en) 1983-01-17 1986-05-27 Director Of National Food Research Institute Ministry Of Agriculture, Forstry And Fisheries Process for saccharification of starch using enzyme produced by fungus belonging to genus Chalara
EP0184438A2 (en) 1984-12-05 1986-06-11 Gist-Brocades N.V. Transforming aspergillus niger, and plasmids for use therein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0238023A2 (en) 1986-03-17 1987-09-23 Novo Nordisk A/S Process for the production of protein products in Aspergillus oryzae and a promoter for use in Aspergillus
US4727026A (en) 1985-11-26 1988-02-23 Godo Shusei Co., Ltd. Method for direct saccharification of raw starch using enzyme produced by a basidiomycete belonging to the genus Corticium
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
WO1990000609A1 (en) 1988-07-08 1990-01-25 The University Of British Columbia Cellulose binding fusion proteins
WO1991014772A1 (en) 1990-03-23 1991-10-03 Gist-Brocades N.V. Production of enzymes in seeds and their use
WO1991017243A1 (en) 1990-05-09 1991-11-14 Novo Nordisk A/S A cellulase preparation comprising an endoglucanase enzyme
WO1994024158A1 (en) 1993-04-14 1994-10-27 The Regents Of The University Of California Cellulose binding domain
WO1995016782A1 (en) 1993-12-17 1995-06-22 Genencor International, Inc. Novel cellulase enzymes and systems for their expression
WO1995033836A1 (en) 1994-06-03 1995-12-14 Novo Nordisk Biotech, Inc. Phosphonyldipeptides useful in the treatment of cardiovascular diseases
WO1996000787A1 (en) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
WO1998014601A1 (en) 1996-09-30 1998-04-09 Exseed Genetics L.L.C. Encapsulation of polypeptides within the starch matrix
WO1998016633A1 (en) 1996-10-11 1998-04-23 Novo Nordisk A/S Alpha-amylase fused to cellulose binding domain, for starch degradation
WO1999019467A1 (en) 1997-10-13 1999-04-22 Novo Nordisk A/S α-AMYLASE MUTANTS
WO1999028448A1 (en) 1997-11-26 1999-06-10 Novo Nordisk A/S Thermostable glucoamylase
WO2000024883A1 (en) 1998-10-26 2000-05-04 Novozymes A/S Constructing and screening a dna library of interest in filamentous fungal cells
US6060305A (en) 1994-06-30 2000-05-09 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system
WO2000077165A2 (en) 1999-06-11 2000-12-21 Landbouwuniversiteit Wageningen Expression in plants of starch binding domains and/or of protein fusions containing starch binding domains
WO2001092502A1 (en) 2000-06-02 2001-12-06 Novozymes A/S Cutinase variants
WO2004055178A1 (en) 2002-12-17 2004-07-01 Novozymes A/S Thermostable alpha-amylases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070079A (en) * 1983-01-28 1985-04-20 シタス　コ−ポレイシヨン Glucoamylase gene
NO840200L (en) 1983-01-28 1984-07-30 Cefus Corp GLUCOAMYLASE CDNA.
DK135983D0 (en) 1983-03-25 1983-03-25 Novo Industri As THE AMYLASEENZYM SYMBOL PRODUCT AND PROCEDURE FOR ITS MANUFACTURING AND USING
US4536477A (en) 1983-08-17 1985-08-20 Cpc International Inc. Thermostable glucoamylase and method for its production
DE3475209D1 (en) 1983-09-11 1988-12-22 Gist Brocades Nv Novel enzyme product and its use in the saccharification of starch
US4628031A (en) 1984-09-18 1986-12-09 Michigan Biotechnology Institute Thermostable starch converting enzymes
US4727046A (en) * 1986-07-16 1988-02-23 Fairchild Semiconductor Corporation Method of fabricating high performance BiCMOS structures having poly emitters and silicided bases
WO1989001969A1 (en) 1987-09-04 1989-03-09 Novo-Nordisk A/S Process for the production of protein products in aspergillus and promoters for use in aspergillus
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162210A (en) 1990-06-29 1992-11-10 Iowa State University Research Foundation Process for enzymatic hydrolysis of starch to glucose
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
DE4343591A1 (en) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6093562A (en) 1996-02-05 2000-07-25 Novo Nordisk A/S Amylase variants
DE69637940D1 (en) 1995-02-03 2009-07-09 Novozymes As A METHOD FOR THE DESIGN OF ALPHA AMYLASE MUTANTS WITH SPECIFIC CHARACTERISTICS
AR000862A1 (en) 1995-02-03 1997-08-06 Novozymes As VARIANTS OF A MOTHER-AMYLASE, A METHOD TO PRODUCE THE SAME, A DNA STRUCTURE AND A VECTOR OF EXPRESSION, A CELL TRANSFORMED BY SUCH A DNA STRUCTURE AND VECTOR, A DETERGENT ADDITIVE, DETERGENT COMPOSITION, A COMPOSITION FOR AND A COMPOSITION FOR THE ELIMINATION OF
EP0904360B1 (en) 1996-04-30 2013-07-31 Novozymes A/S alpha-AMYLASE MUTANTS
US6537792B1 (en) * 1996-07-24 2003-03-25 Iowa State University Protein engineering of glucoamylase to increase pH optimum, substrate specificity and thermostability
DE69734936T2 (en) 1996-09-19 2006-08-24 Novozymes A/S HOST CELLS AND METHODS FOR PRODUCING PROTEINS
DE69812699T2 (en) 1997-12-02 2004-03-11 Rockwool International A/S METHOD FOR PRODUCING GLASS-TYPE ARTIFICIAL FIBERS
DE29721138U1 (en) * 1997-12-03 1999-04-08 Iro Patent Ag, Baar Thread brake device
CN103352033B (en) 1998-02-27 2016-05-11 诺维信公司 Maltogenic alpha-amylase variants
US6352851B1 (en) * 1998-07-15 2002-03-05 Novozymes A/S Glucoamylase variants
WO2000004136A1 (en) 1998-07-15 2000-01-27 Novozymes A/S Glucoamylase variants
AU1774000A (en) 1998-12-23 2000-07-31 Novozymes A/S Methods for producing polypeptides in aspergillus mutant cells
EP2278016B1 (en) 1999-03-22 2012-09-26 Novozymes Inc. Promoter sequences derived from Fusarium Venenatum and uses thereof
EP1818396B1 (en) 1999-03-30 2014-06-18 Novozymes A/S Alpha-amylase variants
AU5061000A (en) * 1999-06-02 2000-12-28 Novozymes A/S Novel glucoamylase
WO2001004273A2 (en) 1999-07-09 2001-01-18 Novozymes A/S Glucoamylase variant
EP2308979A3 (en) 2000-08-01 2011-05-04 Novozymes A/S Alpha-amylase mutants with altered properties
ITBO20010102A1 (en) 2001-02-26 2002-08-26 Gd Spa METHOD AND UNIT FOR THE FORMATION OF A TOBACCO CORD
AUPR968801A0 (en) * 2001-12-21 2002-01-24 Unisearch Limited Improvements in enzyme stability
PT1581617E (en) 2002-02-08 2011-05-05 Danisco Us Inc Methods for producing end-products from carbon substrates
US20030180900A1 (en) 2002-02-08 2003-09-25 Oreste Lantero Methods for producing ethanol from carbon substrates
WO2004011218A1 (en) 2002-07-29 2004-02-05 Tagawasangyo Co., Ltd. Method of patterning molded article surface
BRPI0407108A (en) 2003-02-06 2006-01-24 Novozymes As Method for producing a human functional immunoglobulin
CN1788083B (en) 2003-03-10 2011-10-05 诺维信公司 Alcohol product processes
CN1780560B (en) 2003-03-10 2011-05-25 布罗因联合公司 Method for producing ethanol using raw starch
ATE441664T1 (en) 2003-03-31 2009-09-15 Novozymes Inc METHOD FOR PRODUCING BIOLOGICAL SUBSTANCES IN ENZYME DEFICIENCY MUTANTS OF ASPERGILLUS NIGER
WO2004111218A2 (en) * 2003-06-13 2004-12-23 Novozymes A/S Method for producing glucoamylases and their uses
WO2004113551A1 (en) * 2003-06-25 2004-12-29 Novozymes A/S Process for the hydrolysis of starch
WO2005003311A2 (en) 2003-06-25 2005-01-13 Novozymes A/S Enzymes for starch processing
MXPA06004463A (en) * 2003-10-28 2006-06-27 Novozymes North America Inc Hybrid enzymes.
EP1888835A4 (en) * 2004-12-02 2013-11-13 Novozymes North America Inc Desizing process
WO2006069289A2 (en) * 2004-12-22 2006-06-29 Novozymes North America, Inc Polypeptides having glucoamylase activity and polynucleotides encoding same
US20060147581A1 (en) * 2004-12-22 2006-07-06 Novozymes A/S Hybrid enzymes
WO2006066582A1 (en) * 2004-12-22 2006-06-29 Novozymes A/S Fermentation product processes
CN101087888A (en) * 2004-12-22 2007-12-12 诺维信公司 Starch process
US20060257964A1 (en) * 2005-05-16 2006-11-16 Biosafe Systems L.L.C. Method of measuring the concentration of hydrogen peroxide, peroxyacetic acid, chlorinated compounds and other aqueous oxidizer compounds

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4009074A (en) 1975-03-13 1977-02-22 Cpc International Inc. Preparation of levulose from granular starch
USRE32153E (en) 1978-09-01 1986-05-20 Cpc International Inc. Highly thermostable glucoamylaseand process for its production
US4591560A (en) 1983-01-17 1986-05-27 Director Of National Food Research Institute Ministry Of Agriculture, Forstry And Fisheries Process for saccharification of starch using enzyme produced by fungus belonging to genus Chalara
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
US4587215A (en) 1984-06-25 1986-05-06 Uop Inc. Highly thermostable amyloglucosidase
EP0171218A2 (en) 1984-08-06 1986-02-12 Genencor, Inc. Enzymatic hydrolysis of granular starch directly to glucose
EP0184438A2 (en) 1984-12-05 1986-06-11 Gist-Brocades N.V. Transforming aspergillus niger, and plasmids for use therein
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US4727026A (en) 1985-11-26 1988-02-23 Godo Shusei Co., Ltd. Method for direct saccharification of raw starch using enzyme produced by a basidiomycete belonging to the genus Corticium
EP0238023A2 (en) 1986-03-17 1987-09-23 Novo Nordisk A/S Process for the production of protein products in Aspergillus oryzae and a promoter for use in Aspergillus
WO1990000609A1 (en) 1988-07-08 1990-01-25 The University Of British Columbia Cellulose binding fusion proteins
WO1991014772A1 (en) 1990-03-23 1991-10-03 Gist-Brocades N.V. Production of enzymes in seeds and their use
WO1991017243A1 (en) 1990-05-09 1991-11-14 Novo Nordisk A/S A cellulase preparation comprising an endoglucanase enzyme
WO1994024158A1 (en) 1993-04-14 1994-10-27 The Regents Of The University Of California Cellulose binding domain
WO1995016782A1 (en) 1993-12-17 1995-06-22 Genencor International, Inc. Novel cellulase enzymes and systems for their expression
WO1995033836A1 (en) 1994-06-03 1995-12-14 Novo Nordisk Biotech, Inc. Phosphonyldipeptides useful in the treatment of cardiovascular diseases
US6060305A (en) 1994-06-30 2000-05-09 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic Fusarium expression system
WO1996000787A1 (en) 1994-06-30 1996-01-11 Novo Nordisk Biotech, Inc. Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
WO1998014601A1 (en) 1996-09-30 1998-04-09 Exseed Genetics L.L.C. Encapsulation of polypeptides within the starch matrix
WO1998016633A1 (en) 1996-10-11 1998-04-23 Novo Nordisk A/S Alpha-amylase fused to cellulose binding domain, for starch degradation
WO1999019467A1 (en) 1997-10-13 1999-04-22 Novo Nordisk A/S α-AMYLASE MUTANTS
WO1999028448A1 (en) 1997-11-26 1999-06-10 Novo Nordisk A/S Thermostable glucoamylase
WO2000024883A1 (en) 1998-10-26 2000-05-04 Novozymes A/S Constructing and screening a dna library of interest in filamentous fungal cells
WO2000077165A2 (en) 1999-06-11 2000-12-21 Landbouwuniversiteit Wageningen Expression in plants of starch binding domains and/or of protein fusions containing starch binding domains
WO2001092502A1 (en) 2000-06-02 2001-12-06 Novozymes A/S Cutinase variants
WO2004055178A1 (en) 2002-12-17 2004-07-01 Novozymes A/S Thermostable alpha-amylases

Non-Patent Citations (57)

* Cited by examiner, † Cited by third party
Title
"Ainsworth and Bisby's Dictionary of The Fungi", 1995, CAB INTERNATIONAL, UNIVERSITY PRESS, article "Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota"
"Program Manual for the Wisconsin Package", August 1994, MADISON
"Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology", 1992, ACADEMIC PRESS INC
"Useful proteins from recombinant bacteria", SCIENTIFIC AMERICAN, vol. 242, 1980, pages 74 - 94
BECKER; GUARENTE: "Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology", vol. 194, ACADEMIC PRESS, INC., pages: 182 - 187
BIOCHEM. J., vol. 372, 2003, pages 905 - 910
BOURNE, Y.; HENRISSAT, B.: "Glycoside hydrolases and glycosyltransferases: families and functional modules", CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 11, 2001, pages 593 - 600
CHEN ET AL., PLANT AND CELL PHYSIOLOGY, vol. 39, no. 9, 1998, pages 935 - 941
CHRISTENSEN AH; SHARROCK RA; QUAIL: "Maize polyubiquitin genes: structure, thermal perturbation of expression and transcript splicing, and promoter activity following transfer to protoplasts by electroporation", PLANT MO. BIOL., vol. 18, 1992, pages 675 - 689
CHRISTOU, PLANT J., vol. 2, 1992, pages 275 - 281
CONRAD U. ET AL., JOURNAL OF PLANT PHYSIOLOGY, vol. 152, no. 6, 1998, pages 708 - 711
COUTINHO, P.M.; HENRISSAT, B., CAZY - CARBOHYDRATE-ACTIVE ENZYMES SERVER, 1999, Retrieved from the Internet <URL:http://afmb.cnrs-mrs.fr/-cazy/CAZY/index.html>
COUTINHO, P.M.; HENRISSAT, B.: "Genetics, Biochemistry and Ecology of Cellulose Degradation", 1999, UNI PUBLISHERS CO., article "The modular structure of cellulases and other carbohydrate-active enzymes: an integrated database approach", pages: 15 - 23
DEBOER ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 80, 1983, pages 21 - 25
EDWARDS; CORUZZI, ANNU. REV. GENET., vol. 24, 1990, pages 275 - 303
EHRLICH, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 75, 1978, pages 1433
FEINBERG, A. P.; VOGELSTEIN, B., ANAL. BIOCHEM., vol. 132, 1983, pages 6 - 13
FRANCK ET AL., CELL, vol. 21, 1980, pages 285 - 294
GASSER ET AL., SCIENCE, vol. 244, pages 1293
GORINSTEIN. S.; LII. C., STARCH/STARKE, vol. 44, no. 12, 1992, pages 461 - 466
GREENWOOD ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 44, 1994, pages 1295 - 1305
GUO; SHERMAN, MOLECULAR CELLULAR BIOLOGY, vol. 15, 1995, pages 5983 - 5990
HAWKSWORTH ET AL.: "Ainsworth and Bisby's Dictionary of The Fungi", 1995, CAB INTERNATIONAL, UNIVERSITY PRESS
HINNEN ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 75, 1978, pages 1920
HOOYKAS; SCHILPEROORT, PLANT MOL. BIOL., vol. 19, 1992, pages 15 - 38
INNIS ET AL.: "PCR: A Guide to Methods and Application", 1990, ACADEMIC PRESS
ITO ET AL., JOURNAL OF BACTERIOLOGY, vol. 153, 1983, pages 163
ITO ET AL., PLANT MOL. BIOL., vol. 24, 1994, pages 863 - 878
J. BIOL. CHEM., vol. 272, no. 15, 1997, pages 9720 - 9727
JOERGENSEN ET AL., BIOTECHNOL. LETT., vol. 19, 1997, pages 1027 - 1031
KAGAYA ET AL., MOLECULAR AND GENERAL GENETICS, vol. 248, no. 6, 1995, pages 668 - 674
KYOZUKA ET AL., PLANT PHYSIOLOGY, vol. 102, no. 3, 1993, pages 991 - 1000
LASSEN ET AL., APPLIED AND ENVIRONMENTAL MICORBIOLOGY, vol. 67, 2001, pages 4701 - 4707
MALARDIER ET AL., GENE, vol. 78, 1989, pages 147 - 156
MATTHES ET AL., EMBO J., vol. 3, 1984, pages 801 - 805
MITRA, A.; HIGGINS, DW, PLANT MOLECULAR BIOLOGY, vol. 26, no. 1, 1994, pages 85 - 93
MORINAGA ET AL., BIOTECHNOLOGY, vol. 2, 1984, pages 646 - 639
NEEDLEMAN, S.B.; WUNSCH, C.D., JOURNAL OF MOLECULAR BIOLOGY, vol. 48, 1970, pages 443 - 453
NELSON; LONG, ANALYTICAL BIOCHEMISTRY, vol. 180, 1989, pages 147 - 151
NUCLEIC ACIDS RESEARCH, vol. 20, no. 14, 1992, pages 3790
OMIRULLEH S ET AL., PLANT MOLECULAR BIOLOGY, vol. 21, no. 3, 1993, pages 415 - 428
POTRYKUS, BIO/TECHN., vol. 8, 1990, pages 535
R.K. SAIKI ET AL., SCIENCE, vol. 239, 1988, pages 487 - 491
ROMANOS ET AL., YEAST, vol. 8, 1992, pages 423 - 488
S.L. BEAUCAGE; M.H. CARUTHERS, TETRAHEDRON LETTERS, vol. 22, 1981, pages 1859 - 1869
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR
See also references of EP1831385A4
SHIMAMOTO ET AL., NATURE, vol. 338, 1989, pages 274
SHIMAMOTO, CURR. OPIN. BIOTECHNOL., vol. 5, 1994, pages 158 - 162
SIMONEN; PALVA, MICROBIOLOGICAL REVIEWS, vol. 57, 1993, pages 109 - 137
TAGUE ET AL., PLANT PHYS., vol. 86, 1988, pages 506
VASIL ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 667 - 674
VILLA-KAMAROFF ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 75, 1978, pages 3727 - 3731
WU ET AL., PLANT AND CELL PHYSIOLOGY, vol. 39, no. 8, 1998, pages 885 - 889
XU ET AL., PLANT MOLECULAR BIOLOGY, vol. 22, no. 4, 1993, pages 573 - 588
YELTON ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 81, 1984, pages 1470 - 1474
ZHANG W; MCELROY D.; WU R: "Analysis of rice Act1 5' region activity in transgenic rice plants", PLANT CELL, vol. 3, 1991, pages 1155 - 1165

Cited By (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106533A1 (en) 2003-05-30 2004-12-09 Novozymes A/S Alcohol product processes
EP2336308A3 (en) * 2003-06-25 2011-11-09 Novozymes A/S Enzymes for starch processing
US8263381B2 (en) 2003-06-25 2012-09-11 Novozyms A/S Enzymes for starch processing
WO2007035730A2 (en) 2005-09-20 2007-03-29 Novozymes North America, Inc. Process of producing a fermentation product
WO2007076388A2 (en) 2005-12-22 2007-07-05 Novozymes North America, Inc. Processes for producing a fermentation product
WO2007109750A2 (en) 2006-03-22 2007-09-27 Novozymes North America, Inc. Fermentation processes
WO2008134259A1 (en) 2007-04-24 2008-11-06 Novozymes North America, Inc. Detoxifying pre-treated lignocellulose-containing materials
EP3219804A1 (en) 2007-04-24 2017-09-20 Novozymes North America, Inc. Detoxifying pre-treated lignocellulose-containing materials
WO2009030713A1 (en) 2007-09-03 2009-03-12 Novozymes A/S Detoxifying and recycling of washing solution used in pretreatment of lignocellulose-containing materials
WO2009030728A2 (en) * 2007-09-05 2009-03-12 Novozymes A/S Enzyme compositions with stabilizing constituent
WO2009030728A3 (en) * 2007-09-05 2009-05-07 Novozymes As Enzyme compositions with stabilizing constituent
US7906303B2 (en) 2008-03-11 2011-03-15 Danisco Us Inc. Use of Rhizopus amylases in granular starch hydrolysis
CN101970672A (en) * 2008-03-11 2011-02-09 丹尼斯科美国公司 Use of rhizopus amylases in granular starch hydrolysis
WO2009114403A1 (en) * 2008-03-11 2009-09-17 Danisco Us Inc., Genencor Division Use of rhizopus amylases in granular starch hydrolysis
US8530216B2 (en) 2008-05-16 2013-09-10 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2009140504A1 (en) * 2008-05-16 2009-11-19 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2010008841A2 (en) 2008-06-23 2010-01-21 Novozymes A/S Processes for producing fermentation products
WO2010039812A2 (en) 2008-09-30 2010-04-08 Novozymes North America, Inc. Improvement of enzymatic hydrolysis of pre-treated lignocellulose-containing material with distillers dried grains
WO2010059413A2 (en) 2008-11-20 2010-05-27 Novozymes, Inc. Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
EP2857515A2 (en) 2008-11-20 2015-04-08 Novozymes Inc. Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
WO2010078391A2 (en) 2008-12-30 2010-07-08 Novozymes North America, Inc. Improvement of enzymatic hydrolysis of pretreated lignocellulose-containing material with dissolved air flotation sludge
WO2010078392A2 (en) 2008-12-31 2010-07-08 Novozymes North America, Inc. Processes of producing fermentation products
WO2010088447A1 (en) * 2009-01-30 2010-08-05 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2011008785A2 (en) 2009-07-17 2011-01-20 Novozymes A/S A method of analyzing cellulose decay in cellulosic material hydrolysis
WO2011039324A1 (en) 2009-09-30 2011-04-07 Novozymes A/S Steamed bread preparation methods and steamed bread improving compositions
US9127262B2 (en) 2009-11-30 2015-09-08 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US8735130B2 (en) 2009-11-30 2014-05-27 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
AU2010276468B2 (en) * 2009-11-30 2015-05-14 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
AU2010276470B2 (en) * 2009-11-30 2015-05-14 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US8916359B2 (en) 2009-11-30 2014-12-23 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011066560A1 (en) * 2009-11-30 2011-06-03 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US10125380B2 (en) 2009-11-30 2018-11-13 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US9624480B2 (en) 2009-11-30 2017-04-18 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011066576A1 (en) 2009-11-30 2011-06-03 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
CN102869771A (en) * 2009-11-30 2013-01-09 诺维信公司 Polypeptides having glucoamylase activity and polynucleotides encoding same
CN104169417A (en) * 2009-12-01 2014-11-26 诺维信公司 Polypeptides having glucoamylase activity and polynucleotides encoding same
US8557541B2 (en) 2009-12-01 2013-10-15 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
AU2010276471B2 (en) * 2009-12-01 2015-05-14 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011068803A1 (en) * 2009-12-01 2011-06-09 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US9873869B2 (en) 2009-12-01 2018-01-23 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
US9752134B2 (en) 2009-12-01 2017-09-05 Novozymes North America, Inc. Polypeptides having glucoamylase activity and polynucleotides encoding same
US9102928B2 (en) 2009-12-01 2015-08-11 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
CN104169417B (en) * 2009-12-01 2020-05-08 诺维信公司 Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2011087836A2 (en) 2009-12-22 2011-07-21 Novozymes A/S Pullulanase variants and uses thereof
US11603522B2 (en) 2010-01-04 2023-03-14 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
US9416355B2 (en) 2010-01-04 2016-08-16 Novozymes North America, Inc. Alpha-amylase variants and polynucleotides encoding same
US10550373B2 (en) 2010-01-04 2020-02-04 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
WO2011100161A1 (en) 2010-02-09 2011-08-18 Novozymes North America, Inc. Addition of alpha - glucosidase and cobalt for producing fermentation products from starch
WO2011126897A2 (en) 2010-03-30 2011-10-13 Novozymes A/S Methods for enhancing by-products from fermentation processes
EP3070171A1 (en) 2010-03-30 2016-09-21 Novozymes A/S Processes of producing a fermentation product
WO2011123505A1 (en) 2010-03-30 2011-10-06 Novozymes North America, Inc. Processes of producing a fermentation product
WO2011154529A1 (en) 2010-06-11 2011-12-15 Novozymes A/S Enzymatic flour correction
WO2012018775A1 (en) 2010-08-02 2012-02-09 Novozymes North America, Inc. Process of producing a fermentation product
WO2012064350A1 (en) * 2010-11-08 2012-05-18 Novozymes A/S Polypeptides Having Glucoamylase Activity and Polynucleotides Encoding Same
WO2012068047A2 (en) 2010-11-19 2012-05-24 Novozymes North America, Inc. Processes of producing a fermentation product
WO2012088303A2 (en) 2010-12-22 2012-06-28 Novozymes North America, Inc. Processes for producing fermentation products
WO2012109119A2 (en) 2011-02-07 2012-08-16 Novozymes North America, Inc. Process of producing a fermentation product
US9765316B2 (en) 2011-07-06 2017-09-19 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
US9267124B2 (en) 2011-07-06 2016-02-23 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
EP2729572B1 (en) * 2011-07-06 2019-03-20 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
WO2013006756A3 (en) * 2011-07-06 2013-05-02 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
WO2013006756A2 (en) 2011-07-06 2013-01-10 Novozymes A/S Alpha amylase variants and polynucleotides encoding same
WO2013016115A1 (en) 2011-07-22 2013-01-31 Novozymes North America, Inc. Processes for pretreating cellulosic material and improving hydrolysis thereof
WO2013029496A1 (en) 2011-08-26 2013-03-07 Novozymes A/S Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2013036526A1 (en) 2011-09-06 2013-03-14 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
EP2748189A1 (en) * 2011-09-09 2014-07-02 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
US11788078B2 (en) 2011-09-09 2023-10-17 Novozymes A/S Processes for producing ethanol
WO2013034106A1 (en) 2011-09-09 2013-03-14 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
US11180746B2 (en) 2011-09-09 2021-11-23 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
US9994834B2 (en) 2011-09-09 2018-06-12 Novozymes A/S Polynucleotides encoding polypeptides having alpha-amylase activity and methods of making the same
EP2748189A4 (en) * 2011-09-09 2015-01-14 Novozymes As Polypeptides having alpha-amylase activity and polynucleotides encoding same
US10626384B2 (en) 2011-09-09 2020-04-21 Novozymes A/S Process for producing a fermentation product
US9909112B2 (en) 2011-09-30 2018-03-06 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
EP2751131A4 (en) * 2011-09-30 2015-01-28 Novozymes As Polypeptides having alpha-amylase activity and polynucleotides encoding same
EP2751131A1 (en) * 2011-09-30 2014-07-09 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2013053801A1 (en) 2011-10-11 2013-04-18 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2013055676A1 (en) 2011-10-11 2013-04-18 Novozymes North America, Inc. Processes for producing fermentation products
WO2013082486A1 (en) 2011-12-02 2013-06-06 Novozymes A/S Processes for producing fermentation products
WO2013096652A1 (en) 2011-12-21 2013-06-27 Novozymes, Inc. Methods for determining the degradation of a biomass material
EP4209595A1 (en) 2012-03-30 2023-07-12 Novozymes North America, Inc. A method of dewatering whole stillage
WO2013148993A1 (en) 2012-03-30 2013-10-03 Novozymes North America, Inc. Processes of producing fermentation products
US8945889B2 (en) 2012-05-11 2015-02-03 Danisco Us Inc. Method of using alpha-amylase from Aspergillus clavatus for saccharification
WO2014006140A1 (en) 2012-07-06 2014-01-09 Novozymes A/S Liquid enzyme composition and method for enzyme recovery
WO2014028436A1 (en) * 2012-08-16 2014-02-20 Danisco Us Inc. Method of using alpha-amylase from aspergillus clavatus and isoamylase for saccharification
WO2014027062A1 (en) 2012-08-17 2014-02-20 Novozymes A/S Thermostable asparaginase variants and polynucleotides encoding same
WO2014058572A1 (en) * 2012-10-10 2014-04-17 Danisco Us Inc. Method of using alpha-amylase from talaromyces emersonii for saccharification
WO2014085439A1 (en) 2012-11-30 2014-06-05 Novozymes A/S Processes for producing fermentation products
WO2014099653A1 (en) 2012-12-17 2014-06-26 Novozymes A/S Alpha-amylases and polynucleotides encoding same
US11252968B2 (en) 2013-04-05 2022-02-22 Novozymes A/S Method of producing a baked product with alpha-amylase, lipase and phospholipase
EP2981170B1 (en) 2013-04-05 2019-11-13 Novozymes A/S Method of producing a baked product with alpha-amylase, lipase and phospholipase
US11963537B2 (en) 2013-04-05 2024-04-23 Novozymes A/S Methods and compositions for preparing bread
WO2015007639A1 (en) 2013-07-17 2015-01-22 Novozymes A/S Pullulanase chimeras and polynucleotides encoding same
WO2015031477A1 (en) 2013-08-30 2015-03-05 Novozymes A/S Enzyme composition and uses thereof
US10450551B2 (en) 2013-08-30 2019-10-22 Novozymes A/S Enzyme composition and uses thereof
EP3039131A4 (en) * 2013-08-30 2017-02-08 Novozymes A/S Enzyme composition and uses thereof
US11155798B2 (en) 2013-08-30 2021-10-26 Novozymes A/S Enzyme composition and uses thereof
WO2015035914A1 (en) 2013-09-11 2015-03-19 Novozymes A/S Processes for producing fermentation products
EP3712274A1 (en) 2013-09-11 2020-09-23 Novozymes A/S Processes for producing fermentation products
EP3415624A1 (en) 2014-01-22 2018-12-19 Novozymes A/S Pullulanase variants and polynucleotides encoding same
EP3712240A1 (en) 2014-02-07 2020-09-23 Novozymes A/S Compositions for producing glucose syrups
WO2015143144A1 (en) 2014-03-19 2015-09-24 Novozymes A/S Method for enhancing activity of an x143 polypeptide
EP3000324A1 (en) 2014-09-29 2016-03-30 Puratos Improved cake batters
WO2016062875A2 (en) 2014-10-23 2016-04-28 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2016087445A1 (en) 2014-12-01 2016-06-09 Novozymes A/S Improved production of glucose syrups
WO2016138437A1 (en) 2015-02-27 2016-09-01 Novozymes A/S Processes of producing ethanol using a fermenting organism
WO2016205127A1 (en) 2015-06-18 2016-12-22 Novozymes A/S Polypeptides having trehalase activity and the use thereof in process of producing fermentation products
WO2017015329A1 (en) 2015-07-23 2017-01-26 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
WO2017112540A1 (en) 2015-12-22 2017-06-29 Novozymes A/S Processes for producing fermentation products
WO2018098381A1 (en) 2016-11-23 2018-05-31 Novozymes A/S Improved yeast for ethanol production
WO2018222990A1 (en) 2017-06-02 2018-12-06 Novozymes A/S Improved yeast for ethanol production
EP4015524A1 (en) 2017-06-28 2022-06-22 Novozymes A/S Polypeptides having trehalase activity and polynucleotides encoding same
WO2019005755A1 (en) 2017-06-28 2019-01-03 Novozymes A/S Polypeptides having trehalase activity and polynucleotides encoding same
WO2019030165A1 (en) 2017-08-08 2019-02-14 Novozymes A/S Polypeptides having trehalase activity and the use thereof in process of producing fermentation products
WO2019148192A1 (en) 2018-01-29 2019-08-01 Novozymes A/S Microorganisms with improved nitrogen utilization for ethanol production
WO2019161227A1 (en) 2018-02-15 2019-08-22 Novozymes A/S Improved yeast for ethanol production
US11377648B2 (en) 2018-04-09 2022-07-05 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2019197318A1 (en) 2018-04-09 2019-10-17 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
CN108611339B (en) * 2018-05-11 2021-05-25 中国农业科学院北京畜牧兽医研究所 Glucoamylase TlGa15 and gene and application thereof
CN108611339A (en) * 2018-05-11 2018-10-02 中国农业科学院饲料研究所 Glucoamylase TlGa15 and its gene and application
WO2019231944A2 (en) 2018-05-31 2019-12-05 Novozymes A/S Processes for enhancing yeast growth and productivity
WO2020023411A1 (en) 2018-07-25 2020-01-30 Novozymes A/S Enzyme-expressing yeast for ethanol production
WO2020076697A1 (en) 2018-10-08 2020-04-16 Novozymes A/S Enzyme-expressing yeast for ethanol production
CN109385413A (en) * 2018-10-09 2019-02-26 中国农业科学院饲料研究所 Glucoamylase TlGA1931 and its gene and application
WO2020206058A1 (en) 2019-04-02 2020-10-08 Novozymes A/S Process for producing a fermentation product
WO2021021458A1 (en) 2019-07-26 2021-02-04 Novozymes A/S Microorganisms with improved nitrogen transport for ethanol production
WO2021026201A1 (en) 2019-08-05 2021-02-11 Novozymes A/S Enzyme blends and processes for producing a high protein feed ingredient from a whole stillage byproduct
WO2021055395A1 (en) 2019-09-16 2021-03-25 Novozymes A/S Polypeptides having beta-glucanase activity and polynucleotides encoding same
WO2021119304A1 (en) 2019-12-10 2021-06-17 Novozymes A/S Microorganism for improved pentose fermentation
WO2021163030A2 (en) 2020-02-10 2021-08-19 Novozymes A/S Polypeptides having alpha-amylase activity and polynucleotides encoding same
WO2022090564A1 (en) 2020-11-02 2022-05-05 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
WO2022261003A1 (en) 2021-06-07 2022-12-15 Novozymes A/S Engineered microorganism for improved ethanol fermentation
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
WO2024088549A1 (en) 2022-10-24 2024-05-02 Novozymes A/S Baking method with thermostable amg variant and alpha-amylase
WO2024088550A1 (en) 2022-10-24 2024-05-02 Novozymes A/S Baking method for pulse protein fortified bread employing thermostable amyloglucosidase variante (ec 3.2.1.3)
WO2024089126A1 (en) 2022-10-28 2024-05-02 Novozymes A/S A method for obtaining a plant-based food ingredient
WO2024137246A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Carbohydrate esterase family 1 (ce1) polypeptides having ferulic acid esterase and/or acetyl xylan esterase activity and polynucleotides encoding same
WO2024137248A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Compositions comprising arabinofuranosidases and a xylanase, and use thereof for increasing hemicellulosic fiber solubilization
WO2024137252A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Process for reducing syrup viscosity in the backend of a process for producing a fermentation product
WO2024137250A1 (en) 2022-12-19 2024-06-27 Novozymes A/S Carbohydrate esterase family 3 (ce3) polypeptides having acetyl xylan esterase activity and polynucleotides encoding same
WO2024137704A2 (en) 2022-12-19 2024-06-27 Novozymes A/S Processes for producing fermentation products using fiber-degrading enzymes with engineered yeast

Also Published As

Publication number Publication date
DK2365068T3 (en) 2017-05-15
ES2543131T3 (en) 2015-08-14
EP2365068A2 (en) 2011-09-14
EP1831385A2 (en) 2007-09-12
JP2008525035A (en) 2008-07-17
EP1831384A2 (en) 2007-09-12
EP2365068B1 (en) 2017-03-01
US8148127B2 (en) 2012-04-03
EP1831385A4 (en) 2009-02-18
JP5160899B2 (en) 2013-03-13
US20080090271A1 (en) 2008-04-17
JP5452869B2 (en) 2014-03-26
AU2005319073B2 (en) 2011-03-17
AR051864A1 (en) 2007-02-14
AU2005319074A1 (en) 2006-06-29
DK1831385T3 (en) 2015-07-13
WO2006069289A2 (en) 2006-06-29
ES2552635T3 (en) 2015-12-01
DK1831384T3 (en) 2015-11-23
EP2365068A3 (en) 2011-12-21
CA2591745A1 (en) 2006-06-29
JP2008525036A (en) 2008-07-17
MX2007007107A (en) 2007-08-08
WO2006069289A3 (en) 2007-05-31
CA2592104C (en) 2016-05-10
WO2006069290A3 (en) 2007-05-31
MX2007007030A (en) 2007-08-14
US20060148054A1 (en) 2006-07-06
EP1831384A4 (en) 2009-01-21
US8512986B2 (en) 2013-08-20
EP1831384B1 (en) 2015-08-12
AU2005319074B2 (en) 2011-03-24
CA2591745C (en) 2018-10-16
EP1831385B1 (en) 2015-04-22
US20100216213A1 (en) 2010-08-26
US20110104759A1 (en) 2011-05-05
US7326548B2 (en) 2008-02-05
US20060172403A1 (en) 2006-08-03
ES2621921T3 (en) 2017-07-05
AU2005319073A1 (en) 2006-06-29
CA2592104A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
US8512986B2 (en) Enzymes for starch processing
US9777304B2 (en) Enzymes for starch processing
US7883883B2 (en) Enzymes for starch processing
EP2638154B1 (en) Polypeptides having glucoamylase activity and polynucleotides encoding same
DK2507372T3 (en) Polypeptides with glucoamylase activity and polynucleotides encoding them
US7871800B2 (en) Polypeptides having glucoamylase activity and polynucleotides encoding same
WO2005003311A9 (en) Enzymes for starch processing
CN106397601A (en) Enzymes for starch processing
EP2637515A1 (en) Polypeptides Having Glucoamylase Activity and Polynucleotides Encoding Same
AU2011203101B2 (en) Enzymes for starch processing

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580048598.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005319074

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007030

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007548502

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2592104

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005319074

Country of ref document: AU

Date of ref document: 20051222

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005855308

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)